

DUKE UNIVERSITY MEDICAL CENTER

CURRICULUM VITAE

for
Permanent Record
and the
Appointments and Promotions Committee

July 2, 2024

Name:	Priya S. Kishnani, MD
Primary Academic Appointment:	Professor of Pediatrics
Primary Academic Department (not DUAP):	Department of Pediatrics Division of Medical Genetics
Secondary Appointment:	Professor of Molecular Genetics and Microbiology
Present Academic Rank and Title:	C.L. and Su Chen Professor of Pediatrics Professor of Molecular Genetics and Microbiology
Date and Rank of First Duke Faculty Appointment:	Associate in Pediatrics, July 1995
Specialty Certification(s) and Dates:	American Board of Pediatrics, 1992 American Board of Pediatrics, Recertification 1999, not recertified since American Board of Medical Clinical Genetics, 1996, recertified in January 2020 American Board of Clinical Biochemical Genetics, 1996, recertified in January 2020
Place:	Bombay, India
Citizen of:	US Citizen
Visa Status:	NA

Education	Institution	Date (Year)	Degree
High School	Convent of Jesus and Mary, Bombay, India	1978	Diploma
Jai Hind College	Bombay, India	1980	Diploma

Education	Institution	Date (Year)	Degree
Bachelor of Medicine and Bachelor of Surgery	Bombay University – Bombay, India	10/1985	M.B.B.S.
Diploma in Child Health – Pediatrics	College of Physicians and Surgeons of Bombay – Bombay, India	4/1989	D.C.H.
Pediatrics	Bombay University - Bombay, India	3/1990	M.D.
PL-III Resident	Duke University Medical Center	1991-1992	M.D.
Clinical Fellowship Pediatric Genetics & Metabolism	Duke University Medical Center	1992-1994	
Research Fellowship Pediatric Genetics & Metabolism	Duke University Medical Center	1994-1995	

Professional Training and Academic Career:

Institution	Position/Title	Dates
B.Y.L. Nair Charitable Hospital, Bombay, India	Internship	1986-1987
B.Y.L. Nair Charitable Hospital, Bombay, India	House Officer (Pediatrics)	2/1987-7/1987
B.Y.L. Nair Charitable Hospital, Bombay, India	House Officer (Hematology)	8/1987-1/1988
B.Y.L. Nair Charitable Hospital, Bombay, India	House Officer (ICCU & Cardiology)	2/1988-7/1988
Children’s Hospital of Philadelphia, Philadelphia, PA	Research Pediatrician	1990-1991
Duke University Medical Center, Durham, NC	PL-III Resident	1991-1992
Duke University Medical Center, Durham, NC	Clinical Fellowship, Pediatric Genetics & Metabolism	1992-1994
Duke University Medical Center, Durham, NC	Research Fellowship, Pediatrics Genetics & Metabolism	1994-1995

Institution	Position/Title	Dates
Duke University Medical Center, Durham, NC	Associate in Pediatrics	1995-1997
Duke University Medical Center, Durham, NC	Co-Director of Down Syndrome	1996-2021
Duke University Medical Center, Durham, NC	Assistant Professor of Pediatrics	1997-2002
Duke University Medical Center, Durham, NC	Director of Glycogen and Lysosomal Storage Disease Program	1997-Present
Duke University Medical Center, Durham, NC	Director of Biochemical Genetics Training Program	1997-2015
Duke University Medical Center, Durham, NC	Director of Metabolic Clinic	1998-Present
Duke University Medical Center, Durham, NC	Director of Clinical Trials	2002-Present
Duke University Medical Center, Durham, NC	Associate Professor of Pediatrics	2002-Sept. 2007
Duke University Medical Center, Durham, NC	Interim Chief, Division of Medical Genetics	2005-2006
Duke University Medical Center, Durham, NC	Chief, Division of Medical Genetics	Jan. 2007-Present
Duke University Medical Center, Durham, NC	Medical Director, YT and Alice Chen Pediatrics Genetics and Genomics Center	July 2007-Present
Duke University Medical Center, Durham, NC	Professor, Molecular Genetics and Microbiology Department	Feb. 2019-Present
National Organization for Rare Disorder, Danbury, CT	Director, Duke Health NORD Rare Disease Center for Excellence	Oct. 2021-Present

Publications:

Refereed Journals (<https://pubmed.ncbi.nlm.nih.gov/?term=Kishnani+P>)

1. Silber JH, Radcliffe J, Peckham V, Perilongo G, **Kishnani PS**, Fridman M, Goldwein JW, Meadows AT. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J Clin Oncol 1992 Sep; 10(9):1390-6. PMID: 1517781

2. **Kishnani P**, Iafolla AK, McConkie-Rosell A, Van Hove JL, Kanter RJ, Kahler SG. Hemangioma, supraumbilical midline raphe, and coarctation of the aorta with a right aortic arch: single casual entity? *Am J Med Genet* 1995 Oct 23; 59(1):44-8. PMID: 8849010
3. Van Hove JL, **Kishnani PS**, Muenzer J, Wenstrup RJ, Summar ML, Brummond MR, Lachiewicz AM, Millington DS, Kahler SG. Benzoate therapy and carnitine deficiency in non-ketotic hyperglycinemia. *Am J Med Genet* 1995 Dec 4; 59(4):444-53. PMID: 8585564
4. **Kishnani PS**, Bengur AR, Chen YT. Pulmonary hypertension in glycogen storage disease type I. *J Inherit Metab Dis*. 1996; 19(2):213-6. PMID: 8739968
5. McConkie-Rosell A, Wilson C, Piccoli DA, Boyle J, DeClue T, **Kishnani PS**, Shen JJ, Boney A, Brown B, Chen YT. Clinical and laboratory findings in four patients with the non-progressive hepatic form of type IV glycogen storage disease. *J Inherit Metab Dis*. 1996; 19(1):51-8. PMID: 8830177
6. Bao Y, **Kishnani PS**, Wu JY, Chen YT. Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzyme gene. *J Clin Invest*. 1996 Feb 15; 97(4):941-8. PMID: 8613547
7. Wang M, **Kishnani PS**, Decker-Phillips M, Kahler SG, Chen YT, Godfrey M. Double mutant fibrillin-1 (FBN1) allele in a patient with neonatal Marfan syndrome. *J Med Genet*. 1996 Sep; 33(9):760-3. PMID: 8880577
8. **Kishnani PS**, Van Hove JL, Shoffner JS, Kaufman A, Bossen EH, Kahler SG. Acute pancreatitis in an infant with lactic acidosis and a mutation at nucleotide 3243 in the mitochondrial DNA tRNA^{Leu}(UUR) gene. *Eur J Pediatr*. 1996 Oct; 155(10):898-903. PMID: 8891562
9. **Kishnani PS**, Bao Y, Wu JY, Brix AE, Lin JL, Chen YT. Isolation and nucleotide sequence of canine glucose-6-phosphatase mRNA: identification of mutation in puppies with glycogen storage disease type Ia. *Biochem Mol Med*. 1997 Aug; 61(2):168-77. PMID: 9259982
10. **Kishnani PS**, Sullivan JA, Walter BK, Spiridigliozzi GA, Doraiswamy PM, Krishnan KR. Cholinergic therapy for Down's syndrome. *Lancet*. 1999 Mar 27; 353(9158):1064-5. PMID: 10199357
11. **Kishnani PS**, Boney A, Chen YT. Nutritional deficiencies in a patient with glycogen storage disease type Ib. *J Inherit Metab Dis*. 1999 Oct; 22(7):795-801. PMID: 10518279
12. Ahmad A, Amalfitano A, Chen YT, **Kishnani PS**, Miller C, Kelley R. Dubowitz syndrome: a defect in the cholesterol biosynthetic pathway? *Am J Med Genet*. 1999 Oct 29; 86(5):503-4. PMID: 10508998
13. Ahmad A, Kahler SG, **Kishnani PS**, Artigas-Lopez M, Pappu AS, Steiner R, Millington DS, Van Hove JL. Treatment of pyruvate carboxylase deficiency with high doses of citrate and aspartate. *Am J Med Genet*. 1999 Dec 3; 87(4):331-8. PMID: 10588840
14. Shaiu WL, **Kishnani PS**, Shen J, Liu HM, Chen YT. Genotype-phenotype correlation in two frequent mutations and mutation update in type III glycogen storage disease. *Mol Genet Metab*. 2000 Jan; 69(1):16-23. PMID: 10655153
15. Van Hove JL, **Kishnani PS**, Demaerel P, Kahler SG, Miller C, Jaeken J, Rutledge SL. Acute hydrocephalus in nonketotic hyperglycemia. *Neurology*. 2000 Feb 8; 54(3):754-6. PMID: 10680820

16. **Kishnani PS**, Spiridigliozzi GA, Heller JH, Sullivan JA, Doraiswamy PM, Krishnan KR. Donepezil for Down's syndrome. *Am J Psychiatry*. 2001 Jan; 158(1):143. PMID: 11136652
17. **Kishnani PS**, Faulkner E, VanCamp S, Jackson M, Brown T, Boney A, Koeberl D, Chen YT. Canine model and genomic structural organization of glycogen storage disease type Ia (GSD Ia). *Vet Pathol*. 2001 Jan; 38(1):83-91. PMID: 11199168
18. Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, Mackey J, **Kishnani PS**, Smith W, McVie-Wylie A, Sullivan JA, Hoganson GE, Phillips JA 3rd, Schaefer GB, Charrow J, Ware RE, Bossen EH, Chen YT. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. *Genet Med*. 2001 Mar-Apr; 3(2):132-8. PMID: 11286229
19. Mackey J, Treem WR, Worley G, Boney A, Hart P, **Kishnani PS**. Frequency of celiac disease in individuals with Down syndrome in the United States. *Clin Pediatr (Phila)*. 2001 May; 40(5):249-52. PMID: 11388673
20. Beaty RM, Jackson M, Peterson D, Bird A, Brown T, Benjamin DK Jr, Juopperi T, **Kishnani PS**, Boney A, Chen YT, Koeberl DD. Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adeno-associated virus (AAV) vectors. *Gene Ther*. 2002 Aug; 9(15):1015-22. PMID: 12101432
21. Snyder MJ, Bradford WD, **Kishnani PS**, Hale LP. Idiopathic hyperammonemia following an unrelated cord blood transplant for mucopolysaccharidoses I. *Pediatr Dev Pathol*. 2003 Jan-Feb; 6(1):78-83. Epub 2002 Dec 17. PMID: 12481230
22. Koeberl DD, Young SP, Gregersen NS, Vockley J, Smith WE, Benjamin DK Jr, An Y, Weavil SD, Chaing SH, Bali D, McDonald MT, **Kishnani PS**, Chen YT, Millington DS. Rare disorders of metabolism with elevated butyryl- and isobutyryl-carnitine detected by tandem mass spectrometry newborn screening. *Pediatr Res*. 2003 Aug; 54(2):219-23. Epub 2003 May 7. PMID: 12736383
23. Heller, JH, Spiridigliozzi GA, Sullivan JA, Doraiswamy PM, Krishnan RR, **Kishnani PS**. Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial. *Am J Med Genet A*. 2003 Jan 15; 116A (2):111-6. PMID: 12494428
24. Koeberl DD, Millington DS, Smith WE, Weavil SD, Muenzer J, McCandless SE, **Kishnani PS**, McDonald MT, Chaing S, Boney A, Moore E, Frazier DM. Evaluation of 3-methylcrotonyl-CoA carboxylase deficiency detected by tandem mass spectrometry newborn screening. *J Inherit Metab Dis*. 2003; 26(1):25-35. PMID: 12872837
25. Hanna R, McDonald MT, Sullivan JA, Mackey JF, Krishnamurthy V, **Kishnani PS**. Diagnostic and treatment challenges of neuropathic Gaucher disease: two cases with an intermediate phenotype. *J Inherit Metab Dis*. 2004; 27(5):687-90. PMID: 15669686
26. Hardy O, Worley G, Lee MM, Chaing S, Mackey J, Crissman B, **Kishnani PS**. Hypothyroidism in Down syndrome: screening guidelines and testing methodology. *Am J Med Genet A*. 2004 Feb 1; 124A (4):436-7. PMID: 14735598

27. **Kishnani PS**, Sullivan JA, Spiridigliozzi GA, Heller JH, Crissman BG. Donepezil use in Down syndrome. *Arch Neurol.* 2004 Apr; 61(4):605-6. PMID: 15096417
28. **Kishnani PS**, Howell RR. Pompe disease in infants and children. *J Pediatr.* 2004 May; 144(5 Suppl):S35-43. PMID: 15126982
29. Ing RJ, Cook DR, Bengur RA, Williams EA, Eck J, Dear Gde L, Ross AK, Kern FH, **Kishnani PS**. Anesthetic management of infants with glycogen storage disease type II: a physiological approach. *Paediatr Anaesth.* 2004 Jun; 14(6):514-9. PMID: 15153218
30. Worley G, Shbarou R, Heffner AN, Belsito KM, Capone GT, **Kishnani PS**. New onset focal weakness in children with Down syndrome. *Am J Med Genet A.* 2004 Jul 1; 128A (1):15-8. PMID: 15211649
31. Hunley TE, Corzo D, Dudek M, **Kishnani PS**, Amalfitano A, Chen YT, Richards SM, Phillips JA 3rd, Fogo AB, Tiller GE. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. *Pediatrics.* 2004 Oct; 114(4):e532-5. PMID: 15466083
32. Heller JH, Spiridigliozzi GA, Doraiswamy PM, Sullivan JA, Crissman BG, **Kishnani PS**. Donepezil effects on language in children with Down syndrome: result of the first 22-week pilot clinical trial. *Am J Med Genet A.* 2004 Oct 15; 130A (3):325-6. PMID: 15378553
33. Franco LM, Krishnamurthy V, Bali D, Weinstein DA, Arn P, Clary B, Boney A, Sullivan J, Frush DP, Chen YT, **Kishnani PS**. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. *J Inherit Metab Dis.* 2005; 28(2):153-62. PMID: 15877204
34. Van Hove JL, Vande Kerckhove K, Hennermann JB, Mahieu V, Declercq P, Mertens S, De Becker M, **Kishnani PS**, Jaeken J. Benzoate treatment and the glycine index in nonketotic hyperglycinemia. *J Inherit Metab Dis.* 2005; 28(5):651-63. PMID: 16151895
35. Goker-Alpan O, Hruska KS, Orvisky E, **Kishnani PS**, Stubblefield BK, Schiffmann R, Sidransky E. Divergent phenotypes in Gaucher disease implicate the role of modifiers. *J Med Genet.* 2005 Jun; 42(6):e37. PMID: 15937077
36. An Y, Young SP, **Kishnani PS**, Millington DS, Amalfitano A, Corz D, Chen YT. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. *Mol Genet Metab.* 2005 Aug; 85(4):247-54. PMID: 15886040
37. Quigley DI, McDonald MT, Krishnamuthy V, **Kishnani PS**, Lee MM, Haqq AM, Goodman BK. Triploid mosaicism in a 45,X/69,XXY infant. *Am J Med Genet A.* 2005 Oct 1; 138A (2):171-4. PMID: 16152633
38. Smith W, **Kishnani PS**, Lee B, Singh RH, Rhead WJ, Sniderman King L, Smith M, Summar M. Urea cycle disorders: clinical presentation outside the newborn period. *Crit Care Clin.* 2005 Oct; 21(4 Suppl):S9-17. Review. PMID: 16227115
39. **Kishnani PS**, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, Crowley JF, Downs S, Howell RR, Kravitz RM, Mackey J, Marsden D, Martins AM, Millington DS, Nicolino M, O'Grady G, Patterson MC, Rapoport DM, Slonim A, Spencer CT, Tiff CJ, Watson MS. Pompe disease diagnosis and management guideline. *Genet Med.* 2006 May; 8(5):267-88. Erratum in: *Genet Med.* 2006 Jun;

- 8(6):382. ACMG Work Group of Management of Pompe Disease (removed); Case, Laura (corrected to Case, Laura E). PMID: 16702877
40. Howell RR, Byrne B, Darras BT, **Kishnani PS**, Nicolino M, van der Ploeg A. Diagnostic challenges for Pompe disease: an under recognized cause of floppy baby syndrome. *Genet Med.* 2006 May; 8(5):289-96. PMID: 16702878
 41. Ansong AK, Li JS, Nozik-Grayck E, Ing R, Kravitz RM, Idriss SF, Kanter RJ, Rice H, Chen YT, **Kishnani PS**. Electrocardiographic response to enzyme replacement therapy for Pompe disease. *Genet Med.* 2006 May; 8(5):297-301. PMID: 16702879
 42. Zhang H, Kallwass H, Young SP, Carr C, Dai J, **Kishnani PS**, Millington DS, Keutzer J, Chen YT, Bali D. Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease. *Genet Med.* 2006 May; 8(5):302-6. PMID: 16702880
 43. Jack RM, Gordon C, Scott CR, **Kishnani PS**, Bali D. The use of acarbose inhibition in the measurement of acid alpha-glucosidase activity in blood lymphocytes for the diagnosis of Pompe disease. *Genet Med.* 2006 May; 8(5):307-12. PMID: 16702881
 44. Cook AL, **Kishnani PS**, Carbonic MP, Kanter RJ, Chen YT, Ansong AK, Kravitz RM, Rice H, Li JS. Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease. *Genet Med.* 2006 May; 8(5):313-7. PMID: 16702882
 45. Case LE, **Kishnani PS**. Physical therapy management of Pompe disease. *Genet Med.* 2006 May; 8(5):318-27. Review. PMID: 16702883
 46. **Kishnani PS**, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D; Infantile-Onset Pompe Disease Natural History Study Group. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. *J Pediatr.* 2006 May; 148(5):671-676. PMID: 16737883
 47. **Kishnani PS**, Nicolino M, Voit T, Rogers RC, Tsai AC, Waterson J, Herman GE, Amalfitano A, Thurberg BL, Richards S, Davison M, Corzo D, Chen YT. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. *J Pediatr.* 2006 Jul; 149(1):89-97. PMID: 16860134
 48. Heller JH, Spiridigliozzi GA, Crissman BG, Sullivan-Saarela JA, Li JS, **Kishnani PS**. Clinical trials in children with Down syndrome: issues from a cognitive research perspective. *Am J Med Genet C Semin Med Genet.* 2006 Aug 15; 142C (3):187-95. Review. PMID: 16838317
 49. Crissman BG, Worley G, Roizen N, **Kishnani PS**. Current perspective on Down syndrome: selected medical and social issues. *Am J Med Genet C Semin Med Genet.* 2006 Aug 15; 142C (3):127-30. Review. PMID: 17048353
 50. Dixon N, **Kishnani PS**, Zimmerman S. Clinical manifestations of hematologic and oncologic disorders in patients with Down syndrome. *Am J Med Genet C Semin Med Genet.* 2006 Aug 15; 142C (3):149-57. Review. PMID: 17048354

51. Thurberg BL, Lynch Maloney C, Vaccaro C, Afonso K, Tsai AC, Bossen E, **Kishnani PS**, O'Callaghan M. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. *Lab Invest.* 2006 Dec; 86(12):1208-20. Epub 2006 Oct 30. PMID: 17075580
52. Heller JH, Spiridigliozzi GA, Crissman BG, Sullivan JA, Eells RL, Li JS, Doraiswamy PM, Krishnan KR, **Kishnani PS**. Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study. *J Child Adolesc Psychopharmacol.* 2006 Dec; 16(6):755-65. PMID: 17201619
53. **Kishnani PS**, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M, Li J, Dumontier J, Halberthal M, Chien YH, Hopkin R, Vijayaraghavan S, Gruskin D, Bartholomew D, van der Ploeg A, Clancy JP, Parini R, Morin G, Beck M, De la Gastine GS, Jokic M, Thurberg B, Richards S, Bali D, Davison M, Worden MA, Chen YT, Wraith JE. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. *Neurology.* 2007 Jan 9; 68(2):99-109. Epub 2006 Dec 6. Erratum in: *Neurology.* 2008 Nov 18; 71(21):1748. PMID: 17151339
54. Demo E, Frush D, Gottfried M, Koepke J, Boney A, Bali D, Chen YT, **Kishnani PS**. Glycogen storage disease type III-hepatocellular carcinoma a long-term complication? *J Hepatol.* 2007 Mar; 46(3):492-8. Epub 2006 Nov 9. Review. PMID: 17196294
55. Kallwass H, Carr C, Gerrein J, Titlow M, Pomponio R, Bali D, Dai J, **Kishnani PS**, Skrinar A, Corzo D, Keutzer J. Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots. *Mol Genet Metab.* 2007 Apr; 90(4):449-52. Epub 2007 Jan 31. Erratum in: *Mol Genet Metab.* 2007 Nov; 92(3):285. PMID: 17270480
56. Koeberl DD, **Kishnani PS**, Chen YT. Glycogen storage disease types I and II: treatment updates. *J Inherit Metab Dis.* 2007 Apr; 30(2):159-64. Epub 2007 Feb 16. Review. PMID: 17308886
57. Case LE, Hanna R, Frush DP, Krishnamurthy V, DeArme S, Mackey J, Boney A, Morgan C, Corzo D, Bouchard S, Weber TJ, Chen YT, **Kishnani PS**. Fractures in children with Pompe disease: a potential long-term complication. *Pediatr Radiol.* 2007 May; 37(5):437-45. Epub 2007 Mar 7. PMID: 17342521
58. Spiridigliozzi GA, Heller JH, Crissman BG, Sullivan-Saarela JA, Eells, R, Dawson D, Li J, **Kishnani PS**. Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series. *Am J Med Genet A.* 2007 Jul 1; 143A (13):1408-13. PMID: 17542008
59. Wang LY, Ross AK, Li JS, Dearme SM, Mackey, JF, Worden M, Corzo D, Morgan C, **Kishnani PS**. Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series. *Paediatr Anaesth.* 2007 Aug; 17(8):738-48. PMID: 17596219
60. Krishnamurthy V, Eschrich K, Boney A, Sullivan J, McDonald M, **Kishnani PS**, Koeberl DD. Three successful pregnancies through dietary management of fructose-1,6-bisphosphatase deficiency. *J Inherit Metab Dis.* 2007 Oct; 30(5):819. Epub 2007 Aug 20. PMID: 17705024
61. Raben N, Takikita S, Pittis Mg, Bembi B, Marie SK, Roberts A, Page L, **Kishnani PS**, Schoser BG,

- Chien YH, Ralston E, Nagaraju K, Plotz PH. Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand... *Autophagy*. 2007 Nov-Dec; 3(6):546-52. Epub 2007 Jun 15. PMID: 17592248
62. Reddy SK, **Kishnani PS**, Sullivan JA, Koeberl DD, Desai DM, Skinner MA, Rice HE, Clary BM. Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia. *J Hepatol*. 2007 Nov; 47(5):658-63. Epub 2007 Jun 18. PMID: 17637480
63. Smith WE, Sullivan-Saarela JA, Li JS, Cox GF, Corzo D, Chen YT, **Kishnani PS**. Sibling phenotype concordance in classical infantile Pompe disease. *Am J Med Genet A*. 2007 Nov 1; 143A (21):2493-501. Review. PMID: 17705024
64. Sun B, Bird A, Young SP, **Kishnani PS**, Chen YT, Koeberl DD. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. *Am J Hum Genet*. 2007 Nov; 81(5):1042-9. Epub 2007 Sep 21. PMID: 17924344
65. Kemper AR, Hwu WL, Lloyd-Puryear M, **Kishnani PS**. Newborn screening for Pompe disease: synthesis of the evidence and development of screening recommendations. *Pediatrics*. 2007 Nov; 120(5):e1327-34. Review. PMID: 17974725
66. Pompe Disease Diagnostic Working Group, Winchester B, Bali D, Bodamer OA, Caillaud C, Christensen E, Cooper A, Cupler E, Deschauer M, Fumic K, Jackson M, **Kishnani PS**, Lacerda L, Ledvinova J, Lugowska A, Lukacs Z, Maire I, Mandel H, Mengel E, Muller-Felber W, Piraud M, Reuser A, Rupar T, Sinigerska I, Szlago M, Verheijen F, van Diggelen OP, Wuyts B, Zakharova E, Keutzer J. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. *Mol Genet Metab*. 2008 Mar; 93(3):275-81. Epub 2007 Dec 19. PMID: 18078773
67. Koeberl DD, Pinto C, Sun B, Li S, Kozink DM, Benjamin DK Jr, Demaster AK, Kruse MA, Vaughn V, Hillman S, Bird A, Jackson M, Brown T, **Kishnani PS**, Chen YT. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. *Mol Ther*. 2008 Apr; 16(4):665-72. Doi: 10.1038/mt.2008.15. Epub 2008 Mar 11. PMID: 18362924
68. Kroos M, Pomponio RJ, van Vliet L, Palmer RE, Phipps M, Van der Helm R, Halley D, Reuser A; GAA Database Consortium. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. *Hum Mutat*. 2008 June; 29(6):E13-26. Doi: 10.1002/humu.20745. PMID: 18425781
69. McDowell R, Li JS, Benjamin DK Jr, Morgan C, Becker A, **Kishnani PS**, Kanter RJ. Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease. *Genet Med*. 2008 Oct; 10(10):758-62. Doi: 10.1097/GIM.0b013e318183722f. PMID: 18813140
70. Levine JC, **Kishnani PS**, Chen YT, Herlong JR, Li JS. Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease. *Pediatr Cardiol*. 2008 Nov; 29(6):1033-42. Doi: 10.1007/s00246-008-9267-3. Epub 2008 Jul 26. PMID: 18661169
71. Case LE, Koeberl DD, Young SP, Bali D, DeArmev SM, Mackey J, **Kishnani PS**. Improvement with ongoing Enzyme Replacement Therapy in advanced late-onset Pompe disease: a case study. *Mol Genet*

- Metab. 2008 Dec; 95(4):233-5. Doi: 10.1016/j.ymgme.2008.09.001. Epub 2008 Oct 18. PMID: 18930676
72. Mendelsohn NJ, Messinger YH, Rosenberg AS, **Kishnani PS**. Elimination of antibodies to recombinant enzyme in Pompe's disease. *N Engl J Med*. 2009 Jan 8; 360(2):194-5. Doi: 10.1056/NEJMc0806809. PMID: 19129538
73. Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR, Arnold GL, Pivnick EK, Ottinger CJ, Robinson PH, Loo JC, Smitka M, Jardine P, Tato L, Chabrol B, McCandless S, Kimura S, Mehta L, Bali D, Skrinar A, Morgan C, Rangachari L, Corzo D, **Kishnani PS**. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. *Genet Med*. 2009 Mar; 11(3):210-9. Doi: 10.1097/GIM.0b013e31819d0996. PMID: 19287243
74. **Kishnani PS**, DiRocco M, Kaplan P, Mehta A, Pastores GM, Smith SE, Puga AC, Lemay RM, Weinreb NJ. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type I. *Mol Genet Metab*. 2009 Apr; 96(4):164-70. Doi: 10.1016/j.ymgme.2008.12.015. Epub 2009 Feb 4. PMID: 19195916
75. Young SP, Zhang H, Corzo D, Thurberg BL, Bali D, **Kishnani PS**, Millington DS. Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker. *Genet Med*. 2009 Jul; 11(7):536-41. Doi: 10.1097/GIM.0b013e3181a87867. PMID: 19521244
76. Goldstein JL, Young SP, Changela M, Dickerson GH, Zhang H, Dai J, Peterson D, Millington DS, **Kishnani PS**, Bali DS. Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory. *Muscle Nerve*. 2009 Jul; 40(1):32-6. Doi: 10.1002/mus.21376. PMID: 19533645
77. Mozaffar T, Al-Lozi MT, Barohn RJ, Amato AA, Cupler EJ, Leshner RT, **Kishnani, PS**, American Association of Neuromuscular & Electrodiagnostic Medicine. Diagnostic criteria for late-onset (childhood and adult) Pompe disease. *Muscle Nerve*. 2009 Jul; 40(1):149-60. Doi: 10.1002/mus.21393. PMID: 19533647
78. Koeberl DD, **Kishnani PS**, Bali D, Chen YT. Emerging therapies for glycogen storage disease type I. *Trends Endocrinol Metab*. 2009 Jul; 20(5):252-8. Doi: 10.1016/j.tem.2009.02.003. Epub 2009 Jun 21. Review. PMID: 19541498
79. **Kishnani PS**, Sommer BR, Handen BL, Seltzer B, Capone GT, Spirdigliozzi GA, Heller JH, Richardson S, McRae T. The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. *Am J Med Genet A*. 2009 Aug; 149A (8):1641-54. Doi: 10.1002/ajmg.a.32953. PMID: 19606472
80. **Kishnani PS**, Corzo D, Leslie ND, Gruskin D, Van der Ploeg A, Clancy JP, Parini R, Morin G, Beck M, Bauer MS, Jokic M, Tsai CE, Tsai BW, Morgan C, O'Meara T, Richards S, Tsao EC, Mandel H. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. *Pediatr*

- Res. 2009 Sep; 66(3):329-35. Doi: 10.1203/PDR.0b13e3181b24e94. PMID: 19542901
81. Reddy SK, Austin SL, Spencer-Manzon M, Koeberl DD, Clary BM, Desai DM, Smith AD, **Kishnani PS**. Liver transplantation for glycogen storage disease type Ia. *J Hepatol*. 2009 Sep; 51(3):483-90. Doi: 10.1016/j.jhep.2009.05.026. Epub 2009 Jun 17. PMID: 19596478
 82. Skotko BG, Capone GT, **Kishnani PS**; Down Syndrome Diagnosis Study Group. Postnatal diagnosis of Down syndrome: synthesis of the evidence of how best to deliver the news. *Pediatrics*. 2009 Oct; 124(4):e751-8. Doi: 10.1542/peds.2009-0480. Epub 2009 Sep 28. Review. PMID: 19786436
 83. Skotko BG, **Kishnani PS**, Capone GT; Down Syndrome Diagnosis Study Group. Prenatal diagnosis of Down syndrome: how best to deliver the news. *Am J Med Genet A*. 2009 Nov; 149A (11):2361-7. Doi: 10.1002/ajmg.a.33082. PMID: 19787699
 84. Koeberl DD, **Kishnani PS**. Immunomodulatory gene therapy in lysosomal storage disorders. *Curr Gene Ther*. 2009 Dec; 9(6):503-10. Review. PMID: 19807648
 85. **Kishnani PS**, Chuang TP, Bali D, Koeberl D, Austin S, Weinstein DA, Murphy E, Chen YT, Boyette K, Liu CH, Chen YT, Li LH. Chromosomal and genetic alterations in human hepatocellular adenomas associated with type Ia glycogen storage disease. *Hum Mol Genet*. 2009 Dec 15; 18(24):4781-90. Doi: 10.1093/hmg/ddp441. Epub 2009 Sep 16. PMID: 19762333
 86. **Kishnani PS**, Goldenberg PC, DeArme SL, Heller J, Benjamin D, Young S, Bali D, Smith SA, Li JS, Mandel H, Koeberl D, Rosenberg A, Chen YT. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. *Mol Genet Metab*. 2010 Jan; 99(1):26-33. Doi: 10.1016/j.ymgme.2009.08.003. PMID: 19775921
 87. Yanovitch TL, Banugaria SG, Proia AD, **Kishnani PS**. Clinical and histologic ocular findings in Pompe disease. *J Pediatr Ophthalmol Strabismus*. 2010 Jan-Feb; 47(1):34-40. Doi: 10.3928/01913913-20100106-08. Epub 2010 Jan 21. Review. PMID: 20128552
 88. Sun B, Kulis MD, Young SP, Hobeika AC, Li S, Bird A, Zhang H, Li Y, Clay TM, Burks W, **Kishnani PS**, Koeberl DD. Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine Pompe disease. *Mol Ther*. 2010 Feb; 18(2):353-60. Doi: 10.1038/mt.2009.195. Epub 2009 Aug 18. PMID: 19690517
 89. Scales CD Jr, Chandrashekar AS, Robinson MR, Canto DA, Sullivan J, Haleblan GE, Leitao VA, Sur RL, Borawski KM, Koeberl D, **Kishnani PS**, Preminger GM. Stone forming risk factors in patients with type Ia glycogen storage disease. *J Urol*. 2010 Mar; 183(3):1022-5. Doi: 10.1016/j.juro.2009.11.040. Epub 2010 Jan 21. PMID: 20092831
 90. Banugaria SG, Austin SL, Boney A, Weber TJ, **Kishnani PS**. Hypovitaminosis D in glycogen storage disease type I. *Mol Genet Metab*. 2010 Apr; 99(4):434-7. Doi: 10.1016/j.ymgme.2009.12.012. Epub 2009 Dec. 21. PMID: 20060350
 91. Van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, **Kishnani PS**, Laforet P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, Park DJ, Pestronk A, Rosenbloom B, Skrinar A, van Capelle CI, van der Beek NA, Wasserstein M, Zivkovic SA. A

- randomized study of alglucosidase alfa in late-onset Pompe's disease. *N Engl J Med.* 2010 Apr 15; 362(15):1396-406. Doi: 10.1056/NEJMoa0909859. PMID: 20393176
92. Yanovitch TL, Casey R, Banugaria SG, **Kishnani PS**. Improvement of bilateral ptosis on higher dose enzyme replacement therapy in Pompe disease. *J Neurophthalmol.* 2010 Jun; 30(2):165-6. Doi: 10.1097/WNO.0b013e3181ce162a. PMID: 20404746
93. Hobson-Webb LD, Austin SL, Bali DS, **Kishnani PS**. The electrodiagnostic characteristics of Glycogen Storage Disease Type III. *Genet Med.* 2010 Jul; 12(7):440-5. Doi: 10.1097/GIM.0b013e3181cd735b. PMID: 20071996
94. Vertilus SM, Austin SL, Foster KS, Boyette KE, Bali DS, Li JS, **Kishnani PS**, Wechsler SB. Echocardiographic manifestations of Glycogen Storage Disease III: increase in wall thickness and left ventricular mass over time. *Genet Med.* 2010 Jul; 12(7):413-23. Doi: 10.1097/GIM.0b013e3181e0e979. PMID: 20526204
95. **Kishnani PS**, Austin SL, Arn P, Bali DS, Boney A, Case LE, Chung WK, Desai DM, El-Gharbawy A, Haller R, Smit GP, Smith AD, Hobson-Webb LD, Wechsler SB, Weinstein DA, Watson MS; ACMG. Glycogen storage disease type III diagnosis and management guidelines. *Genet Med.* 2010 Jul; 12(7):446-63. Doi: 10.1097/GIM.0b013e3181e6556b6. Erratum in: *Genet Med.* 2010 Sep; 12(9):566. PMID: 20631546
96. Goldstein JL, Austin SL, Boyette K, Kanaly A, Veerapandiyan A, Rehder C, **Kishnani PS**, Bali DS. Molecular analysis of the AGL gene: identification of 25 novel mutations and evidence of genetic heterogeneity in patients with Glycogen Storage Disease Type III. *Genet Med.* 2010 Jul; 12(7):424-30. Doi: 10.1097/GIM.0b013e3181d94eaa. PMID: 20648714
97. Jones HN, Muller CW, Lin M, Banugaria SG, Case LE, Li JS, O'Grady G, Heller JH, **Kishnani PS**. Oropharyngeal dysphagia in infants and children with infantile Pompe disease. *Dysphagia.* 2010 Dec; 25(4):277-83. Doi: 10.1007/s00455-009-9252-x. Epub 2009 Sep 10. PMID: 19763689
98. Dixon NE, Crissman, BG, Smith PB, Zimmerman SA, Worley G, **Kishnani PS**. Prevalence of iron deficiency in children with Down syndrome. *J Pediatr.* 2010 Dec; 157(6):967-971.e1. doi: 10.1016/j.jpeds.2010.06.011. Epub 2010 Jul 21. PMID: 20650467
99. Barker PC, Pasquali SK, Darty S, Ing RJ, Li JS, Kim RJ, DeArme S, **Kishnani PS**, Campbell MJ. Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy. *Mol Genet Metab.* 2010 Dec; 101(4):332-7. Doi: 10.1016/j.ymgme.2010.07.011. Epub 2010 Jul 23. PMID: 20875764
100. **Kishnani PS**, Heller JH, Spiridigliozzi GA, Lott I, Escobar L, Richardson S, Zhang R, McRae T. Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. *Am J Med Genet A.* 2010 Dec; 152A (12):3028-35. Doi: 10.1002/ajmg.a.33730. PMID: 21108390
101. Yanovitch T, Wallace DK, Freedman SF, Enyedi LB, **Kishnani PS**, Worley G, Crissman B, Burner E, Young TL. The accuracy of photo screening at detecting treatable ocular conditions in children with Down syndrome. *J AAPOS.* 2010 Dec; 14(6):472-7. Doi: 10.1016/j.jaapos.2010.09.016. PMID:

21168069

102. Heller JH, Spiridigliozzi GA, Crissman BG, McKillop JA, Yamamoto H, **Kishnani PS**. Safety and efficacy of rivastigmine in adolescents with Down syndrome: long-term follow-up. *J Child Adolesc Psychopharmacol*. 2010 Dec; 20(6):517-20. Doi: 10.1089/cap.2009.0099. PMID: 21186971
103. El-Gharbawy AH, Boney A, Young SP, **Kishnani PS**. Follow-up of a child with pyruvate dehydrogenase deficiency on a less restrictive ketogenic diet. *Mol Genet Metab*. 2011 Feb; 102(2):214-5. Doi: 10.1016/j.ymgme.2010.11.011. Epub 2010 Nov 9. PMID: 21130013
104. Byrne BJ, **Kishnani PS**, Case LE, Merlini L, Muller-Felber W, Prasad S, van der Ploeg A. Pompe disease: design, methodology, and early findings from the Pompe Registry. *Mol Genet Metab*. 2011 May; 103(1):1-11. Epub 2011 Feb 11. Erratum in: *Mol Genet Metab*. 2011 Nov; 104(3):424. PMID: 21439876
105. Bali DS, Tolun AA, Goldstein JL, Dai J, **Kishnani PS**. Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid a-glucosidase activity. *Muscle Nerve*. 2011 May; 43(5):665-70. Doi: 10.1002/mus.21933. PMID: 21484825
106. Wang RY, Bodamer OA, Watson MS, Wilcox WR; ACMG Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. *Genet Med*. 2011 May; 13(5):457-84. Doi: 10.1097/GIM.0b013e318211a7e1. PMID: 21502868
107. Forsha D, Li JS, Smith PB, van der Ploeg AT, **Kishnani PS**, Pasquali SK; Late-Onset Treatment Study Investigators. Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy. *Genet Med*. 2011 Jul; 13(7):625-31. Doi: 10.1097/GIM.0b013e3182142966. PMID: 21543987
108. El-Gharbawy AH, Bhat G, Murillo JE, Thurberg BL, Kampmann C, Mengel KE, **Kishnani PS**. Expanding the clinical spectrum of late-onset Pompe disease: dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncovered. *Mol Genet Metab*. 2011 Aug; 103(4):362-6. Doi: 10.1016/j.ymgme.2011.04.009. Epub 2011 May 5. PMID: 21605996
109. Banugaria SG, Prater SN, Ng YK, Kobori JA, Finkel RS, Ladda RL, Chen YT, Rosenberg AS, **Kishnani PS**. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. *Genet Med*. 2011 Aug; 13(8):729-36. Doi: 10.1087/GIM.0b013e3182174703. PMID: 21637107
110. El-Gharbawy AH, Mackey J, DeArme S, Westby G, Grinnell SG, Malovrh P, Conway R, **Kishnani PS**. An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions. *Mol Genet Metab*. 2011 Sep-Oct; 104(1-2):118-22. Doi: 10.1016/j.ymgme/2011.07.004. Epub 2011 Jul 13. PMID: 21802969
111. Nagral A, Mewawalla P, Jagadeesh S, Kabra M, Phadke SR, Verma IC, Puri RD, Gupta N, **Kishnani PS**, Mistry PK. Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India. *Indian Pediatr*. 2011 Oct; 48(10):779-84. PMID: 22080680

112. Hobson-Webb LD, Dearmey S, **Kishnani PS**. The Clinical and electrodiagnostic characteristics of Pompe disease with post-enzyme replacement therapy findings. *Clin Neurophysiol*. 2011 Nov; 122(11):2312-7. Doi: 10.1016/j.clinph.2011.04.016. Epub 2011 May 13. Review. PMID: 21570905
113. Jones HN, Moss T, Edwards L, **Kishnani PS**. Increased inspiratory and expiratory muscle strength following respiratory muscle strength training (RMST) in two patients with late-onset Pompe disease. *Mol Genet Metab*. 2011 Nov; 104(3):417-20. Doi: 10.1016/j.ymgme.2011.05.006. Epub 2011 May 27. PMID: 21641843
114. Abbott MA, Prater SN, Banugaria SG, Richards SM, Young SP, Rosenberg AS, **Kishnani PS**. Atypical immunologic response in a patient with CRIM-negative Pompe disease. *Mol Genet Metab*. 2011 Dec; 104(4):583-6. Doi: 10.1016/j.ymgme.2011.08.003. Epub 2011 Aug 11. PMID: 21889385
115. Achouitar S, Goldstein JL, Mohamed M, Austin S, Boyette K, Blanpain FM, Rehder CW, **Kishnani PS**, Wortmann SB, den Heijer M, Lefeber DJ, Wevers RA, Bali DS, Morava E. Common mutation in the PHKA2 gene with variable phenotype in patients with liver phosphorylase b kinase deficiency. *Mol Genet Metab*. 2011 Dec;104(4):691-4. Doi: 10.1016/j.ymgme.2011.08.021. Epub 2011 Aug 26. PMID: 21911307
116. Roberts M, **Kishnani PS**, van der Ploeg AT, Muller-Felber W, Merlini L, Prasad S, Case LE. The prevalence and impact of scoliosis in Pompe disease: lessons learned from the Pompe Registry. *Mol Genet Metab*. 2011 Dec; 104(4):574-82. Doi: 10.1016/j.ymgme.2011.08.011. Epub 2011 Aug 16. PMID: 21930409
117. Dubrovsky A, Corderi J, Lin M, **Kishnani PS**, Jones HN. Expanding the phenotype of late-onset Pompe disease; tongue weakness: a new clinical observation. *Muscle Nerve*. 2011 Dec; 44(6):897-901. Doi: 10.1002/mus.22202. Epub 2011 Sep 26. PMID: 21953123
118. Messinger YH, Mendelsohn NJ, Rhead W, Dimmock D, Hershkovitz E, Champion M, Jones SA, Olson R, White A, Wells C, Bali D, Case LE, Young SP, Rosenberg AS, **Kishnani PS**. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. *Genet Med*. 2012 Jan; 14(1):135-42. Doi: 10.1038/gim.2011.4. PMID: 22237443
119. Bashir MR, Merkle EM, **Kishnani PS**. Challenges in screening for hepatocellular carcinoma in the glycogen storage disease type Ia population. *Intern Med*. 2012; 51(13):1811. Epub 2012 Jul 1. PMID: 22790156
120. Austin SL, Proia AD, Spencer-Manzon MJ, Butany J, Wechsler SB, **Kishnani PS**. Cardiac Pathology in Glycogen Storage Disease Type III. *JIMD Rep*. 2012; 6:65-72. Doi: 10.1007/8904_2011_118. Epub 2012 Jan 31. PMID: 23430941
121. Koeberl DD, Li S, Dai J, Thurberg BL, Bali D, **Kishnani PS**. β 2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. *Mol Genet Metab*. 2012 Feb; 105(2):221-7. Doi: 10.1016/j.ymgme.2011.11.005. Epub 2011 Nov 11. PMID: 22154081
122. Hobson-Webb LD, **Kishnani PS**. How common is misdiagnosis in late-onset Pompe disease? *Muscle Nerve*. 2012 Feb; 45(2):301-2. Doi: 10.1002/mus.22293. PMID: 22246895

123. Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, **Kishnani PS**. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. *Am J Med Genet C Semin Med Genet*. 2012 Feb 15; 160(1):40-9. Doi: 10.1002/ajmg.c.31319. Epub 2012 Jan 17. PMID: 22252923
124. Young SP, Piraud M, Goldstein JL, Zhang H, Rehder C, Laforet P, **Kishnani PS**, Millington DS, Bashir MR, Bali DS. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques. *Am J Med Genet C Semin Med Genet*. 2012 Feb 15; 160(1):50-8. Doi: 10.1002/ajmg.c.31320. Epub 2012 Jan 17. PMID: 22252961
125. Case LE, Beckemeyer AA, **Kishnani PS**. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations. *Am J Med Genet C Semin Med Genet*. 2012 Feb 15; 160(1):69-79. Doi: 10.1002/ajmg.c.31321. Epub 2012 Jan 17. Review. PMID: 22252989
126. Spiridigliozzi GA, Heller JH, **Kishnani PS**. Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up. *Am J Med Genet C Semin Med Genet*. 2012 Feb 15; 160(1):22-9. Doi: 10.1002/ajmg.c.31323. Epub 2012 Jan 17. PMID: 22253038
127. **Kishnani PS**, Beckemeyer AA, Mendelsohn NJ. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management. *Am J Med Genet C Semin Med Genet*. 2012 Feb 15; 160C (1):1-7. Doi: 10.1002/ajmg.c.31324. Epub 2012 Jan 17. PMID: 22253049
128. Spiridigliozzi GA, Heller JH, Case LE, Jones HN, **Kishnani PS**. Early cognitive development in children with infantile Pompe disease. *Mol Genet Metab*. 2012 Mar; 105(3):428-32. Doi: 10.1016/j.ymgme.2011.10.012. Epub 2011 Oct 28. PMID: 22217428
129. Banugaria SG, Patel TT, Mackey J, Das S, Amalfitano A, Rosenberg AS, Charrow J, Chen YT, **Kishnani PS**. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. *Mol Genet Metab*. 2012 Apr; 105(4):677-80. Doi: 10.1016/j.ymgme.2012.01.019. Epub 2012 Jan 28. PMID: 22365055
130. Patel TT, Banugaria SG, Case LE, Wenninger S, Schoser B, **Kishnani PS**. The impact of antibodies in late-onset Pompe disease: A case series and literature review. *Mol Genet Metab*. 2012 Jul; 106(3):301-9. Doi: 10.1016/j.ymgme.2012.04.027. Epub 2012 May 9. PMID: 22613277
131. Hobson-Webb LD, Proia AD, Thurberg BL, Banugaria S, Prater SN, **Kishnani PS**. Autopsy findings in late-onset Pompe disease: A case report and systematic review of the literature. *Mol Genet Metab*. 2012 Aug; 106(4):462-9. Doi: 10.1016/j.ymgme.2012.05.007. Epub 2012 May 18. Review. PMID: 22664150
132. Banugaria, SG, Patel TT, **Kishnani PS**. Immune modulation in Pompe disease treated with enzyme replacement therapy. *Expert Rev Clin Immunol*. 2012 Aug; 8(6):497-9. PMID: 229921401

133. Prater SN, Banugaria SG, Dearmey SM, Botha EG, Stege EM, Case LE, Jones HN, Phornphutkul C, Wang RY, Young SP, **Kishnani PS**. The emerging phenotype of long-term survivors with infantile Pompe disease. *Genet Med*. 2012 Sep; 14(9):800-10. Doi: 10.1038/gim.2012.44. Epub 2012 Apr 26. PMID: 22538254
134. Wang DQ, Carreras CT, Fiske LM, Austin S, Boree D, **Kishnani PS**, Weinstein DA. Characterization and pathogenesis of anemia in glycogen storage disease type Ia and Ib. *Genet Med*. 2012 Sep; 14(9):795-9. Doi: 10.1038/gim.2012.41. Epub 2012 Jun 7. PMID: 22678084
135. Yi H, Thurberg BL, Curtis S, Austin S, Fyfe J, Koeberl DD, **Kishnani PS**, Sun B. Characterization of a canine model of glycogen storage disease type IIIa. *Dis Model Mech*. 2012 Nov; 5(6):804-11. Doi: 10.1242/dmm.009712. Epub 2012 Jun 26. PMID: 22736456
136. van der Ploeg AT, Barohn R, Carlson L, Charrow J, Clemens PR, Hopkin RJ, **Kishnani PS**, Laforet P, Morgan C, Nations S, Pestronk A, Plotkin H, Rosenbloom BE, Sims KB, Tsao E. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. *Mol Genet Metab*. 2012 Nov; 107(3):456-61. Doi: 10.1016/j.ymgme.2012.09.015. Epub 2012 Sep 17. PMID: 23031366
137. Horvath JJ, Austin SL, Jones HN, Drake EJ, Case LE, Soher BJ, Bashir MR, **Kishnani PS**. Bulbar muscle weakness and fatty lingual infiltration in glycogen storage disorder type IIIa. *Mol Genet Metab*. 2012 Nov; 107(3):496-500. Doi: 10.1016/j.ymgme.2012.09.025. Epub 2012 Sep 28. PMID: 23062577
138. Tolun AA, Scarbrough PM, Zhang H, McKillop JA, Wang F, **Kishnani PS**, Millington DS, Young SP, Il'yasova D. Systemic oxidative stress, as measured by urinary allantoin and F(2)-isoprostanes, is not increased in Down syndrome. *Ann Epidemiol*. 2012 Dec; 22(12):892-4. Doi: 10.1016/j.annepidem.2012.09.005. Epub 2012 Oct 11. PMID: 23063134
139. Taylor KM, Meyers E, Phipps M, **Kishnani PS**, Cheng SH, Scheule RK, Moreland RJ. Dysregulation of multiple facets of glycogen metabolism in a murine model of Pompe disease. *PLoS One*. 2013; 8(2):e56181. Doi: 10.1371/journal.pone.0056181. Epub 2013 Feb 14. PMID: 23457523
140. Banugaria SG, Prater SN, McGann JK, Feldman JD, Tannenbaum JA, Bailey C, Gera R, Conway RL, Viskochil D, Kobori JA, Rosenberg AS, **Kishnani PS**. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. *Genet Med*. 2013 Feb; 15(2):123-31. Doi: 10.1038/gim.2012.110. Epub 2012 Oct 11. PMID: 23060045
141. Tan QK, Cheah SM, Dearmey SM, **Kishnani PS**. Low anal sphincter tone in infantile-onset Pompe Disease: An emerging clinical issue in enzyme replacement therapy patients requiring special attention. *Mol Genet Metab*. 2013 Feb; 108(2):142-4. Doi: 10.1016/j.ymgme.2012.11.013. Epub 2012 Nov 29. PMID: 23266370
142. Sun B, Fredrickson, K, Austin S, Tolun AA, Thurberg BL, Kraus WE, Bali D, Chen YT, **Kishnani PS**. Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III. *Mol Genet Metab*. 2013 Feb; 108(2):145-7. Doi: 10-1016/j.ymgme.2012.12.002. Epub 2012 Dec 27. PMID: 23318145

143. Beckemeyer AA, Mendelsohn NJ, **Kishnani, PS**. Response to the letter “How to describe the clinical spectrum in Pompe disease?” *Am J Med Genet A*. 2013 Feb; 161A (2):401-2. Doi: 10.1002/ajmg.a.35668. Epub 2013 Jan 14. PMID: 23319415
144. Ben Turkia H, Gonzalez DE, Barton NW, Zimran A, Kabra M, Lukina EA, Giraldo P, Kisinovsky I, Bavdekar A, Ben Dridi MF, Gupta N, **Kishnani PS**, Sureshkumar EK, Wang N, Crombez E, Bhirangi K, Mehta A. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. *Am J Hematol*. 2013 Mar; 88(3):179-84. Doi: 10.1002/ajh.23382. Epub 2013 Feb 9. Erratum in: *Am j Hematol*. 2013 Jul; 88(7):632. PMID: 23400823
145. Spiridigliozzi GA, Heller JH, **Kishnani PS**, Van der Ploeg AT, Ebbink BJ, Aarsen FK, van Gelder CM, Van den Hout JM. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy. *Neurology*. 2013 Mar 19; 80(12):1173. Doi: 10.1212/WNL.0b013e31828b8af0. PMID: 23509050
146. Hobson-Webb LD, Jones HN, **Kishnani PS**. Oropharyngeal dysphagia many occur in late-onset Pompe disease, implicating bulbar muscle involvement. *Neuromuscul Disord*. 2013 Apr; 23(4):319-23. Doi: 10.1016/j.nmd.2012.12.003. Epub 2013 Jan 16. PMID: 23332114
147. Patel TT, Banugaria SG, Frush DP, Enterline DS, Tanpaiboon P, **Kishnani PS**. Basilar artery aneurysm: a new finding in classic infantile Pompe disease. *Muscle Nerve*. 2013 Apr; 47(4):613-5. Doi: 10.1002/mus.23659. Epub 2013 Feb 10. PMID: 23401069
148. Brooks ED, Little D, Arumugam R, Sun B, Curtis S, Demaster A, Maranzano M, Jackson MW, **Kishnani P**, Freemark MS, Koeberl DD. Pathogenesis of growth failure and partial reversal with gene therapy in murine and canine Glycogen Storage Disease type 1a. *Mol Genet Metab*. 2013 Jun; 109(2):161-70. Doi: 10.1016/j.ymgme.2013.03.018. Epub 2013 Apr 6. PMID: 23623482
149. Prater, SN, Patel TT, Buckley, AF, Mandel H, Vlodayski, E, Banugaria SG, Feeney EF, Raben, N, **Kishnani PS**. Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy. *Orphanet J Rare Dis*. 2013 Jun 20; 8:90. Doi: 10.1186/1172-8-90. PMID: 23787031
150. Banugaria SG, Prater SN, Patel TT, Dearmey SM, Milleson C, Sheets KB, Bali DS, Rehder CW, Raiman JA, Wang RA, Labarthe F, Charrow J, Harmatz P, Chakraborty P, Rosenberg AS, **Kishnani PS**. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile Pompe disease: a step towards improving the efficacy of ERT. *PLoS One*. 2013 Jun 25; 8(6):e67052. Doi: 10.1371/journal.pone.0067052. Print 2013. PMID: 23825616
151. Krosschell KJ, Maczulski JA, Scott C, King W, Hartman JT, Case LE, Viazzo-Trussell D, Wood J, Roman CA, Hecker E, Meffert M, Leveille M, Kienitz K, Swoboda KJ, Project Cure SMA Investigators Network. Reliability and validity of the TIMPSI for infants with spinal muscular atrophy type I. *Pediatr Phys Ther*. 2013 Summer; 25(2):140-8; discussion 149. Doi: 10.1097/PEP.0b013e31828a205f. PMID: 23542189
152. Yi H, Fredrickson KB, Das S, **Kishnani PS**, Sun B. Stbd1 is highly elevated in skeletal muscle of Pompe

- disease mice but suppression of its expression does not affect lysosomal glycogen accumulation. *Mol Genet Metab.* 2013 Jul; 109(3):312-4. Doi: 10.1016/j.ymgme.2013.05.004. Epub 2013 May 18. PMID: 23726947
153. Javan R, Horvath JJ, Case LE, Austin S, Corderi J, Dubrovsky A, **Kishnani PS**, Bashir MR. Generating color-coded anatomic muscle maps for correlation of quantitative magnetic resonance imaging analysis with clinical examination in neuromuscular disorders. *Muscle Nerve.* 2013 Aug; 48(2):293-5. Doi: 10.1002/mus.23780. Epub 2013 Jun 26. PMID: 23801454
154. **Kishnani PS**, Amartino HM, Lindberg C, Miller TM, Wilson A, Keutzer J; Pompe Registry Boards of Advisors. Timing of diagnosis of patients with Pompe disease: Data from the Pompe registry. *Am J Med Genet A.* 2013 Oct; 161A (10):2431-43. Doi: 10.1002/ajmg.a.36110. Epub 2013 Aug 30. PMID: 23997011
155. Kansagra S, Austin S, Dearmey S, **Kishnani PS**, Kravitz RM. Polysomnographic findings in infantile Pompe disease. *Am J Med Genet A.* 2013 Dec; 161A (12):3196-200. Doi: 10.1002/ajmg.a.36227. Epub 2013 Oct 2. PMID: 24123966
156. Austin SL, El-Gharbawy AH, Kasturi VG, James A, **Kishnani PS**. Menorrhagia in patients with type 1 glycogen storage disease. *Obstet Gynecol.* 2013 Dec; 122(6):1246-54. Doi: 10.1097/01.AOG.0000435451.86108.82. PMID: 24201678
157. Prater SN, Banugaria SG, Morgan C, Sung CC, Rosenberg AS, **Kishnani PS**. Letter to the Editors: Concerning “CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy” by Al Khallaf et al. *J Inherit Metab Dis.* 2014 Jan; 37(1):141-3. Doi: 10.1007/s10545-013-9637-8. Epub 2013 Jul 26. PMID: 23887636
158. Jones HN, Crisp KD, Moss T, Strollo K, Robey R, Sank J, Canfield M, Case LE, Mahler L, Kravitz RM, **Kishnani PS**. Effects of respiratory muscles training (RMT) in children with infantile-onset Pompe disease and respiratory muscle weakness. *J Pediatr Rehabil Med.* 2014; 7(3):255-65. Doi: 10.3233/PRM-140294. PMID: 25260508
159. Feeney EJ, Austin S, Chien YH, Mandel H, Schoser B, Prater S, Hwu WL, Ralston E, **Kishnani PS**, Raben N. The value of muscle biopsies in Pompe disease: identifying lipofuscin in juvenile-and adult-onset patients. *Acta Neuropathol Commun.* 2014 Jan 2; 2:2. Doi: 10.1186/2051-5960-2-2. PMID: 24383498
160. Bali DS, Goldstein JL, Fredrickson K, Rehder C, Boney A, Austin S, Weinstein DA, Lutz R, Boneh A, **Kishnani PS**. Variability of disease spectrum in children with liver phosphorylase kinase deficiency caused by mutations in the PHKG2 gene. *Mol Genet Metab.* 2014 Mar; 111(3):309-313. Doi: 10.1016/j.ymgme.2013.12.008. Epub 2013 Dec 19. PMID: 24389071
161. Mazariegos G, Shneider B, Burton B, Fox IJ, Hadzic N, **Kishnani P**, Morton DH, McIntire S, Sokol RJ, Summar M, White D, Chavanon V, Vockley J. Liver transplantation for pediatric metabolic disease. *Mol Genet Metab.* 2014 Apr; 111(4):418-27. Doi: 10.1016/j.ymgme.2014.01.006. Epub 2014 Jan 17. Review. PMID: 24495602

162. Goldstein JL, Dickerson G, **Kishnani PS**, Rehder C, Bali DS. Blood-based diagnostic testing for Pompe disease: consistency between GAA enzyme activity in dried blood spots and GAA gene sequencing results. *Muscle Nerve*. 2014 May; 49(5):775-6. Doi: 10.1002/mus.24149. PMID: 24338800
163. Koeberl DD, Austin S, Case LE, Smith EC, Buckley AF, Young SP, Bali D, **Kishnani PS**. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease. *FASEB J*. 2014 May; 28(5):2171-6. Doi: 10.1096/fj.13-241893. Epub 2014 Jan 17. PMID: 24443373
164. Yi H, Brooks ED, Thurberg BL, Fyfe JC, **Kishnani PS**, Sun B. Correction of glycogen storage disease type III with rapamycin in a canine model. *J Mol Med I(Berl)*. 2014 Jun; 92(6):641-50. Doi: 10.1007/s00109-014-1127-4. Epub 2014 Feb 8. PMID: 24509886
165. Chiu LY, **Kishnani PS**, Chuang TP, Tang CY, Liu CY, Bali D, Koeberl D, Austin S, Boyette K, Weinstein DA, Murphy E, Yao A, Chen YT, Li LH. Identification of differentially expressed microRNAs in human hepatocellular adenoma associated with type I glycogen storage disease: a potential utility as biomarkers. *J Gastroenterol*. 2014 Aug; 49(8):1274-84. Doi: 10.1007/s00535-013-0890-2. Epub 2013 Oct 16. PMID: 24129885
166. **Kishnani PS**, Amartino HM, Lindberg C, Miller TM, Wilson A, Keutzer J. Methods of diagnosis of patients with Pompe disease: Data from the Pompe Registry. *Mol Genet Metab*. 2014 Sep-Oct; 113(1-2):84-91. Doi: 10.1016/J.ymgme.2014.07.014. Epub 2014 Jul 16. PMID: 25085280
167. **Kishnani PS**, Beckemeyer AA. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond. *Pediatr Endocrinol Rev*. 2014 Sep; 12 Suppl 1:114-24. Review. PMID: 25345093
168. Prasun P, Bailey LA, **Kishnani PS**. Right frontal lobe encephalomalacia in an adult propionic acidemia patient with neuropsychiatric manifestations. *Mol Genet Metab Rep*. 2014 Sep 21; 1:412-413. eCollection 2014. PMID: 27896115
169. Sun B, Banugaria SG, Prater SN, Patel TT, Fredrickson K, Ringler DJ, de Fougerolles A, Rosenberg AS, Waldmann H, **Kishnani PS**. Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease. *Mol Genet Metab Rep*. 2014 Oct 12; 1:446-450. eCollection 2014. PMID: 27896120
170. Prakalapakorn SG, Proia AD, Yanovitch TL, DeArme S, Mendelsohn NJ, Aleck KA, **Kishnani PS**. Ocular and Histologic Findings in a Series of Children With Infantile Pompe Disease Treated With Enzyme Replacement Therapy. *J Pediatr Ophthalmol Strabismus*. 2014 Nov-Dec; 51(6):355-62. Doi: 10.3928/01913913-20140813-01. Epub 2014 Aug 20. PMID: 25139343
171. **Kishnani PS**, Austin SL, Abdenur JE, Arn P, Bali DS, Boney A, Chung WK, Dagil AI, Dale D, Koeberl D, Somes MJ, Wechsler SB, Weinstein DA, Wolfsdorf, JL, Watson MS. Diagnosis and management of glycogen storage disease type 1: a practice guideline of the American College of Medical Genetics and Genomics. *Genet Med*. 2014 Nov; 16(11):e1. PMID: 25356975
172. McNamara ER, Sullivan J, Nagaraj, SK, Wiener JS, **Kishnani PS**. Neurogenic Bladder Dysfunction Presenting as Urinary Retention in Neuropathic Gaucher Disease. *JIMD Rep*. 2015; 15:67-70. Doi: 10.1007/8904_2014_299. Epub 2014 Mar 25. PMID: 24664877

173. McNamara ER, Austin S, Case L, Wiener JS, Peterson AC, **Kishnani PS**. Expanding our understanding of lower urinary tract symptoms and incontinence in adults with Pompe disease. *JIMD Reg.* 2015; 20:5-10. Doi: 10.1007/8904_2014_381. Epub 2015 Jan 23. PMID: 25614307
174. Chien YH, Goldstein JL, Hwu WL, Smith PB, Lee NC, Chiang SC, Tolun AA, Zhang H, Vaisnins AE, Millington DS, **Kishnani PS**, Young SP. Baseline Urinary Glucose Tetrasaccharide Concentrations in Patients with Infantile-and-Late-Onset Pompe Disease Identified by Newborn Screening. *JIMD Rep.* 2015; 19:67-73. Doi: 10.1007/8904_2014_366. Epub 2015 Feb 15. PMID: 25681082
175. Pena LD, Proia AD, **Kishnani PS**. Postmortem Findings and Clinical Correlates in Individuals with Infantile-Onset Pompe Disease. *JIMD Rep.* 2015;23:45-54. Doi: 10.1007/8904_2015_426. Epub 2015 Mar 13. PMID: 25763511
176. **Kishnani PS**, Kazi ZB, Berrier KL, Dearmey SM, Bali BS, Rosenberg AS. Immunological Factors in Pompe Disease Management: Clinical Experience and Implications for Newborn Screening. *J Neuromuscul Dis.* 2015;2(s1):S7. PMID: 27858605
177. Chien YH, van der Ploeg A, Jones S, Byrne B, Vellodi A, Leslie N, Mengel E, Shankar SP, Tanpaiboon P, Stockton DW, Hennermann JB, Devecseri Z, Kempf J, Keutzer J, **Kishnani P**. Survival and Developmental Milestones among Pompe Registry Patients with Classic Infantile-Onset Pompe Disease with Different Timing of Initiation of Treatment with Enzyme Replacement Therapy. *J Neuromuscul Dis.* 2015; 2(s1):S61-S62. PMID: 27858651
178. Raval KK, Tao R, White BE, De Lange WJ, Koonce CH, Yu J, **Kishnani PS**, Thomson JA, Mosher DF, Ralphe JC, Kamp TJ. Pompe disease results in Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes. *J Biol Chem.* 2015 Jan 30;290(5):3121-36. doi: 10.1074/jbc.M114.628628. Epub 2014 Dec 8. PMID: 25488666
179. Case LE, Bjartmar C, Morgan C, Casey R, Charrow J, Clancy JP, Dasouki M, DeArme y S, Nedd K, Nevins M, Peters H, Phillips D, Spigelman Z, Tiff C, **Kishnani PS**. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease. *Neuromuscul Disord.* 2015 Apr; 25(4):321-32. Doi: 10.1016/j.nmd.2014.12.004. Epub 2014 Dec 19. PMID: 25617983
180. Tan QK, Stockton DW, Pivnick E, Choudhri AF, Hines-Dowell S, Pena LD, Deimling MA, Freemark MS, **Kishnani PS**. Premature pubarche in children with Pompe disease. *J Pediatr.* 2015 Apr; 166(4):1075-8.e1. Doi: 10.1016/j.peds.2014.12.074. Epub 2015 Feb 14. PMID: 25687635
181. Kansagra S, Austin S, DeArme y S, Kazi Z, Kravitz RM, **Kishnani PS**. Longitudinal polysomnographic findings in infantile Pompe disease. *Am J Med Genet A* 2015 Apr; 167A (4):858-61. Doi: 10.1002/ajmg.a.37007. Epub 2015 Feb 23. PMID: 25706820
182. Hobson-Webb LD, Austin SL, Jain S, Case LE, Greene K, **Kishnani PS**. Small-fiber neuropathy in Pompe disease: first reported cases and prospective screening of a clinic cohort. *Am J Case Rep.* 2015 Apr 3; 16:196-201. Doi: 10.12659/AJCR.893309. PMID: 25835646
183. Horvath JJ, Austin SL, Case LE, Green KB, Jones HN, Soher BJ, **Kishnani PS**, Bashir MR. Correlation

- between quantitative whole-body muscle MRI and clinical muscle weakness in Pompe disease. *Muscle Nerve*. 2015 May; 51(5):722-30. Doi: 10.1002/mus.24437. Epub 2015 Mar 26. PMID: 25155446
184. Jones HN, Crisp K, Asrani P, Sloane R, **Kishnani PS**. Quantitative assessment of lingual strength in late-onset Pompe disease. *Muscle Nerve*. 2015 May; 51(5):731-5. Doi: 10.1002/mus.24523. Epub 2015 Jan 16. PMID: 25399907
185. Berrier, KL, Kazi ZB, Prater, SN, Bali DS, Goldstein J, Stefanescu MC, Rehder CW, Botha EG, Ellaway C, Bhattacharya K, Tylki-Szymanska A, Karabul N, Rosenberg, AS, **Kishnani PS**. CORRIGENDUM: CRIM-negative infantile Pompe disease: characterization of immune response in patients treated with ERT monotherapy. *Genet Med*. 2015 Jul; 17(7):596. Doi: 10.1038/gim.2018.57. PMID: 26133565
186. Worley G, Crissman BG, Cadogan E, Milleson C, Adkins DW, **Kishnani PS**. Down syndrome Disintegrative Disorder: New-Onset Autistic Regression, Dementia, and Insomnia in Older Children and Adolescents with Down syndrome. *J Child Neurol*. 2015 Aug; 30(9):1147-52. Doi: 10.1177/0883073814554654. Epub 2014 Nov 3. PMID: 25367918
187. Halldorson J, Kazi Z, Mekeel K, Kuo A, Hassanein T, Loomba R, Austin S, Valasek MA, **Kishnani P**, Hemming AW. Successful combined liver/kidney transplantation from a donor with Pompe disease. *Mol Genet Metab*. 2015 Aug; 115(4):141-4. Doi: 10.1016/j.ymgme.2015.05.007. Epub 2015 May 13. Review. PMID: 26031770
188. Stenger EO, Kazi Z, Lisi E, Gambello MJ, **Kishnani P**. Immune Tolerance Strategies in Siblings with Infantile Pompe Disease-Advantages for a Preemptive Approach to High-Sustained Antibody Titers. *Mol Genet Metab Rep*. 2015 Sep 1; 4:30-34. PMID: 26167453
189. Berrier KL, Kazi ZB, Prater SN, Bali DS, Goldstein J, Stefanescu MC, Rehder CW, Botha EG, Ellaway C, Bhattacharya K, Tylki-Symanska A, Karabul N, Rosenberg AS, **Kishnani PS**. CRIM-negative infantile Pompe disease: characterization of immune response in patients treated with ERT monotherapy. *Genet Med* 2015 Nov; 17(11):912-8. Doi: 10.1038/gim.2015.6. Epub 2015 Mar 5. Erratum in: *Genet Med*. 2015 Jul; 17(7):596. Rosenberg, Amy S(corrected to Rosenberg, Amy S). PMID: 25741864
190. Lavigne J, Sharr C, Ozonoff A, Prock LA, Baumer N, Brasington C, Cannon S, Crissman B, Davidson E, Florez JC, **Kishnani P**, Lombardo A, Lyerly J, McCannon JB, McDonough ME, Schwartz A, Berrier KL, Sparks S, Stock-Guild K, Toler TL, Vellody K, Voelz L, Skotko BG. National Down syndrome patient database: Insights from the development of a multi-center registry study. *Am J Med Genet A*. 2015 Nov; 167A (11):2520-6. Doi: 10.1002/ajmg.a.37267. Epub 2015 Aug 6. PMID: 26249752
191. McIntosh PT, Case LE, Chan JM, Austin SL, **Kishnani P**. Characterization of gait in late onset Pompe disease. *Mol Genet Metab*. 2015 Nov; 116(3):152-6. Doi: 10.1016/j.ymgme.2015.09.001. Epub 2015 Sep 5. PMID: 26372341
192. Liogier d'Ardhuy X, Edgin JO, Bouis C, de Sola S, Goeldner, C, **Kishnani P**, Noldeke J, Rice S, Sacco S, Squassante L, Spiridigliozzi G, Visootsak J, Heller J, Khwaja O. Assessment of Cognitive Scales to Examine Memory, Executive Function and Language in Individuals with Down syndrome: Implications of a 6-month Observation Study. *Front Behav Neurosci*. 2015 Nov 18; 9:300. Doi:

10.3389/fnbeh.2015.00300. eCollection 2015. PMID: 26635554

193. Bali, DS, Goldstein JL, Rehder C, Kazi ZB, Berrier KL, Dai J, **Kishnani PS**. Clinical Laboratory Experience of Blood CRIM Testing in Infantile Pompe Disease. *Mol Genet Metab Rep*. 2015 Dec 1; 5:76-79. PMID: 26693141
194. Ajay D, McNamara ER, Austin S, Wiener JS, **Kishnani P**. Lower Urinary Tract Symptoms and Incontinence in Children with Pompe Disease. *JIMD Rep*. 2016; 28:59-67. Epub 2015 Nov 5. PMID: 26537578
195. Yi H, Zhang Q, Yang C, **Kishnani PS**, Sun B. A Modified Enzymatic Method for Measurement of Glycogen Storage Disease Type IV. *JIMD Rep*. 2016; 30:89-94. Epub 2016 Jun 26. PMID: 27344645
196. Levesque S, Auray-Blais C, Gravel E, Boutin M, Dempsey-Nunez L, Jacques PE, Chenier S, Larue S, Rioux MF, Al-Hertani W, Nadeau A, Mathieu J, Maranda B, Desilets V, Waters PJ, Keutzer J, Austin S, **Kishnani P**. Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing. *Orphanet J Rare Dis*. 2016 Jan 25; 11:8. Doi: 10.1186/s13023-016-0390-6. PMID: 26809617
197. Jones HN, Crisp KD, Robey RR, Case LE, Kravitz RM, **Kishnani PS**. Respiratory muscle training (RMT) in late-onset Pompe disease (LOPD): Effects of training and detraining. *Mol Genet Metab*. 2016 Feb; 117(2):120-8. Doi: 10.1016/j.ymgme.2015.09.003. Epub 2015 Sep 8. PMID: 26381077
198. Balwani M, Burrow TA, Charrow J, Goker-Alpan O, Kaplan P, **Kishnani PS**, Mistry P, Ruskin J, Weinreb N. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. *Mol Genet Metab*. 2016 Feb; 117(2):95-103. Doi: 10.1016/j.ymgme.2015.09.002. Epub 2015 Sep 7. Review. PMID: 26387627
199. Han SO, Pope R, Li S, **Kishnani PS**, Steet R, Koeberl DD. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease. *Mol Genet Metab*. 2016 Feb; 117(2):114-9. Doi: 10.1016/j.ymgme.2015.09.012. Epub 2015 Oct 3. PMID: 26454691
200. **Kishnani, PS**, Dickson PI, Muldowney L, Lee JJ, Rosenberg A, Abichandani R, Bluestone JA, Burton BK, Dewey M, Freitas A, Gavin D, Griebel D, Hogan M, Holland S, Tanpaiboon P, Turka LA, Utz JJ, Wang YM, Whitley CB, Kazi ZB, Pariser AR. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of Immune tolerance induction. *Mol Genet Metab*. 2016 Feb; 117(2):66-83. Doi: 10.1016/j.ymgme.2015.11.001. Epub 2015 Nov 10. Review. PMID: 26597321
201. Brooks ED, Yi H, Austin SL, Thurberg BL, Young SP, Fyfe JC, **Kishnani PS**, Sun B. Natural Progression of Canine Glycogen Storage Disease Type IIIa. *Comp Med*. 2016 Feb; 66(1):41-51. PMID: 26884409
202. Rosenberg AS, Pariser AR, Diamond B, Yao L, Turka LA, Lacana E, **Kishnani PS**. A role of plasma cell targeting agents in immune tolerance induction in autoimmune disease and antibody responses to therapeutic proteins. *Clin Immunol*. 2016 Apr: 165-55-9. Doi: 10.1016/j.clim.2016.02.009. Epub 2016 Feb 27. Review. PMID: 26928739
203. Spiridigliozzi GA, Hart SJ, Heller JH, Schneider HE, Baker JA, Weadon C, Capone GT, **Kishnani PS**.

- Safety and efficacy of rivastigmine in children with Down syndrome: A double blind placebo controlled trial. *Am J Med Genet A*. 2016 Jun; 170(6):1545-55. Doi: 10.1002/ajmg.a.37650. Epub 2016 Apr 8. PMID: 27061338
204. Champaigne NL, Leroy JG, **Kishnani PS**, Decaestecker J, Steenkiste E, Chaubey A, Li J, Verslype C, Van Dorpe J, Pollard L, Goldstein JL, Libbrecht L, Basehore M, Chen N, Hu H, Wood T, Friez MJ, Huizing M, Stevenson RE. New observation of sialuria prompts detection of liver tumor in previously reported patient. *Mol Genet Metab*. 2016 Jun; 118(2); 92-9. Doi: 10.1016/j.ymgme.2016.04.004. Epub 2016 Apr 16. PMID: 27142465
205. Kansagra S, Austin S, DeArme y S, Koeberl D, **Kishnani PS**. Death from supine asphyxia in late onset Pompe disease: Two patients. *Am J Med Genet A*. 2016 Jul; 170(7):1928-9. Doi: 10.1002/ajmg.a.37687. Epub 2016 May 4. PMID: 27145023
206. Kazi ZB, Prater SN, Kobori JA, Viskochil D, Bailey C, Gera R, Stockton DW, McIntosh P, Rosenberg AS, **Kishnani PS**. Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses. *JCI Insight*, 2016 Jul 21; 1(11). Pii: e86821. PMID: 27493997
207. Sun T, Yi H, Yang C, **Kishnani PS**, Sun B. Starch Binding Domain-containing Protein 1 Plays a Dominant Role in Glycogen Transport to Lysosomes in Liver. *J Biol Chem*. 2016 Aug 5; 291(32):16479-84. Doi: 10.1074/jbc.C116.741397. Epub 2016 Jun 29. PMID: 27358407
208. Phillips D, Case LE, Griffin D, Hamilton K, Lara SL, Leiro B, Monfreda J, Westlake E, **Kishnani PS**. Physical therapy management of infants and children with hypophosphatasia. *Mol Genet Metab*. 2016 Sep; 119(1-2): 14-9. Doi: 10.1016/j.ymgme.2016.06.010. Epub 2016 Jun 22. PMID: 27386757
209. Bentler K, Zhai S, Elsbecker SA, Arnold GL, Burton BK, Vockley J, Cameron CA, Hiner SJ, Edick MJ, Berry SA; **Inborn Errors of Metabolism Collaborative**. 221 newborn-screened neonates with medium-chain acyl-coenzyme A dehydrogenase deficiency: Findings from the Inborn Errors of Metabolism Collaborative. *Mol Genet Metab*. 2016 Sep; 119(1-2):75-82. Doi: 10.1016/j.ymgme.2016.07.002. Epub 2016 Jul 15. PMID: 27477829
210. Weber TJ, Sawyer EK, Moseley S, Odrlijin T, **Kishnani PS**. Burden of disease in adult patients with hypophosphatasia: Results from two patient-reported surveys. *Metabolism*. 2016 Oct; 65(10):1522-30. Doi: 10.1016/j.metabol.2016.07.006. Epub 2016 Jul 19. PMID: 27621187
211. Sharr C, Lavigne J, Elsharkawi, IM, Ozonoff A, Baumer N, Brasington C, Cannon S, Crissman B, Davidson E, Florez JC, **Kishnani P**, Lombardo A, Lyerly J, McDonough ME, Schwartz A, Berrier KL, Sparks S, Stock-Guild K, Toler TL, Vellody K, Voelz L, Skotko BG. Detecting celiac disease in patients with Down syndrome. *Am J Med Genet A*. 2016 Dec; 170(12):3098-3105. Doi: 10.1002/ajmg.a.37879. Epub 2016 Sep 8. PMID: 27605215
212. Yi H, Gao F, Austin, S, **Kishnani PS**, Sun B. Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV. *Mol Genet Metab Rep* 2016 Oct 4; 9:31-33. eCollection 2016 Dec. PMID: 27747161
213. Mori M, DeArme y SL, Weber TJ, **Kishnani PS**. Case series: Odontohypophosphatasia or missed

- diagnosis of childhood/adult-onset hypophosphatasia? – Call for a long-term follow-up of premature loss of primary teeth. *Bone Rep.* 2016 Aug 26; 5:228-232. Doi: 10.1016/j.bonr.2016.08.004. eCollection 2016 Dec. PMID: 28580391
214. Mori M, Bailey LA, Estrada J, Rehder CW, Li JS, Rogers JG, Bali DS, Buckley AF, **Kishnani PS**. Severe Cardiomyopathy as the Isolated Presenting Feature in an Adult with Late-Onset Pompe Disease: A Case Report. *JIMD Rep.* 2017; 31:79-83. Doi: 10.1007/8904_2016_563. Epub 2016 May 4. PMID: 27142047
215. Austin SL, Chiou A, Sun B, Case LE, Govendrageloo K, Hansen P, **Kishnani PS**. Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation. *Mol Genet Metab.* 2017 Jan – Feb; 120(1-2):96-100. Doi: 10.1016/j.ymgme.2016.09.006. Epub 2016 Sep 28. PMID: 27692944
216. Bali DS, Goldstein JL, Fredrickson K, Austin S, Pendyal S, Rehder C, **Kishnani PS**. Clinical and Molecular Variability in Patients with PHKA2 Variants and Liver Phosphorylase b Kinase Deficiency. *JIMD Rep.* 2017; 37:63-72. doi: 10.1007/8904_2017_8. Epub 2017 Mar 12. PMID: 28283841
217. Yi H, Zhang Q, Brooks ED, Yang C, Thurberg BL, **Kishnani PS**, Sun B. Systemic Correction of Murine Glycogen Storage Disease Type IV by an AAV-Mediated Gene Therapy. *Hum Gene Ther.* 2016 Nov. 10. PMID: 27832700
218. Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-Webb LD, Case LE, Jones HN, **Kishnani PS**. The emerging phenotype of late-onset Pompe disease: A systematic literature review. *Mol Genet Metab.* 2017 Mar; 120(3):163-172. Doi: 10.1016/j.ymgme.2016.12.004. Epub 2016 Dec 11. Review. PMID: 28185884
219. Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Goker-Alpan O, Watman N, El-Beshlawy A, **Kishnani PS**, Pedroso ML, Gaemers SJ, Tayag R, Peterschmitt MJ. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy. *Blood.* 2017 Apr 27; 129(17):2375-2383. Doi: 10.1182/blood-2016-12-758409. Epub 2017 Feb 6. PMID: 28167660
220. Yi H, Sun T, Armstrong D, Borneman S, Yang C, Austin S, **Kishnani PS**, Sun B. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease. *J Mol Med (Berl).* 2017 May; 95(5):513-521. Doi: 10.1007/s00109-017-1505-9. Epub 2017 Feb 2. PMID: 28154884
221. **Kishnani P**, Tarnopolsky M, Roberts M, Sivakumar K, Dasouki M, Dimachkie MM, Finanger E, Goker-Alpan O, Guter KA, Mozaffar T, Pervaiz MA, Laforet P, Levine T, Adera M, Lazauskas R, Sitaraman S, Khanna R, Benjamin E, Feng J, Flanagan JJ, Barth J, Barlow C, Lockhart DJ, Valenzano KJ, Boudes P, Johnson FK, Byrne B. Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid a-Glucosidase in Pompe Patients Co-administered with Alglucosidase a. *Mol Ther.* 2017 May 3; 25(5):1199-1208. Doi: 10.1016/j.ymthe.2017.02.017. Epub 2017 Mar 22. PMID: 28341561
222. Lavigne J, Sharr C, Elsharkawi I, Ozonoff A, Baumer N, Brasington C, Cannon S, Crissman B, Davidson

- E, Florez JC, **Kishnani P**, Lombardo A, Lyerly J, McDonough ME, Schwartz A, Berrier K, Sparks S, Stock-Guild K, Toler TL, Vellody K, Voelz L, Skotko BG. Thyroid dysfunction in patients with Down syndrome: Results from a multi-institutional registry study. *Am J Med Genet A*. 2017 Jun; 173(6):1539-1545. Doi. 10.1002/ajmg.a.38219. Epub 2017 Mar 23. PMID: 28332275
223. Spiridigliozzi GA, Keeling LA, Stefanescu M, Li C, Austin S, **Kishnani PS**. Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: A longitudinal follow-up. *Mol Genet Metab*. 2017 Jun; 121(2):127-137. Doi: 10.1016/j.ymgme.2017.04.014. Epub 2017 May 1. PMID: 28495044
224. **Kishnani PS**, Hwu WL; Pompe Disease Newborn Screening Working Group. Introduction to the Newborn Screening, Diagnosis, and Treatment for Pompe Disease Guidance Supplement. *Pediatrics*. 2017. Jul; 140(Suppl 1):S1-S3. Doi: 10.1542/peds.2016-2080B. PMID: 29162672
225. Burton BK, Kronn DF, Hwu WL, **Kishnani PS**; Pompe Disease Newborn Screening Working Group. The Initial Evaluation of Patients after Positive Newborn Screening: Recommended Algorithms Leading to a Confirmed Diagnosis of Pompe Disease. *Pediatrics*. 2017 Jul; 140(Suppl 1):S14-S23. Doi: 10.1542/peds.2016-0280D. PMID: 29162674
226. Kronn DF, Day-Salvatore D, Hwu WL, Jones SA, Nakamura K, Okuyama T, Swoboda KJ, **Kishnani PS**; Pompe Disease Newborn Screening Work Group. Management of Confirmed Newborn-Screened Patients with Pompe Disease across the Disease Spectrum. *Pediatrics*. 2017 Jul; 140(Suppl 1):S24-S45. Doi: 10.1542/peds.2016-0280E. PMID: 29162675
227. Rofail D, Froggatt D, de la Torre R, Edgin J, **Kishnani PS**. Health-Related Quality of Life in Individuals with Down syndrome: Results from a Non-Interventional Longitudinal Multi-National Study. *Adv Ther*. 2017 Aug; 34(8):2058-2069. Doi: 10.1007/s12325-017-0591-y. Epub 2017 Aug 9. PMID: 28795347
228. Kazi ZB, Desai AK, Berrier, KL, Troxler RB, Wang RY, Abdul-Rahman OA, Tanpaiboon P, Mendelsohn NJ, Herskovitz E, Kronn D, Inbar-Feigenberg M, Ward-Melver C, Polan M, Gupta P, Rosenberg AS, **Kishnani PS**. Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with Infantile Pompe disease. *JCI Insight*. 2017 Aug 17; 2(16). Pii:94328. Doi: 10.1172/jci.insight.94328. (Epub ahead of print) PMID: 28814660
229. Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, **Kishnani PS**, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. *Am J Hematol*. 2017 Sep; 92(9):929-939. Doi: 10.1002/ajh.24801. Epub 2017 Jul 7. PMID: 28569047
230. Rairikar M, Kazi ZB, Desai A, Walters C, Rosenberg A, **Kishnani PS**. High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient. *Mol Genet Metab*. 2017 Sep; 122(1-2):76-79. Doi: 10.1016/j.ymgme.2017.05.006. Epub 2017 May 18. PMID: 28648664
231. Ha CI, DeArme S, Cope H, Rairikar M, **Kishnani PS**. Treatment of profound thrombocytopenia in a

- patient with Gaucher disease type 1: Is there a role for substrate reduction therapy. *Mol Genet Metab Rep*. 2017 Jun 22; 12:82-84. Doi: 10.1016/j.ymgmr.2017.06.003. eCollection 2017 Sep. PMID: 28702360
232. **Kishnani PS**, Rush ET, Arundel P, Bishop N, Dahir K, Fraser W, Harmatz P, Linglart A, Munns CF, Nunes ME, Saal HM, Seefried L, Ozono K. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. *Mol Genet Metab*. 2017 Sep;122(1-2):4-17. Doi: 10.1016/j.ymgme.2017.07.010. Epub 2017 Jul 25. Review. PMID: 28888853
233. McIntosh P, Austin S, Sullivan J, Bailey L, Bailey C, Viskochil D, **Kishnani PS**. Three cases of multi-generational Pompe disease: Are current practices missing diagnostic and treatment opportunities? *Am J Med Genet A*. 2017 Oct; 173(10):2628-2634. Doi: 10.1002/ajmg.a.38369. Epub 2017 Aug. 1. PMID: 28763149
234. Herbert M, Kazi ZB, Richards S, Rosenberg AS, **Kishnani PS**. Response to de Vries et al. *Genet Med*. 2017 Nov; 19(11):1281-1282. Doi: 10.1038/gim.2017.48. Epub 2017 May 11. PMID: 28492534
235. Torok RD, Austin SL, Phornphutkul C, Rotondo KM, Bali D, Tatum GH, Wechsler SB, Buckley AF, **Kishnani PS**. PRKAG2 mutations presenting in infancy. *J Inherit Metab Dis*. 2017 Nov; 40(6):823-830. Doi: 10.1007/s10545-017-0072-0. Epub 2017 Aug 11. PMID: 28801758
236. Keeling LA, Spiridigliozzi GA, Hart SJ, Baker JA, Jones HN, **Kishnani PS**. Challenges in measuring the effects of pharmacological interventions on cognitive and adaptive functioning in individuals with Down syndrome: A systematic review. *Am J Med Genet A*, 2017 Nov; 173(11):3058-3066. Doi: 10.1002/ajmg.a.38416. Epub 2017 Aug 31. Review. PMID: 28857390
237. Hart SJ, Visootsak J, Tamburri P, Phuong P, Baumer N, Hernandez MC, Skotko BG, Ochoa-Lubinoff C, Liogier D'Arhuy X, **Kishnani PS**, Spiridigliozzi GA. Pharmacological interventions to improve cognition and adaptive functioning in Down syndrome: Strides to date. *Am J Med Genet A*. 2017 Nov; 173(11):3029-3041. Doi: 10.1002/ajmg.a.38465. Epub 2017 Sep 8. Review. PMID: 28884975
238. Rairikar MV, Case LE, Bailey LA, Kazi ZB, Desai AK, Berrier KL, Coats J, Gandy R, Quinones R, **Kishnani PS**. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant. *Mol Genet Metab*. 2107 Nov; 122(3):99-107. Doi: 10.1016/j.ymgme.2017.09.008. Epub 2017 Sep 19. PMID: 28951071
239. Lim HH, Yi H, Kishimoto TK, Gao F, Sun B, **Kishnani PS**. A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease. *Mol Genet Metab Rep* 2017 Jul 23; 13:18-22. Do: 10.1016/j.ymgmr.2017.03.005. eCollection 2017 Dec. PMID: 28761815
240. Mori M, Haskell G, Kazi Z, Zhu X, DeArmev SM, Goldstein JL, Bali D, Rehder C, Cirulli ET, **Kishnani PS**. Sensitivity of whole exome sequencing in detecting infantile-and- late-onset Pompe disease. *Mol Genet Metab*. 2017 Dec; 122(4):189-197.doi: 10.1016/j.ymgme.2017.10.008. Epub 2017 Oct 17. PMID: 29122469
241. Patel B, Pendyal S, **Kishnani PS**, McDonald M, Bailey L. Early Diagnosed and Treated Glutaric

- Acidemia Type I Female Presenting with Subependymal Nodules in Adulthood. *JIMD Rep.* 2018; 40:85-90. Doi. 10.1007/8904_2017_66. Epub 2017 Nov. 1. PMID: 29086383
242. Krosschell KJ, Kissel JT, Townsend EL, Simeone SD, Zhang RZ, Reyna SP, Crawford TO, Schroth MK, Acsadi G, **Kishnani PS**, Von Kleist-Retzow JC, Hero B, D'Anjou G, Smith EC, Elsheikh B, Simard LR, Prior TW, Scott CB, Lasalle B, Sakonju A, Wirth B, Swoboda KJ; Project Cure SMA Investigator's Network. Clinical trial of L-Carnitine and valproic acid in spinal muscular atrophy type I. *Muscle Nerve*, 2018 Feb; 57(2):193-199. Doi. 10.1002/.mus.25776. Epub 2017 Sep 18. PMID: 28833236
243. McIntosh PT, Hobson-Webb LD, Kazi ZB, Prater SN, Banugaria SG, Austin S, Wang R, Enterline DS, Frush DP, **Kishnani PS**. Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy. *Mol Genet Metab.* 2018 Feb; 123(2):85-91. DOI: 10.1015/j.ymgme.2017.10.005. Epub 2017 Oct 13. PMID: 29050825
244. Desai AK, Walters CK, Cope HL, Kazi ZB, DeArmev SM, **Kishnani PS**. Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation. *Mol Genet Metab.* 2018 Feb; 123(2):92-96. Doi: 10.1016/j.ymgme.2017.12.435. Epub 2017 Dec 23. PMID: 29289479
245. Puri RD, Kapoor S, **Kishnani PS**, Dalai A, Gupta N, Muranjan M, Phadke Sr, Sachdeva A, Verma IC, Mistry PK; Gaucher Disease Task Force. Diagnosis and Management of Gaucher Disease in India – Consensus Guidelines of the Gaucher Disease Task Force of the Society for Indian Academy of Medical Genetics and the Indian Academy of Pediatrics. *Indian Pediatr.* 2018 Feb 15; 55(2):143-153. PMID: 29503270
246. Schwartz IVD, Goker-Alpan O, **Kishnani PS**, Zimran A, Renault L, Panahloo Z, Deegan P; GOS Study group. Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey. *Mol Genet Metab Rep.* 2017 Dec 27; 14:73-79. Doi: 10.1016/j.ymgmr.2017.10.011. eCollection 2018 Mar. PMID: 29326879
247. Herbert M, Cope H, Li JS, **Kishnani PS**. Severe cardiac involvement is rare in late-onset Pompe disease associated with the c.-32-13T>G variant. *J Pediatr.* 2018 Jul; 198:308-312. Doi: 10.1016/j.jpeds.2018.02.007. Epub 2018 Apr 4. PMID: 29627187
248. Mistry PK, Balwani M, Baris HN, Turkia HB, Burrow TA, Charrow J, Cox GF, Danda S, Dragosky M, Drelichman G, El-Beshlawy A, Fraga C, Freisens S, Gaemers S, Hadjiev E, **Kishnani PS**, Lukina E, Maison-Blanche, P, Martins Am, Pastores G, Petakov M, Peterschmitt MJ, Rosenbaum H, Rosenbloom B, Underhill LH, Cox TM. Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. *Blood Cells Mol Dis.* 2018 Jul; 71:71-74. Doi: 10.1016/j.bcmd.2018.04.001. Epub 2018 Apr 9. PMID: 29680197
249. Koeberl DD, Case LE, Smith EC, Walters C, Han SO, Li Y, Chen W, Hornik CP, Huffman KM, Kraus WE, Thurberg BL, Corcoran DL, Bali D, Bursac N, **Kishnani PS**. Correction of Abnormalities and Improved Muscle Function in a Phase I/II Clinical Trial of Clenbuterol in Pompe Disease. *Mol Ther.* 2018 Jul 5. Pii: S1525-0016(18)30309-5. Doi: 10.1016/j.ymthe.2018.06.023. (Epub ahead of print) PMID: 30025991

250. Hahn SH, Kronn D, Leslie ND, Pena LDM, Tanpaiboon P, Gambello MJ, Gibson JB, Hillman R, Stockton DW, Day JW, Wang RY, An Haack K, Shafi R, Sparks S, Zhao Y, Wilson C, **Kishnani PS**. Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study. *Genet Med*. 2018 Mar 22. Doi: 10.1038/gim.2018.2 (Epub ahead of print) PMID: 29565424
251. Herbert M, Goldstein JL, Rehder C, Austin S, **Kishnani PS**, Bali DS. Phosphorylase Kinase Deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. *GeneReviews* (Internet) Seattle (WA): University of Washington, Seattle; 1993-2018. 2011 May 31 (updated 2018 Nov 1). PMID: 21634085
252. Herbert M, Pendyal S, Rairikar M, Halaby C, Benjamin RW, **Kishnani PS**. Role of continuous glucose monitoring in the management of glycogen storage disorders. *J Inherit Metab Dis*. 2018 May 25. Doi: 10.1007/s10545-018-0200-5. (Epub ahead of print) PMID: 29802555
253. Brooks ED, Landau DJ, Everitt JI, Brown TT, Grady KM, Waskowicz L, Bass CR, D'Angelo J, Asfaw YG, Williams K, **Kishnani PS**, Koeberl DD. Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy. *J Inherit Metab Dis*. 2018 Jul 24. Doi: 10.1007/s10545-018-0223-y. (Epub ahead of print) PMID: 30043186
254. Brooks, ED, **Kishnani PS**, Koeberl DD. Letter to the Editors: Concerning “Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia” by Lee et al. *J Inherit Metab Dis*. 2018 Sep 25. Doi: 10.1007/s10545-018-0248-2. (Epub ahead of Print) No abstract available. PMID: 30255460
255. Potnis KC, Flueckinger LB, DeArmev SM, Alcalay RN, Cooney JW, **Kishnani PS**. Corticobasal syndrome in a man with Gaucher disease type 1: Expansion of the understanding of the neurological spectrum. *Mol Genet Metab Pre*. 2018 Oct 18; 17:69-72. Dio: 10.1016/j.ymgmr.2018.10.001. eCollection 2018 Dec. PMID: 30364808
256. Dale DC, Bolyard AA, Marrero T, Kelley ML, Makaryan V, Tran E, Leung J, Boxer LA, **Kishnani PS**, Austin S, Wanner C, Ferrecchia IA, Khalaf D, Maze D, Kurtzberg J, Zeidler C, Welte K, Weinstein DA. Neutropenia in glycogen storage disease 1b: outcomes for patients treated with granulocyte colony-stimulating factor. *Curr Opin Hematol*. 2019 Jan; 26(1):16-21. Doi: 10.1097/MOH.0000000000000474. PMID: 30451720
257. Spiridigliozzi GA, Goeldner C, Edgin J, Hart SJ, Noeldeke J, Squassante L, Visootsak J, Heller JH, Khwaja O, **Kishnani PS**, Liogier d'Ardhuy X. Adaptive behavior in adolescents and adults with Down syndrome: Results from a 6-month longitudinal study. *Am J Med Genet A*. 2019 Jan; 179(1):85-93. Doi: 10.1002/ajmg.a.60685. Epub 2018 Dec 20. PMID: 30569586
258. Potnis KC, Flueckinger LB, Ha CI, Upadia J, Frush DP, **Kishnani PS**. Bone manifestations in neuropathic Gaucher disease while receiving high-dose enzyme replacement therapy. *Mol Genet Metab*. 2018 Nov 9. Pii: S1096-7192(18)30376-7. Doi: 10.1016/j.ymgme.2018.11.004. (Epub ahead of print) PMID: 30448006

259. Herbert M, Case LE, Rairikar M, Cope H, Bailey L, Austin SL, **Kishnani PS**. Early-onset of symptoms and clinical course of Pompe disease associated with the c.-32-13 T>G variant. *Mol Genet Metab*. 2019 Feb; 126(2): 106-116. Doi:10.1016/j.ymgme.2018.08.009. Epub 2018 Aug 23. PMID: 30655185
260. Hogler W, Langman C, Gomes da Silva H, Fang S, Linglart A, Ozono K, Petryk A, Rockman-Greenberg C, Seefried L, **Kishnani PS**. Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. *BMC Musculoskelet Disord*. 2019 Feb 14; 20(1):80. Doi: 10.1186/s12891-019-2420-8. PMID: 30764793
261. De Groot As, Kazi ZB, Martin RF, Terry FE, Desai AK, Martin WD, **Kishnani PS**. HLA-and genotype-based risk assessment model to identify infantile onset Pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA). *Clin Immunol*. 2019 Mar; 200:66-70. Doi: 10.1016/j.clim.2019.01.009. Epub 2019 Jan 31. PMID: 30711607
262. Jauhari P, Saini Ag, Suthar R, Sankhyan N, Rehder C, **Kishnani P**, Gupta N, Kabra M, Singhi P. Thenar Hypertrophy and Electrical Myotonia in Pompe Disease. *J Clin Neuromuscul Dis*. 2019 Mar; 20(3):135-137. Doi: 10.1097/CND 000000000000195. No abstract available. PMID: 30801484
263. Lim JA, Yi H, Gao F, Raben N, **Kishnani PS**, Sun B. Intravenous injection of an AVV-PHP.B Vector Encoding Human Acid a-Glucosidase Rescues Both Muscle and CNS Defects in Murine Pompe Disease. *Mol Ther Methods Clin Dev*. 2019 Jan 25; 12:233-245. Doi: 10.1016/j.omtm.2019.01.006. eCollection 2018 Mar 15. PMID: 30809555
264. Kazi ZB, Desai AK, Troxler RB, Kronn D, Packman S, Sabbadini M, Rizzo WB, Scherer K, Abdul-Rahman O, Tanpaiboon P, Nampoothiri S, Gupta N, Feigenbaum A, Niyazov DM, Sherry L, Segel R, McVie-Wylie A, Sung C, Joseph AM, Richards S, **Kishnani PS**. An immune tolerance approach using transient-low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease. *Genet Med*. 2018 Sep 14. Doi: 10.1038/s41436-018-0270-7. (Epub ahead of Print) PMID: 30214072
265. **Kishnani PS**, Rockman-Greenberg C, Rauch, F, Bhatti MT, Moseley S, Denker AE, Watsky E, Whyte MP. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. *Bone*. 2019 Apr; 121:149-162. Doi: 10.1016/j.bone.2018.12.011. Epub 2018 Dec 18. PMID: 30576866
266. **Kishnani PS**, Goldstein J, Austin SL, Arn P, Bachrach B, Bali Ds, Chung WK, El-Gharbawy A, Brown LM, Kahler S, Pendyal S, Ross KM, Tsilianidis L, Weinstein DA, Watson MS; ACMG Work Group on Diagnosis and Management of Glycogen Storage Disease Type VI and IX. *Genet Med*. 2019 Jan 19. Doi: 10.1038/s41436-018-0364-2. (Epub ahead of print) PMID: 30659246
267. Cardinale KM, Bocharnikov A, Hart SJ, Baker JA, Eckstein C, Jasien JM, Gallentine W, Worley G, **Kishnani PS**, Van Mater H. Immunotherapy in selected patients with Down syndrome disintegrative disorder. *Dev Med Child Neurol*. 2018 Dec 12. Doi: 10.1111/dmcn014127 (Epub ahead of print) PMID: 30548468
268. Gospe SM 3rd, Santiago-Turla C, DeArmev SM, Cummings TJ, **Kishnani PS**, Bhatti MT. Ectopic Ocular

- Surface Calcification in Patients with Hypophosphatasia Treated with Asfotase Alfa. *Cornea*. 2019 Apr 8. Doi: 10.1097/ICO.0000000000001947. [Epub ahead of print] PMID: 30969260
269. Mistry PK, Balwani M, Baris HN, Turkia HB, Burrow TA, Charrow J, Cox GF, Danda S, Dragosky M, Drelichman G, El-Beshlawy A, Fraga C, Gaemers S, Hadjiev E, **Kishnani PS**, Lukina E, Maison-Blanche P, Martins AM, Pastores G, Petakov M, Peterschmitt MJ, Rosenbaum H, Rosenbloom B, Underhill LH, Cox TM. Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. *Blood Cells Mol Dis*. 2019 Jul; 77:101-102. Doi: 10.1016/j.bcmd.2019.04.003. Epub 2019 Apr 9. No abstract available. PMID: 31029022
270. Jones HN, Crisp KD, Kuchibhatla M, Mahler L, Risoli T Jr, Jones CW, **Kishnani P**. Auditory-Perceptual Speech Features in Children with Down syndrome. *Am J Intellect Dev Disabil*. 2019 Jul; 124(4):324-338. Doi: 10.1352/1944-7558-124.4.324. PMID: 31199683
271. Desai AK, Kazi ZB, Bali DS, **Kishnani PS**. Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy. *Mol Genet Metab Rep*. 2018 May 10; 20:100475. Doi: 10.1016/j.ymgmr.2019.100475. eCollection 2019 Sep. PMID: 31193175
272. **Kishnani PS**, Koeberl DD. Liver Depot Gene Therapy for Pompe Disease. *Ann Transl Med*. 2019 Jul; 7(13):288. Doi: 10.21037/atm.2019.05.02. Review. PMID: 31392200
273. Korlimarla A, Lim JA, **Kishnani PS**, Sun B. An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond. *Ann Transl Med*. 2019 Jul; 7(13):289. Doi: 10.21037/atm.2019.04.49. Review. PMID: 31392201
274. Bond JE, **Kishnani PS**, Koeberl DD. Immunomodulatory, liver depot gene therapy for Pompe disease. *Cell Immunol*. 2019 Aug;342:103737. doi: 10.1016/j.cellimm.2017.12.011. Epub 2017 Dec 29. PMID: 29295737
275. Jones HN, Kuchibhatla M, Crisp KD, Hobson Webb LD, Case L, Batten MT, Marcus JA, Kravitz RM, **Kishnani PS**. Respiratory muscle training (RMT) in late-onset Pompe disease (LOPD): A protocol for a sham-controlled clinical trial. *Mol Genet Metab*. 2019 May 8. Pii: S1096-7192(19)30213-6. Doi: 10/1016/j.ymgme.2019.05.001. (Epub ahead of print) Spanish. PMID: 31303277
276. Desai AK, Kazi ZB, Bali DS, **Kishnani PS**. Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy. *Mol Genet Metab Rep*. 2019 May 10;20:100475. doi: 10.1016/j.ymgr.2019.100475/ eCollection 2019 Sep. PMID: 31193175
277. **Kishnani PS**, Sun B, Koeberl DD. Gene therapy for glycogen storage diseases. *Hum Mol Genet*. 2019 Jun 22. Pii: ddz133. Doi: 10.1093/hmg/ddz133. (Epub ahead of print) PMID: 31227835
278. **Kishnani PS**, Gibson JB, Gambello MJ, Hillman R, Stockton DW, Kronn D, Leslie ND, Pena LDM, Tanpaiboon P, Day JW, Wang RY, Goldstein JL, AQn Haack K, Sparks SE, Zhao Y, Hahn SH; Pompe ADVANCE Study Consortium. Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease. *Genet Med*. 2019 May

14. Doi: 10.1038/s41436-019-0527-9. [Epub ahead of print] PMID: 31086307
279. Reuser AJJ, van der Ploeg AT, Chien YH, Llerena J Jr, Abbott MA, Clemens PR, Kimonis VE, Leslie N, Maruti SS, Sanson BJ, Araujo R, Periquet M, Toscano A, **Kishnani PS**, GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry. *Hum Mutat.* 2019 Nov; 40(11):2146-2164. Doi: 10.1002/humu.23878. Epub 2019 Aug 7. PMID: 31342611
280. Halaby CA, Young SP, Austin S, Stefanescu E, Bali D, Clinton LK, Smith B, Pendyal S, Upadia J, Schooler GR, Mavis AM, **Kishnani PS**. Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring. *Genet Med.* 2019 Jul 2. Doi: 10.1038/s41436-019-0561-7. (Epub ahead of print) PMID: 31263214
281. Gupta N, Kazi ZB, Nampoothiri S, Jagdeesh S, Kabra M, Puri RD, Muranjan M, Kalaivani M, Rehder C, Bali D, Verma IC, **Kishnani PS**. Clinical and Molecular Disease Spectrum and Outcomes in Patients with Infantile-Onset Pompe Disease. *J Pediatr.* 2019 Oct 9. Pii: S0022-3476(19)31121-7. Doi: 10.1016/j.peds.2019.08.058. [Epub ahead of print] PMID: 31606152
282. Crisp KD, Case LE, Kravitz RM, **Kishnani PS**, Jones HN. Training, detraining, and retraining: Two 12-week respiratory muscle training regimens in a child with infantile-onset Pompe disease. *J Pediatr Rehabil Med.* 2020; 13(1):71-80. Doi: 10.3233/PRM-190601. PMID: 32176666
283. Hart SJ, Zimmerman K, Linardic CM, Cannon S, Pastore A, Patsiogiannis V, Rossi P, Santoro SL, Skotko BG, Torres A, Valentini D, Vellody K, Worley G, **Kishnani PS**. Detection of iron deficiency in children with Down syndrome. *Genet Med.* 2019 Aug 16. Doi: 10.1038/s41436-019-0637-4. [Epub ahead of print] PMID: 31417190
284. Han SO, Haynes AC, Li S, Abraham DM, **Kishnani PS**, Steet R, Koeberl DD. Evaluation of antihypertensive drugs in combination with enzyme replacement therapy in mice with Pompe disease. *Mol Genet Metab.* 2019 Oct 17. Pii: S1096-7192(19)30679-1. Doi: 10.1016/j.ymgme.2019.10.005 [Epub ahead of print] PMID: 31645300
285. Koeberl DD, Case LE, Desai A, Smith EC, Walters C, Han SO, Thurberg BL, Young SP, Bali D, **Kishnani PS**. Improved muscle function in a phase I/II clinical trial of albuterol in Pompe disease. *Mol Genet Metab.* 2020 Feb; 129(2):67-72. Doi: 10.1016/J.ymgme.2019.12.008. Epub 2019 Dec 10. PMID: 31839530
286. Hart SJ, Zimmerman K, Linardic CM, Cannon S, Pastore A, Patsiogiannis V, Rossi P, Santoro SL, Skotko BG, Torres A, Valentini D, Vellody K, Worley G, **Kishnani PS**. Response to Zhang et al. *Genet Med.* 2019 Nov 12. Doi: 10.1038/s41436-019-0690-z. [Epub ahead of print] No abstract available. PMID: 31712672
287. ElMallah MK, Desai AK, Nading EB, DeArmev S, Kravitz RM, **Kishnani PS**. Pulmonary outcome measures in long-term survivors of infantile Pompe disease on enzyme replacement therapy: A case series. *Pediatr Pulmonol.* 2020 Mar; 55(3):674-681. Doi: 10.1002/ppul.24621. Epub 2020 Jan 3. PMID: 31899940
288. Santoro SL, Cannon S, Capone G, Franklin C, Hart SJ, Hobensack V, **Kishnani PS**, Macklin EA,

- Manickam K, McCormick A, Nash P, Oreskovic NM, Patsiogiannis V, Steingass K, Torres A, Valentini D, Vellody K, Skotko BG. Unexplained regression in Down syndrome: 35 cases from an international Down syndrome database. *Genet Med.* 2019 Nov 26. Doi: 10.1038/s41436-019-0706-8. (Epub ahead of print) PMID: 31767984
289. Khan AA, Boggs T, Bowling M, Austin S, Stefanescu M, Case L, **Kishnani PS**. Whole-body MRI in Late-onset Pompe Disease: Clinical utility and correlation with functional measures. *J Inherit Metab Dis.* 2019 Nov 11. Doi: 10.1002/jimd.12190. [Epub ahead of print] PMID: 31710733
290. Khan AA, Case LE, Herbert M, DeArmedy S, Jones H, Crisp K, Zimmerman K, ElMallah MK, Young SP, **Kishnani PS**. Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature. *Genet Med.* 2020 Jan 6. Doi: 10.1038/s41436-019-0738-0. (Epub ahead of print) PMID: 31904026
291. Julien DC, Woolgar K, Pollard L, Miller H, Desai A, Lindstrom K, **Kishnani PS**. Immune Modulation for Enzyme Replacement Therapy in A Female Patient with Hunter Syndrome. *Front Immunol* 2020 May 21;11:1000 doi: 10.3389/fimmu.2020.01000. eCollection 2020. PMID: 32508845
292. Jones HN, Fernandes S, Hannah WB, Kansagra S, Raynor EM, **Kishnani PS**. Adenotonsillectomy should be avoided whenever possible in infantile-onset Pompe disease. *Mol Genet Metab Rep.* 2020 Feb 15; 23:100574. Doi: 10.1016/j.ymgmr.2020.100574. eCollection 2020 Jun. No abstract available. PMID: 32090020
293. Rossi A, Hoogeveen IJ, Bastek VB, de Boer F, Montanari C, Meyer U, Maiorana A, Bordugo A, Dianin A, Campana C, Rigoldi M, **Kishnani PS**, Pendyal S, Strisciuglio P, Gasperini S, Parenti G, Parini R, Paci S, Melis D, Derks TGJ. Dietary lipids in glycogen storage disease type III: A systematic literature study, case studies, and future recommendations. *J Inherit Metab Dis.* 2020 Feb 16. Doi: 10.1002/jimd.12224. (Epub ahead of print) PMID: 32064649
294. Mistry PK, Balwani M, Charrow J, **Kishnani P**, Niederau C, Underhill LH, McClain MR. Real-World Effectiveness of Eliglustat in Treatment-Naïve and Switch Patients Enrolled in the International Collaborative Gaucher Group Gaucher Registry. *Am J Hematol.* 2020 May 21. Doi: 10.1002/ajh.25875. Online ahead of print. PMID: 32438452
295. Synder HM, Bain LJ, Brickman AM, Carrillo MC, Esbensen AJ, Espinosa JM, Fernandez F, Fortea J, Hartley SL, Head E, Hendrix J, **Kishnani PS**, Lai F, Lao P, Lemere C, Mobley W, Mufson EJ, Potter H, Zaman SH, Granholm AC, Rosas HD, Strydom A, Whitten MS, Rafi MS. Further understanding the connection between Alzheimer's disease and Down syndrome. *Alzheimers Dement.* 2020 Jun 16. Doi: 10.1002/alz.12112. Online ahead of print. PMID: 32544310 Review.
296. Desai AK, Baloh CH, Sleasman JW, Rosenberg AS, **Kishnani PS**. Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients with Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort. *Front Immunol.* 2020 Aug 6;11:1727. Doi: 10.3389/fimmu.2020.01727. eCollection 2020. PMID: 32849613.
297. Korlimarla A, Spiridigliozzi GA, Crisp K, Herbert M, Chen S, Malinzak M, Stefanescu M, Austin SL,

- Cope H, Zimmerman K, Jones H, Provenzale JM, **Kishnani PS**. Novel approaches to quantify CNS involvement in children with Pompe disease. *Neurology*. 2020 Jun 9;10.1212/WNL.0000000000009979. Doi: 10.1212/WNL.0000000000009979. Online ahead of print. PMID: 32518148
298. Mistry PK, Balwani M, Charrow J, **Kishnani P**, Niederau C, Underhill LH, McClain MR. Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry. *Am J Hematol*. 2020 Sep;95(9):1038-1046. doi: 10.1002/ajh.25875. Epub 2020 Jun 24. PMID: 32438452
299. Gupta P, Shayota BJ, Desai AK, Kiblawi F, Myridakis D, Messina J, Tah P, Tambini-king L, **Kishnani PS**. A Race Against Time-Changing the Natural History of CRIM Negative Infantile Pompe Disease. *Front Immunol*. 2020 Sep 4;11:1929. Doi: 10.3389/fimmu.2020.01929. eCollection 2020. PMID: 33013846.
300. Lim JA, Choi SJ, Gao F, **Kishnani PS**, Sun B. A Novel Gene Therapy Approach for GSDIII Using an AVV Vector Encoding a Bacterial Glycogen Debranching Enzyme. *Mol Ther Methods Clin Dev*. 2020 Jun 2; 18:240-249. Doi:10.1016/j.omtm.2020.05.034. eCollection 2020 Sep 11. PMID: 32637453 Free PMD article
301. Goker-Alpan O, Kasturi VG, Sohi MK, Lingala RP, Austin SL, Jennell T, Banikazemi M, **Kishnani PS**. Pregnancy Outcomes in Late Onset Pompe Disease. *Life (Basel)*. 2020 Sep 11;10(9):E194. Doi: 10.3390/Life10090194. PMID: 32932790.
302. Stockton DW, **Kishnani P**, van der Ploeg A, Llerena J Jr, Boentert M, Roberts M, Byrne BJ, Araujo R, Maruti SS, Thibault N, Verhulst K, Berger KI. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start. *J Neurol*. 2020 Jun 10. Doi: 10.1007/s00415-020-09936-8. Online ahead of print. PMID: 32524257
303. Desai AK, Rosenberg AS, **Kishnani PS**. The potential impact of timing of IVIG administration on safety and efficacy of rituximab administration in the setting of immune tolerance induction for patients with Pompe disease. *Clin Immunol*. 2020 Jul 15:108541. Doi: 10.1016/j.clim.2020.108541. Online ahead of print. PMID: 32681978.
304. Harfouche M, **Kishnani PS**, Krusinska E, Gault J, Sitaraman S, Sowinski A, Katz I, Austin S, Goldstein M, Mulberg AE. Use of the patient-reported outcomes measurement information system (PROMIS®) to assess late-onset Pompe disease severity. *J Patient Rep Outcomes*. 2020 Oct 9; 4(1):83. Doi: 10.1186/s41687-020-00245-2. PMID: 33034771.
305. Seefried L, Dahir K, Petryk A, Hogler W, Linglart A, Martos-Moreno GA, Ozono K, Fang S, Rockman-Greenberg C, **Kishnani PS**. Burden of Illness in Adults with Hypophosphatasia; Data from the Global Hypophosphatasia Patient Registry. *J Bone Miner Res*. 2020 Jul 12. Doi: 10.1002/jbmr.4130. Online ahead of print. PMID: 32654183.
306. Young SP, Khan AA, Austin SL, **Kishnani PS**. Response to Heiner-Fokkema et al. *Genet Med*. 2020 Jul 13. Doi: 10.1038/s41436-020-0879-1. Online ahead of print. PMID: 32655140 No abstract available.

307. Jones, HN, Kuchibhatla M, Crisp KD, Hobson-Webb LD, Case L, Batten MT, Marcus JA, Kravitz RM, **Kishnani PS**. Respiratory muscle training in late-onset Pompe disease: Results of a sham-controlled clinical trial. *Neuromuscul Disord*. 2020 Nov; 30(11):904-914. Doi: 10.1016/j.nmd.2020.09.023. Epub 2020 Sep 28. PMID: 33127291.
308. Fernandes SA, Cooper GE, Gibson RA, **Kishnani PS**. Benign or not benign? Deep phenotyping of liver Glycogen Storage Disease IX. *Mol Genet Metab*. 2020 Nov; 31(3):299-305. Doi: 10.1016/j.ymgme.2020.10.004. Epub 2020 Oct 10. PMID: 33317799.
309. Korlimarla, A, Spiridigliozzi GA, Stefanescu M, Austin SL, **Kishnani PS**. Behavioral, social and school functioning in children with Pompe disease. *Mol Genet Metab Rep*. 2020 Aug 5:25:100635. Doi: 10.1016/j.ymgmr.2020.100635. eCollection 2020 Dec. PMID: 32793419.
310. Huggins E, Ong R, Rockman-Greenberg C, Flueckinger LB, Dahir KM, **Kishnani PS**. Multigenerational case examples of hypophosphatasia: Challenges in genetic counseling and disease management. *Mol Genet Metab Rep*. 2020 Oct 21; 25:100661. Doi: 10.1016/j.ymgmr.2020.100661. PMID: 33034771.
311. Seefried L, **Kishnani PS**, Moseley S, Denker AE, Watsky E, Whyte MP, Dahir KM. Pharmacodynamics of Asfotase Alfa in Adults with Pediatric-Onset Hypophosphatasia. *Bone* 2020 Sept 25:115664. Doi: 10.1016/j.bone.2020.115664. Online ahead of print. PMID: 32987199.
312. Fernandes SA, Khan AA, Boggs T, Bowling M, Austin S, Stefanescu M, Case L, **Kishnani PS**. Quantitative whole-body magnetic resonance imaging in children with Pompe disease: Clinical tools to evaluate severity of muscle disease. *JIMD Ref*. 2020 Oct 14;57(1):94-101. Doi: 10.1002/jmd2.12174. eCollection 2021 Jan. PMID: 33473345.
313. Vernuccio F, Austin S, Meyer M, Guy CD, **Kishnani PS**, Marin D. “Bull’s eye” appearance of hepatocellular adenomas in patients with glycogen storage disease type I – atypical magnetic resonance imaging findings: Two case reports. *World J Clin Cases*. 2021 Feb 6; 9(4):871-877. Doi: 10.120998/wjcc.v9.i4.871. PMID: 33585634
314. Young SP, Khan A, Stefanescu E, Seifts AM, Hijazi G, Austin S, **Kishnani PS**. Diurnal variability of glucose tetrasaccharide (Glc4) excretion in patients with glycogen storage disease type III. *JIMD Rep*. 2020 Nov 2; 58(1):37-43. Doi: 10.1002/jmd2.12181. eCollection 2021 Mar. PMID: 33728245
315. Hart SJ, Worley G, **Kishnani PS**, Van Mater H. Case Report: Improvement Following Immunotherapy in an Individual with Seronegative Down syndrome Disintegrative Disorder. *Front Neurol*. 2021 Mar 26; 12:621637. Doi: 10.3389/fneur.2021.621637. eCollection 2021. PMID: 33841297.
316. Hendrix JA, Airey DC, Britton A, Burke AD, Capone GT, Chavez R, Chen J, Chicoine B, Costa ACS, Dage JL, Doran E, Esbensen A, Evans CL, Faber KM, Foroud TM, Hart S, Haugen K, Head E, Hendrix S, Hillerstrom H, **Kishnani PS**, Krell K, Ledesma DL, Lai F, Lott I, Ochoa-Lubinoff C, Mason J, Nicodemus-Johnson J, Proctor NK, Pulsifer MB, Revta C, Rosas HD, Rosser TC, Santoro S, Schaefer K, Scheidemantel T, Schmitt F, Skotko BG, Stasko MR, Talboy A, Torres A, Wilmes K, Woodward J, Zimmer JA, Feldman HH, Mobley W. Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer’s disease in Down syndrome: Early Data from the Longitudinal Investigation for Enhancing

- Down Syndrome Research (LIFE-DSR) Study. *J Clin Med.* 2021 Apr 28; 10(9):1907. Doi: 10.3390/jcm10091907. PMID: 33924960
317. Li C, Desai AK, Gupta P, Dempsey K, Bhambhani V, Hopkin RJ, Ficicioglu C, Tanpaiboon P, Craigen WJ, Rosenberg AS, **Kishnani PS**. Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction. *Genet Med.* 2021 May;23(5):845-955. Doi: 10.1038/s41436-020-01080-y. Epub 2021 Jan 25. PMID: 33495531.
318. Puri RD, Setia N, N V, Jagadeesh S, Nampoothiri S, Gupta N, Muranjan M, Bhat M, Girisha KM, Kabra M, Verma J, Thomas DC, Biji I, Raja J, Makkar R, Verma IC, **Kishnani PS**. Late onset Pompe Disease in India – Beyond the Caucasian phenotype. *Neuromuscul Disord.* 2021 Feb 16:S0960-8966(21)00041-9. Doi: 10.1016/j.nmd.2021.02.013. Online ahead of print. PMID: 33741225.
319. **Kishnani PS**, Del Angel G, Zhou S, Rush ET. Investigation of ALPL variant states and clinical outcomes: An analysis of adults and adolescents with hypophosphatasia treated with asfotase alfa. *Mol Genet Metab.* 2021 Mar 26:S1096-7192(21)00077-9. Doi: 10.1016/j.ymgme.2021.03.011. Online ahead of print. PMID: 33814268.
320. Wang J, Zhou CJ, Khodabukus A, Tran S, Han SO, Carlson AL, Madden L, **Kishnani PS**, Koeberl DD. Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease. *Bursac N. Commun Biol.* 2021 May 5; 4(1):524. Doi: 10.1038/s42003-021-02059-4. PMID: 33953320
321. Stiles AR, Huggins E, Fierro, L, Jung SH, Balwani M, **Kishnani PS**. The role of glucosylsphingosine as an early indicator of disease progression in early symptomatic type 1 Gaucher disease. *Mol Genet Metab Rep.* 2021 Feb 8; 27:100729. Doi: 10.1016/j.ymgmr.2021.100729. ECollection 2021 Jun. PMID: 33614410.
322. De Groot AS, Desai AK, Lelias S, Miah SMS, Terry FE, Khan S, Li C, Yi JS, Ardito M, Martin WD, **Kishnani PS**. Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease. *Front Immunol.* 2021 June 16:12:636731. Doi: 10.3389/fimmu.2021.636731. eCollection 2021. PMID: 34220802
323. Jones HN, Hobson-Webb LD, Kuchibhatla M, Crisp KD, Whyte-Rayson A, Batten MT, Zwelling PJ, **Kishnani PS**. Tongue weakness and atrophy differentiates late-onset Pompe disease from other forms of acquired/hereditary myopathy. *Mol Genet Metab.* 2021 May 12:@1096-7192 (21)00706-X. Doi: 10.1016/j.ymgme.2021.05.005. Online ahead of print. PMID: 34053870
324. Gibson RA, Lim JA, Choi SJ, Flores L, Clinton L, Bali D, Young S, Asokan A, Sun B, **Kishnani PS**. Characterization of liver GSD IX γ 2 pathophysiology in a novel *Phkg2*^{-/-} mouse model. *Mol Genet Metab.* 2021 May 25:S1096-7192(21)00716-2. Doi: 10.1016/j.ymgme.2021.05.008. Online ahead of print. PMID: 34083142
325. Korlimarla A, Lim JA, McIntosh P, Zimmerman K, Sun BD, **Kishnani PS**. New Insights into Gastrointestinal Involvement in Late-Onset Pompe Disease: Lessons Learned from Bench and Bedside. *J Clin Med.* 2021 Jul 20; 10(15):3395. Doi: 10.3390/jcm10153395. PMID: 34362174

326. Ezekian JE, Rehder C, **Kishnani PS**, Landstrom AP. Interpretation of Incidental Genetic Findings Localizing to Genes Associated With Cardiac Channelopathies and Cardiomyopathies. *Circ Genom Precis Med.* 2021 Aug; 14(4):e003200. Doi: 10.1161/CIRCGEN.120.003200. Epub 2021 Aug 13. PMID: 34384235
327. Miller DE, Sulovari A, Wang T, Loucks H, Hoekzema K, Munsom KM, Lewis AP, Fuerte EPA, Paschal CR, Walsh T, Thies J, Bennett JT, Glass I, Dipple KM, Patterson K, Bonkowski ES, Nelson Z, Squire A, Sikes M, Beckman E, Bennett RL, Earl D, Lee W, Allikmets R, Perlman SJ, Chow P, Hing AV, Wenger TL, Adam MP, Sun A, Lam C, Chang I, Zou X, Austin SL, Huggins E, Safi A, Iyengar AK, Reddy TE, Majoros WH, Allen AS, Crawford GE, **Kishnani PS**, University of Washington Center for Mendelian Genomics, King MC, Cherry T, Chong JX, Bamshad MJ, Nickerson DA, Mefford HC, Doherty D, Eichler EE. Targeted long-read sequencing identifies missing disease-causing variation. *Am J Hum Genet.* 2021 Jun 25:S0002-9297(21)00230-5. Doi: 10.1016/j.ajhg.2021.06.006. Online ahead of print. PMID: 34216551
328. Crisp, KD, Neel AT, Amarasekara S, Marcus J, Nichting G, Korlimarla A, **Kishnani PS**, Jones HN. Assessment of Dysphonia in Children with Pompe Disease Using Auditory-Perceptual and Acoustic/Physiologic Methods. *J Clin Med.* 2021 Aug 16; 19(16):3617. Doi: 10.3390/jcm10163617. PMID: 34441913
329. Hobson-Webb LD, Zwelling PJ, Raja SS, Pifer AN, **Kishnani PS**. Quantitative muscle ultrasound and electrical impedance myography in late onset Pompe disease: A pilot study of reliability, longitudinal change and correlation with function. *Mol Genet Metab Rep.* 2021 Jul 30; 28:100785. Doi: 10.1016/j.ymgmr.2021.100785. eCollection 2021 Sep. PMID: 34401343
330. Bali DS, El-Gharbawy A, Austin S, Pendyal S, **Kishnani PS**, Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A. Glycogen Storage Disease Type I. *GeneReviews (Internet)*, 2006 Apr 19 (updated 2021 Oct 14), PMID: 20301489
331. Dornelles AD, Junges APP, Pereira TV, Krug BC, Goncalves CBT, Llerena JC Jr, **Kishnani PS**, de Oliveira HA Jr, Schwartz IVD. A Systematic Review and Meta-Analysis of Enzyme Replacement Therapy in Late-Onset Pompe Disease. *J Clin Med.* 2021 Oct 21; 10(21):4828. Doi: 10.3390/jcm10214818. PMID: 34768348
332. Paschall A, Khan AA, Enam SF, Boggs T, Hijazi G, Bowling M, Austin S, Case LE, **Kishnani PS**. Physical therapy assessment and whole-body magnetic resonance imaging findings in children with glycogen storage disease type IIIa. *Mol Genet Metab.* 2021 Nov; 134(3):223-234. Doi: 10.1016/j.ymgme.2021.10.002. Epub 2021 Oct 9. PMID: 34649782
333. Diaz-Manera J, **Kishnani PS**, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg At, Berger KI, Clemens PR, Chien YH, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Goker-Alpan O, Kostera-Pruszczyk A, Haack KA, Hug C, Huynh-Ba O, Johnson J, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late onset Pompe disease

- (COMET): A Phase 3, randomized, multicenter trial. *Lancet Neurol.* 2021 Dec; 20(12):1012-1026. Doi: 10.1016/S1474-4422(21)00241-6. PMID: 34800399
334. Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Laforet P, Toscano A, Castelli J, Diaz-Manera J, Goldman M, van der Ploeg AT, Bratkovic D, Kuchipudi S, Mozaffar T, **Kishnani PS**; PROPEL Study Group. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL); an international, randomized, double-blind, parallel-group, phase 3 trial. *Lancet Neurol.* 2021 Dec; 20(12):1027-1037. Doi: 10.1016/S1474-4422(21)00331-8. PMID: 34800400
335. Hijazi G, Paschall A, Young SP, Smith B, Case LE, Boggs T, Amarasekara S, Austin SL, Pendyal S, El-Gharbawy A, Deak KL, Muir AJ, **Kishnani PS**. A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III. *Mol Genet Metab Rep.* 2021 Nov 11; 29:100821. Doi: 10.1016/j.ymgmr.2021.100821. eCollection 2021 Dec. PMID: 34820282
336. Lucia A, Martinuzzi A, Nogales-Gadea G, Quinlivan R, Reason S; International Association of Muscle Glycogen Storage Disease study group. Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group. *Neuromuscul Disord.* 2021 Dec; 31(12):1296-1310. Doi: 10.1016/j.nmd.2021.10.006. Epub 2021 Oct 28. PMID: 34848128
337. Duong T, **Kishnani PS**, An Haack K, Foster M, Gibson JB, Wilson C, Hahn SH, Hillman R, Kronn D, Leslie ND, Pena LDM, Sparks SE, Stockton DW, Tanpaiboon P, Day JW; Pompe ADVANCE Study Consortium. Motor Responses in Pediatric Pompe Disease in the ADVANCE Participant Cohort. *J Neuromuscul Dis.* 2022;9(6):713-730. Doi: 10.3233/JND-210784. PMID: 36214004
338. **Kishnani PS**, Al-Hertani W, Balwani M, Goker-Alpan O, Lau HA, Wasserstein M, Weinreb NJ, Grabowski G. Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus. *Mol Genet Metab.* 2021 Dec 22:S1096-7192(21)01194-X. Doi: 10.1016/j.ymgme.2021.12009. Online ahead of print. PMID: 34972655
339. Goeldner C, **Kishnani PS**, Skotko BG, Casero JL, Hipp JF, Derks M, Hernandez MC, Khwaja O, Lennon-Chrimes S, Noeldeke J, Pellicer S, Dquassante L, Visootsak J, Wandel C, Fontoura P, d'Ardhuy XL; Clematis Study Group. A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA- α 5 NAM (basmisanil) on intellectual disability associated with Down syndrome. *J Neurodev Disord.* 2022 Feb 5; 14(1):10. Doi: 10.11186/s11689-022-09418-0. PMID: 35123401
340. Byrne BJ, Colan SD, **Kishnani PS**, Foster MC, Sparks SE, Gibson JB, An Haack K, Stockton DW, Pena LDM, Hahn SH, Johnson J, Tanpaiboon PX, Leslie ND, Kronn D, Hillman RE, Wang RY; Pompe ADVANCE Study Consortium. Cardiac response in paediatric Pompe disease in the ADVANCE patient cohort. *Cardiol Young.* 2022 Mar;32(3):364-373. doi: 10.1017/S1047951121002079. Epub 2021 Aug 23. PMID: 34420548
341. Huggins E, Holland M, Case LE, Blount J, Landstrom AP, Jones HN, **Kishnani, PS**. Early clinical phenotype of late onset Pompe disease: Lessons learned from newborn screening. *Mol Genet Metab.*

- 2022 Jan 23:S1096-7192(22)00017-8. Doi: 10.1016/j.ymgme.2022.01.003. Online ahead of print. PMID: 35123877
342. Weinreb NJ, Goker-Alpan O, **Kishnani PS**, Longo N, Burrow TA, Bernat JA, Gupta P, Henderson N, Pedro H, Prada CE, Vats D, Pathak RR, Wright E, Ficicioglu C. The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here? *Mol Genet Metab*. 2022 Mar 9:S1096-7192(22)00152-4. Doi: 10.1016/j.ymgme.2022.03.001. Online ahead of print. PMID: 35367141
343. Dimachkie MM, Barohn RJ, Byrne B, Goker-Alpan O, **Kishnani PS**, Ladha S, Laforêt P, Mengel KE, Peña LDM, Sacconi S, Straub V, Trivedi J, Van Damme P, van der Ploeg AT, Vissing J, Young P, Haack KA, Foster M, Gilbert JM, Miossec P, Vitse O, Zhou T, Schoser B; NEO-EXT investigators. Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease. *Neurology*. 2022 May 26:10.1212/WNL.0000000000200746. Doi: 10.1212/WNL.0000000000200746. Online ahead of print. PMID: 35618441
344. Hannah WB, Ong RC, Moreno MN, Pendyal S, Abdelmalak M, Kelsen J, McGreal NM, **Kishnani PS**. Very early-onset inflammatory bowel disease: Novel description in glycogen storage disease type Ia. *Mol Genet Metab Rep*. 2022 Feb 15; 31:100848. Doi: 10.1016/j.ymgmr.2022.100848. eCollection 2022 Jun. PMID: 35242580
345. El-Gharbawy A, Tolun AA, Halaby CA, Austin SL, **Kishnani PS**, Bali DS. Beyond predicting diagnosis: Is there a role for measuring biotinidase activity in liver glycogen storage disease? *Mol Genet Metab Rep*. 2022 Feb 28;31:100856. Doi: 10.1016/j.ymgmr.2022.100856. eCollection 2022 Jun. PMID: 35782603
346. Dahir KM, Seefried L, **Kishnani PS**, Petryk, Högler W, Linglart A, Martos-Moreno GÁ, Ozono K, Fang S, Rockman-Greenberg C. Clinical profiles of treated untreated adults with hypophosphatasia in the Global HPP Registry. *Orphanet J Rare Dis*. 2022 Jul 19;17(1):277. Doi: 10.1186/s13023-022-02393-8. PMID: 35854311
347. Roger AL, Sethi R, Huston ML, Scarrow E, Bao-Dai, J, Lai E, Biswas DD, El Haddad L, Strickland LM, **Kishnani PS**, ElMallah MK. What's new and what's next for gene therapy in Pompe disease? *Expert Opin Biol Ther*. 2022 Apr 15. Doi: 10.1080/14712598.2022.2067476. Online ahead of print. PMID: 35428407
348. Curelaru S, Desai AK, Fink D, Zehavi Y, **Kishnani PS**, Spiegel R. A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation. *Mol Genet Metab Rep*. 2022 Jul 6;32:100893. Doi: 10.1016/j.ymgmr.2022.100893. eCollection 2022 Sep. PMID: 35813979
349. Kiely BT, Koch RL, Flores L, Burner D, Kaplan S, **Kishnani PS**. A novel approach to characterize phenotypic variation in GSD IV: Reconceptualizing the clinical continuum. *Front Genet*. 2022 Sep 13;13:992406. Doi: 10.3389/fgene.2022.992406. eCollection 2022. PMID: 36176296
350. Goomer S, Huggins E, Rehder CW, Cohen JL, Bali DS, **Kishnani PS**. Development of a clinically validated *in vitro* functional assay to assess pathogenicity of novel GAA variants in patients with Pompe

- disease identified *via* newborn screening. *Front Genet.* 2022 Sep 30;13:1001154. Doi: 10.3389/fgene.2022.1001154. eCollection 2022. PMID: 36246652
351. Santoro SL, Baumer NT, Cornacchia M, Franklin C, Hart SJ, Haugen K, Hojlo MA, Horick N, **Kishnani PS**, Krell K, McCormick A, Milliken AL, Oreskovic NM, Pawlowski KG, Sargado S, Torres A, Valentini D, Vellody K, Skotko BG. Unexplained regression in Down syndrome: Management of 51 patients in an international patient database. *Am J Med Genet A.* 2022 Aug 4. Doi: 10.1002/ajmg.a.62922. Online ahead of print. PMID: 35924793
352. Mistry PK, **Kishnani PS**, Wanner C, Dong D, Bender J, Bastista JL, Foster J. Rare lysosomal disease registries: lessons learned over three decades of real-world evidence. *Orphanet J Rare Dis.* 2022 Oct 17;17(1):362. Doi: 10.1186/s13023-022-02517-0. PMID: 36244992
353. Hannah WB, Ryan K, Pendyal S, Burrow TA, Harley SE, Cordell M, McCall CM, Mavis AM, Tan QK, **Kishnani PS**. Clinical insights from Wolman disease: Evaluating infantile hepatosplenomegaly. *Am J Med Genet A.* 2022 Aug 16. Doi: 10.1002/ajmg.a.62923. Online ahead of print. PMID: 35972026
354. Gayed MM, Jung SH, Huggins E, Rodriguez-Rassi E, DeArme S, **Kishnani PS**, Stiles AR. Glucosylsphingosine (Lyso-Gb¹): An Informative Biomarker in the Clinical Monitoring of Patients with Gaucher Disease. *Int J Mol Sci.* 2022 Nov 29;23(23):14938. Doi: 10.3390/ijms232314938. PMID: 36499264
355. Lim JA, **Kishnani PS**, Sun B. Suppression of pullulanase-induced cytotoxic T cell response with a dual promoter in GSD IIIa mice. *JCI Insight.* 2022 Dec 8;7(23):e152970. Doi: 10.1172/jci.insight152970. PMID: 36264632
356. Cohen JL, Chakraborty P, Fung-Kee-Fung K, Schwab ME, Bali D, Young SP, Gelb MH, Khaledi H, DiBattista A, Smallshaw S, Moretti F, Wong D, Lacroix C, El Demellawy D, Strickland KC, Loughheed J, Moon-Grady A, Lianoglou BR, Harmatz, **Kishnani PS**, MacKenzie TC. In Utero Enzyme-Replacement Therapy for Infantile-Onset Pompe's Disease. *N Engl J Med.* 2022 Dec 8;387(23):2150-2158. Doi: 10.1056/NEJMoa2200587. Epub 2022 Nov 9. PMID: 36351280
357. **Kishnani PS**, Kronn D, Brassier A, Broomfield A, Davison J, Hahn SH, Kumada S, Labarthe F, Ohki H, Pichard S, Prakalapakorn SG, Haack KA, Kittner B, Meng X, Sparks S, Wilson C, Zaher A, Chien YH; Mini-COMET Investigators. Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report. *Genet Med.* 2023 Feb;25(2):100328. Doi: 10.1016/j.gim.2022.10.010. Epub 2022 Dec 21. PMID: 36542086
358. Oreskovic NM, Baumer NT, Di Camillo C, Cornacchia M, Franklin C, Hart SJ, **Kishnani PS**, McCormick A, Milliken AL, Patsiogiannis V, Pawlowski KG, Santoro SL, Sargado S, Scoppola V, Torres A, Valentini D, Vellody K, Villani A, Skotko BG. Cardiometabolic profiles in children and adults with overweight and obesity and down syndrome. *Am J Med Genet A.* 2023 Mar;191(3):813-822. Doi: 10.1002/ajmg.a.63088. Epub 2022 Dec 20. PMID: 36538912
359. Yu TW, Kingsmore SF, Green RC, MacKenzie T, Wasserstein M, Caggana M, Gold NB, Kennedy A,

- Kishnani PS**, Might M, Brooks PJ, Morris JA, Parisi MA, Urv TK. Are we prepared to deliver gene-targeted therapies for rare diseases? *Am J Med Genet C Semin Med Genet.* 2023 Mar;193(1):7-12. Doi: 10.1002/ajmg.c.32029. Epub 2023 Jan 24. PMID: 36691939
360. Koch RL, Soler-Alfonso C, Kiely BT, Asai A, Smith AL, Bali DS, Kang PB, Landstrom AP, Akman HO, Burrow TA, Orthmann-Murphy JL, Goldman DS, Pendyal S, El-Gharbawy AH, Austin SL, Case LE, Schiffmann R, Hirano M, **Kishnani PS**. Diagnosis and management of glycogen storage disease type IV, including adult polyglucosan body disease: A clinical practice resource. *Mol Genet Metab.* 2023 Mar;138(3):107525. Doi: 10.1016/j.ymgme.2023.107535. Epub 2023 Jan 25. PMID: 36796138
361. Buckley AF, Desai AK, Ha CI, Petersen MA, Estrada JC, Waterfield JR, Bossen EH, **Kishnani PS**. Outside the fiber: Endomysial stromal and capillary pathology in skeletal muscle may impede infusion therapy in infantile-onset Pompe disease. *J Neuropathol Exp Neurol.* 2023 Mar 20;82(4):345-362. Doi: 10.1093/jnen/nlad012. PMID: 36864705
362. Dahir KM, **Kishnani PS**, Martos-Moreno GA, Linglart A, Petryk A, Rockman-Greenberg C, Martel SE, Ozono K, Holger W, Seefried L. Impact of muscular symptoms and/or pain on disease characteristics, disability, and quality of life in adult patients with hypophosphatasia: A cross-sectional analysis from the Global HPP Registry. *Front Endocrinol (Lausanne).* 2023 Mar 27;14:1138599. doi: 10.3389/fendo.2023.1138599. eCollection 2023. PMID: 37051203
363. Santoro SL, Baumer NT, Cornacchia M, Franklin C, Hart SJ, Haugen K, Hojlo MA, Horick N, **Kishnani PS**, Krell K, McCormick A, Milliken AL, Oreskovic NM, Pawlowski KG, Sargado S, Torres A, Valentini D, Vellody K, Skotko BG. Response to Letter to the Editor by Palffy and Ghaziuddin. *Am J Med Genet A.* 2023 May;191(5):1470-1473. Doi: 10.1002/ajmg.a.63116. Epub 2023 Jan 6. PMID: 36609854
364. Hoegler W, Linglart A, Petryk A, **Kishnani PS**, Seefried L, Fang S, Rockman-Greenberg C, Ozono K, Dahir K, Martos-Moreno GA. Growth and disease burden in children with hypophosphatasia. *Endocr Connect.* 2023 April 25;12(5):e220240. Doi: 10.1530/EC-22-0240. Print 2023 May 1. PMID: 36917043.
365. Mistry PK, **Kishnani PS**, Balwani M, Charrow JM, Hull J, Weinreb NJ, Cox TM. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). *J. Clin. Med.* 2022, 11, 5158. *J Clin Med.* 2023 May 4;12(9):3269. doi: 10.3390/jcm12093269. PMID: 3717670
366. **Kishnani PS**, Diaz-Manera J, Toscano A, Clemens PR, Ladha S, Berger KI, Kushlaf H, Straub V, Carvalho G, Mozaffar T, Roberts M, Attarian S, Chien YH, Choi YC, Day JW, Erdem-Ozdamar S, Illarioshkin S, Goker-Alpan O, Kostera-Pruszyk A, van der Ploeg AT, An Haack K, Huynh-Ba O, Tammireddy S, Thibault N, Zhou T, Dimackkie MM, Schoser B; COMET Investigator Group. Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial. *JAMA Neurol.* 2023 Jun 1;80(6):558-567. doi: 10.1001/jamaneurol.2023.0552. PMID: 37036722

367. Smith EC, Hopkins S, Case LE, Xu M, Walters C, Dearnley S, Han SO, Spears TG, Chichester JA, Bossen EH, Hornik CP, Cohen JL, Bali D, **Kishnani PS**, Koeberl DD. Phase I Study of Liver Depot Gene Therapy in Late-onset Pompe Disease. *Mol Ther.* 2023 Jul 5;31(7):1994-2004. Doi: 10.1016/j.ymthe.2023.02.014. Epub 2023 Feb 18. PMID: 36805083
368. Koeberl DD, Koch RL, Lim JA, Brooks ED, Arnson BD, Sun B, **Kishnani PS**. Gene therapy for glycogen storage diseases. *J Inherit Metab Dis.* 2023 July 8. doi: 10.1002/JIMD.12654. Online ahead of print. PMID: 37421310
369. Neel AT, Crisp KD, **Kishnani PS**, Jones HN. Speech Disorders in Children with Pompe Disease: Articulation, Resonance, and Voice Measures. *Am J Speech Lang Pathol.* 2023 Jul 10;32(4): 1501-1516. doi: 10.1044/2023_AJSLP-22-00382. Epub 2024 May 17. PMID: 37195639.
370. Martos-Moreno GA, Rockman-Greenberg C, Ozono K, Petryk A, **Kishnani PS**, Dahir KM, Seefried L, Fang S, Hogler W, Linglart A. Clinical Profiles of Children with Hypophosphatasia Prior to Treatment with Enzyme Replacement Therapy: An Observational Analysis from the Global HPP Registry. *Horm Res Paediatr.* 2023 Jul 13. doi: 10.1159/000531865. Online ahead of print. PMID: 37442110
371. Choi SJ, Yi JS, Lim JA, Tedder TF, Koeberl DD, Jeck W, Desai A, Rosenberg A, Sun B, **Kishnani PS**. Successful AAV8 readministration: Suppression of capsid-specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease. *J Gene Med.* 2023 Mar 30:e3509. doi: 10.1002/jgm.3509. Online ahead of print. PMID: 36994804
372. Worley G, Byeon SK, Smith PB, Hart SJ, Young SP, Pandey A, **Kishnani PS**. An exploratory study of plasma ceramides in comorbidities in Down syndrome. *Am J Med Genet A.* 2023 Jun 21. doi: 10.1002/ajmg.a.63325. Online ahead of print. PMID: 37340831
373. Kim KH, Desai AK, Vucko ER, Boggs T, **Kishnani PS**, Burton BK. Development of high sustained anti-drug antibody titers and corresponding clinical decline in a late-onset Pompe disease patient after 11+ years of enzyme replacement therapy. *Mol Genet Metab Rep.* 2023 Jun 13;36:100981. doi: 10.1016/j.ymgmr.2023.100981. eCollection 2023 Sep. PMID: 37342670
374. Jackson DG, Case LE, Huggins E, Holland M, Blount J, Webb LH, **Kishnani PS**. Muscle Ultrasound in patients with late-onset Pompe disease identified by newborn screening. *Mol Genet Metab Rep.* 2023 Jul 5;36:100989. doi: 10.1016/J.ymgmr.2023.100989. eCollection 2023 Sep. PMID: 37670900
375. El Haddad L, Khan M, Soufny R, Mummy D, Driehuys B, Mansour W, **Kishnani PS**, ElMallah MK. Monitoring and Management of Respiratory Function in Pompe Disease: Current Perspectives. *Ther Clin Risk Manag.* 2023 Sep 1;19:71-729. doi: 10.2147/TCRM.S362871. eCollection 2023. PMID: 37680303
376. Hannah WB, Case LE, Smith EC, Walters C, Bali D, **Kishnani PS**, Koeberl DD. Screening data from 19 patients with late-onset Pompe disease for a phase I clinical trial of AAV8 vector-mediated gene therapy. *JIMD Rep.* 2023 Aug 17;64(5):393-400. doi: 10.1002/jmd2.12391. eCollection 2023 Sep. PMID: 37701327
377. Jackson DG, Koch RL, Pendyal S, Benjamin R, **Kishnani PS**. Development of hepatocellular adenomas

- in a patient with glycogen storage disease Ia treated with growth hormone therapy. *JIMD Rep.* 2023 Aug 18;64(5):303-311. doi: 10.1002/jmd2.12381. eCollection 2023 Sep. PMID: 37701330
378. Hannah WB, Derks TGJ, Drumm ML, Grünert SC, **Kishnani PS**, Vissing J. Glycogen Storage Disease. *J. Nat Rev Dis Primers.* 2023 Sep 7;9(1):46. doi: 10.1038/s41572-023-00456-z. PMID: 37679331
379. Dimachkie MM, **Kishnani PS**, Ivanescu C, Flore G, Gwaltney C, van der Beek NAME, Hamed A, An Haack K, Pollissard L, Baranowski E, Sparks SE, DasMahapartra P; for COMET Study Group. Measurement Properties of 2 novel PROs, the Pompe Disease Symptom Scale and Pompe Disease Impact Scale, in the COMET Study. *Neurol Clin Pract.* 2023 Oct;13(5):e200181. doi: 10.1212/CPJ.0000000000200181. Epub 2023 Aug 8. PMID: 37559825
380. Santoro SL, Baloh CH, Hart SJ, Horick N, **Kishnani PS**, Krell K, Oreskovia NM, Shaffer M, Talib N, Torres A, Spiridigliozzi GA, Skotko BG. Pneumonia vaccine response in individuals with Down syndrome at three specialty clinics. *Am J Med Genet C Semin Med Genet.* 2023 Oct20:e32070. doi: 10.1002/ajmg.c.32070. Online ahead of print. PMID: 37864360
381. Farman MR, Rehder C, Malli T, Rockman-Greenberg C, Dahir K, Martos-Moreno GA, Linglart A, Ozono K, Seefried L, Del Angel G, Webersinke G, Barbazza F, John LK, Delana Mudiyansele SMA, Hogler F, Nading EB, Huggins, E, Rush ET, El-Gazzar A, **Kishnani PS**, Hogler W. The Global ALPL gene variant classification project: Dedicated to deciphering variants. *Bone.* 2023 Oct 26;178:116947. doi: 10.1016/J.bone.2023.116947. Online ahead of print. PMID: 37898381
382. Herzeb A, Borges B, Lianoglou BR, Gonzalez-Velez J, Canepa E, Munar D, Young SP, Bali D, Gelb MH, Chakraborty P, **Kishnani PS**, Harmatz P, Cohen JL, MacKenzie TC. Intrauterine enzyme replacement therapies for lysosomal storage disorders: Current development and promising future prospects. *Prenat Diagn.* 2023 Dec;43(13):1638-1649. doi: 10.1002/pd.6460. Epub 2023 Nov 13. PMID: 37955580
383. Byrne BJ, Schoser B, **Kishnani PS**, Bratkovic D, Clemens PR, Goker-Alpan O, Ming X, Roberts M, Vorgerd M, Sivakumar K, van der Ploeg AT, Goldman M, Wright J, Holdbrook F, Jain V, Benjamin ER, Johnson F, Das SS, Wasfi Y, Mozaffar T. Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02). *J Neurol.* 2023 Dec 6. doi: 10.1007/s00415-023-12096-0. Online ahead of print. PMID: 38057636
384. **Kishnani PS**, Kronn D, Suwazono S, Broomfield A, Llernea J, Al-Hassnan ZN, Batista JL, Wilson KM, Periquet M, Daba N, Hahn A, Chien YH. Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry. *Orphanet J Rare Dis.* 2023 Dec6;18(1):381. doi: 10.1186/s13023-023-02981-2. PMID: 38057861
385. Gayed MM, Sgobbi P, Pinto WBVR, **Kishnani PS**, Koch RL. Case Report: Expanding the understanding of the adult polyglucosan body disease continuum: novel presentations, diagnostic pitfalls, and clinical pearls. *Front Genet.* 2023 Dec 18;14:1282790. doi: 10.3389/fgene.2023.1292790 eCollection 2023. PMID: 38164512
386. Toscano A, Pollissard L, Msihid J, van der Beek N, **Kishnani PS**, Dimachkie MM, Berger KI,

- DasMahapatra P, Thibault N, Hamed A, Zhou T, Haack KA, Schoser B. Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trail. *Mol Genet Metab.* 2023 Dec 27;108121. doi: 10.1016/j.ymgme.2023.108121. Online ahead of print. PMID: 38184428
387. Kenney-Jung D, Korlimarla A, Spiridigliozzi GA, Wiggins W, Malinzak M, Nichting G, Jung SH, Sun A, Wang RY, Al Shamsi A, Phornphutkul C, Owens J, Provenzale JM, **Kishnani PS**. Severe CNS involvement in a subset of long-term treated children with infantile-onset Pompe disease. *Mol Genet Metab.* 2023 Dec 22;108119. doi: 10.1016/j.ymgme.2023.108119. Online ahead of print. PMID: 38184429
388. Dahir KM, Rush ET, Diaz-Mendoza S, **Kishnani PS**. A Delphi panel to build consensus on assessing disease severity and disease progression in adult patients with hypophosphatasia in the United States. *J Endocrinol Invest.* 2024 Jan 18. doi: 10.1007/s40618-023-02256-4. Online ahead of print. PMID: 38236379
389. Desai AK, Smith PB, Yi JS, Rosenberg AS, Burt TD, **Kishnani PS**. Immunophenotype associated with high sustained antibody titers against enzyme replacement therapy in infantile-onset Pompe disease. *Front Immunol.* 2024 Jan 4;14:1301912. doi: 10.3389/fimmu.2023.1301912. eCollection 2023. PMID: 38250073
390. **Kishnani PS**, Shohet S, Raza S, Hummel N, Castelli JP, Sitaraman Das S, Jiang H, Kopiec A, Keyzor I, Hahn A. Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS®) physical function questionnaire in late-onset Pompe disease using PROPEL phase 3 data. *J Patient Rep Outcomes.* 2024 Jan 31;8(1):13. doi: 10.1186/s41687-024-00686-z. PMID: 38294575
391. Carter C, Boggs T, Case LE, **Kishnani P**. Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa. *Front Genet.* 2024 Jan 19;15:1309146. doi: 10.3389/fgene.2024.1309146. eCollection 2024. PMID: 38313679
392. Schoser B, **Kishnani PS**, Bratkovic D, Byrne BJ, Claeys KG, Diaz-Manera J, Laforet P, Roberts M, Toscano A, van der Ploeg AT, Castelli J, Goldman M, Holdbrook F, Sitaraman Das S, Wasfi Y, Mozaffar T; ATB200-07 Study Group. 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07). *J Neurol.* 2024 Feb 28. doi: 10.1007/s00415-024-12236-0. Online ahead of print. PMID: 38418563
393. **Kishnani PS**, Martos-Moreno GA, Linglart A, Petryk A, Messali A, Fang S, Rockman-Greenberg C, Ozono K, Hogler W, Seefried L, Dahir KM. Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry. *Orphanet J Rare Dis.* 2024 Mar 8;19(1):109. doi: 10.1186/s13023-024-03048-6. PMID: 38464909
394. Rosamilia MG, Markunas AM, **Kishnani PS**, Landstrom AP. Underrepresentation of Diverse Ancestries Drives Uncertainty in Genetic Variants Found in Cardiomyopathy-Associated Genes. *JACC*

Adv. 2024 Feb;3(2):100767. doi: 10.1016/j.jacadv.2023.100767. Epub 2023 Dec 15. PMID: 38464909

395. Naito C, Kosar K, Kishimoto E, Pena L, Huang Y, Hao K, Bernieh A, Kasten J, Villa C, **Kishnani P**, Deeksha B, Gu M, Asia A. Induced pluripotent stem cell (iPSC) modeling validates reduced GBE1 enzyme activity due to a novel variant, p.Ile694Asn, found in a patient with suspected glycogen storage disease IV. *Mol Genet Metab Rep*. 2024 Mar 14;39:101069. doi: 10.1016/j.ymgmr.2024.101069. eCollection 2024 Jun. PMID: 38516405
396. Desai AK, Shrivastava G, Grant CL, Wang RY, Burt TD, **Kishnani PS**. An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation. *Front Immunol*. 2024 Mar 8;15:1360369. doi: 10.3389/fimmu.2024.1360369. eCollection 2024. PMID: 38524130
397. Mistry PK, Balwani M, Charrow J, Lorber J, Niederau C, Carwile JL, Oliveira-Dos Santos A, Perichon MG, Uslu Cil S, **Kishnani PS**. Long-term effectiveness of eliglustat treatment: A real-world analysis from the International Collaborative Gaucher Group Gaucher Registry. *Am J Hematol*. 2024 Apr 30. doi: 10.1002/ajh.27347. Online ahead of print. PMID: 38686876
398. Chen HA, Hsu RH, Fang CY, Desai AK, Lee NC, Hwu WL, Tsai FJ, **Kishnani PS**, Chien YH. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy. *Front Immunol*. 2024 Apr 23;15:1336599. doi: 10.3389/fimmu.2024.1336599. eCollection 2024. PMID: 38715621
399. **Kishnani PS**, Seefried L, Dahir KM, Martos-Moreno GÁ, Linglart A, Petryk A, Mowrey WR, Fang S, Ozono K, Högler W, Rockman-Greenberg C. New insights into the landscape of ALPL gene variants in patients with hypophosphatasia from the Global HPP Registry. *Am J Med Genet A*. 2024 Jun 17:e63791. doi: 10.1002/ajmg.a.63781. Online ahead of print. PMID: 38884565
400. Berger KI, Chien YH, Dubrovsky A, **Kishnani PS**, Llernea JC Jr, Neilan E, Roberts M, Sheng B, Bastista JL, Periquet M. Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe registry. *J Neurol*. 2024 Jun 19. doi: 10.1007/s00415-024-12489-9. Online ahead of print. PMID: 38896264
401. Koch, RL, Kiely BT, Choi SJ, Jeck WR, Flores LS, Sood V, Alam S, Porta G, LaVecchio K, Soler-Alfonso C, **Kishnani PS**. Natural history study of hepatic glycogen storage disease type IV and comparison to Gbe1ys/ys model. *JCI Insight*. 2024 May 14;9(12):e177722. doi: 10.1172/jci.insight.177722. PMID: 38912588

Non-Refereed Publications

1. Lipshultz SE, **Kishnani PS**, Levine JC. Lysosomal storage diseases: Current status, hope for the future continuing education publication. 2003, R & R Healthcare Communications, Inc.

2. **Kishnani PS.** Understanding Pompe Disease Booklet (Pompe connections, Signs and symptoms of Pompe disease, Adapting to living with Pompe disease, Getting the right care for Pompe disease, Exercise and physical therapy, Nutrition and dietary therapy, Breathing problems in Pompe disease, Common health concerns, Medical progress in Pompe disease, Emotional impact of Pompe disease, Having children when you have Pompe disease, Resources for learning more). 2005, IPA.
3. Li JS, Chen YT, **Kishnani PS.** Developments in the Treatment of Pompe Disease. 2006, US Cardiovascular Disease.
4. Koeberl, DD, **Kishnani PS.** Pompe Disease: Enzyme Replacement Therapy. 2008, Drugs of the Future.
5. Skeletal and Hematologic Pathology of Type 1 Gaucher Disease: Clinical Impact of Enzyme Replacement Therapy with Imiglucerase. 2008, CME Monograph.
6. Early Intervention for LSDs: What is Appropriate Care and Management of the Pre-Symptomatic Individual? A Collaborative Discussion: 2008, CME Monograph.
7. Muller CW, Jones HN, O’Grady G, Suárez AH, Heller JH, **Kishnani PS.** Language and speech function in children with infantile Pompe disease. *J Pediatr Neurol* 2009; 7:147-156.
8. Contributor to Larry Luxner blog for *Quest Media* titled “Moving Forward in Pompe Disease: Optimizing Outcomes in the era of Next-Generation Therapies and Advanced Newborn Screening”, conducted at the MDA Conference – Pompe Disease Researchers Stressed Importance of Newborn Screening and published April 2023.

Book Chapters:

1. Koeberl DD, **Kishnani PS**, Faulkner E, VanCamp S, Jackson M, Brown T, Boney A, Chen YT. Glycogen Storage Disease Type Ia in Maltese Dogs, Proceedings, Annual Meeting of American College of Veterinary Internal Medicine, May 25-27, 2000, Seattle, Washington.
2. **Kishnani PS.** Glycogen Storage Diseases, Pediatric Nutrition in Chronic Diseases and Developmental Disorders - Prevention, Assessment, and Treatment 2nd Edition, Ekvall SW, Ekvall, VK, Editors. 2005.
3. **Kishnani PS**, Chen YT. Defects in metabolism of carbohydrates, Nelson Textbook of Pediatrics 18th Edition, Kliegman R, Behrman R, Jenson H, Stanton B, Zitelli B, Davis H, Editors. 2007.
4. **Kishnani PS**, Decker M, Chen YT. Disorders of Carbohydrate Metabolism, Principles and Practices of Medical Therapy in Pregnancy 3rd Edition, Gleicher N, Editor. 2008 e-publication.
5. **Kishnani PS**, Koeberl D, Chen TY. Glycogen Storage Diseases, The Online Metabolic & Molecular Bases of Inherited Disease, Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Scriver CR, Sly WS, Childs B, Editors. 2008.
6. Demo E, Koeberl DD, **Kishnani PS.** Lysosomal storage and transport disorders, Pathobiology of Ocular Disease 3rd Edition, Garner A, Klintworth GK, Editors. 2008.
7. **Kishnani PS**, Chen YT. Glycogen Storage, Galactose, Fructose, Gluconeogenesis, Pentose Phosphate Pathway, Rudolph’s Pediatrics 22nd Edition, Rudolph AM, Rudolph C, First L, Lister G, Gershon AA, Editors. 2008.

8. **Kishnani PS**, Koeberl DD, Chen YT. Glycogen Storage Diseases, Online Metabolic and Molecular Bases of Inherited Diseases 9th Edition, Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Editors. 2010.
9. **Kishnani PS**, Chen YT. Defects in metabolism of carbohydrates, Nelson Textbook of Pediatrics 19th Edition, Kliegman R, Stanton B, St. Geme J, Schor, N, Behrman R, Editors. 2011.
10. **Kishnani PS**, Chen YT. Disorders of Carbohydrate Metabolism, Emery and Rimoin's Principles and Practice of Medical Genetics, Online 6th Edition, Rimoin DL, Reed, Pyeritz RE, & Korf, Editors. 2011.
11. **Kishnani PS**, Chen YT. Glycogen Storage Diseases and Other Inherited Disorders of Carbohydrate Metabolism, Harrison's Principles of Internal Medicine 18th Edition, Longo D, Fauci A, Kasper D, Hauser S, Jameson J, & Loscalzo J, Editors. 2011.
12. **Kishnani PS**, Glycogen Storage Diseases, Encyclopedia of the Neurological Sciences 2nd Edition. 2014.
13. **Kishnani PS**, Beckemeyer, BA. New Therapeutic Approaches for Pompe Disease: Enzyme Replacement Therapy and Beyond, Pediatric Endocrinology Reviews (PER), June 2014.
14. **Kishnani PS**, Pompe Disease, Medlink Neurology. June 2016.
15. **Kishnani PS**, Chen YT. Disorders of Glycogen Metabolism, Rudolph's Pediatrics, 23rd Edition. December 2016.
16. **Kishnani PS**, Austin S. Glycogen Storage Disease, PG Textbook of Pediatrics, 2nd Edition. November 2016.
17. **Kishnani PS**, Mori, M. Pompe Disease, PG Textbook of Pediatrics, 2nd Edition. November 2016.
18. **Kishnani PS**, Chen YT. Disorders of Galactose and Fructose Metabolism and Gluconeogenesis, Rudolph's Pediatrics, 23rd Edition. December 2016.
19. **Kishnani PS**, Chen YT. Disorders of Pentose Phosphate Pathway, Rudolph's Pediatrics, 23rd Edition. December 2016.
20. **Kishnani PS**, Chen YT. Glycogen Storage Disease and Other Inherited Disorders of Carbohydrate Metabolism, Harrison's Principles of Internal Medicine 20th Edition. Longo D, Fauci A. Kasper D, Hauser S, Jameson J, & Loscalzo J, Editors. March 2017.
21. **Kishnani PS**, Chen YT. Defects in metabolism of carbohydrates, Nelson Textbook of Pediatrics 21st Edition, Kliegman R, Stanton B, St. Geme J, Schor, N, Behrman R, Editors. May 2017.
22. **Kishnani PS**, Pompe Disease. Medlink Neurology, February 2018.
23. **Kishnani PS**. Pompe disease. MedLink, online database, Feb 2019.
24. **Kishnani PS**. Pompe disease. MedLink, online database, Feb 2020.
25. **Kishnani PS**, Chen YT. Disorders of Carbohydrate Metabolism. Emery and Rimoni's Principles and Practices of Medical Genetics and Genomics, 7th Edition. September 2020.
26. **Kishnani PS**, Korlimarla A, Hart SJ, Spiridigliozzi, GA. Down Syndrome: In Cassidy and Allanson's Management of Genetic Syndromes, Wiley and Sons, New York, 4th Edition, J.C. Carey, A. Battaglia, D. Viskochil and SB Cassidy, Editors. February 2021.
27. Korlimarla A, Gibson R, **Kishnani PS**. Glycogen storage diseases. Nutrition Management of Inherited

Metabolic Diseases, Met Ed (submitted in Feb 2021)

28. Bali DS, Austin SL, **Kishnani PS**. Prenatal Diagnosis of Disorders of Carbohydrate Metabolism. In: Genetic disorders and the fetus – diagnosis, prevention, and treatment, Wiley & Sons, New York, 8th Edition, Aubrey and Jeff Milunsky, Editors. July 2021.
29. **Kishnani PS**. Glycogen Storage Diseases and Other Inherited Disorder of Carbohydrate Metabolism, Harrison's Principles of Internal Medicine, 21st Edition. Jameson J, Editor-in-Chief. Submitted October 2021.
30. **Kishnani PS**. Glycogen Storage Diseases, Goldman-Cecil Medicine, 27th Edition, Lee Goldman, Editor-in-Chief. Submitted November 2021.
31. **Kishnani PS**, Korlimarla A. Pompe disease, MedLink Neurology, Roos EP, Editor-in-Chief. Updated: December 2021.
32. Hijazi G, **Kishnani PS**. Glycogen storage diseases, PG Textbook of Pediatrics, 3rd Edition. February 2022.
33. Hijazi G, Murala S, **Kishnani PS**. Pompe disease, PG Textbook of Pediatrics, 3rd Edition. February 2022.
34. Hijazi G, **Kishnani PS**. Defects in metabolism of carbohydrates, Nelson Textbook of Pediatrics, 22nd Edition. Submitted February 2022.
35. Korlimarla A, Gibson R, **Kishnani PS**. Glycogen Storage Diseases, Springer, Cham. In: Bernstein, L.E. Rohr, F, van Calcar S, editor Nutrition Management of Inherited Metabolic Diseases. Published June 2022. Dio.org/10.1007/978-3-030-94510-7_25. Print ISBN: 978-3-030-94509-1; Online ISBN: 978-3-030-94510-7.
36. Reuser A, van der Ploeg A, **Kishnani PS**, Pim Pijnappel WWM. Pompe Disease from PART 2: The Individual Diseases, Wiley & Sons, New York, 2nd Edition, Chapter 17. Atul B. Mehta and Bryan Winchester, Book Editors, Published July 2022. Doi.org/10.1002/9781119697312.ch17. Print ISBN: 9781119697282 and Online ISBN: 9781119697312.

Other

Published Scientific Reviews for Mass Distribution:

1. Abstracts and scientific presentations in newsletters for the National Association for Glycogen Storage Disease.
2. Abstracts and scientific presentations in newsletters for Pompe Disease for International Pompe Association (IPA), Acid Maltase Disease Association (AMDA), Genzyme Corporation.
3. Abstracts & commentaries for the Triangle Down Syndrome Network.
4. Abstracts & commentaries for the Canadian Down Syndrome Network.

Editorial Experience:

Editorial Boards:

Molecular Genetics and Metabolism, 2015- current

Ad Hoc scientific review journals:

American Journal of Medical Genetics
Clinical Pediatrics
European Journal of Pediatrics
Genetics in Medicine
JAMA
JCI
Journal of Genetic Counseling
Journal of Inherited Metabolic Disorders
Journal of Pediatrics
Lancet
Molecular Genetics and Metabolism
Molecular Therapy
Muscle and Nerve
NEJM
Neurology
Pediatrics

Invited Editor for American Journal of Medical Genetics for the Down syndrome, supplement, 2006

Invited Editor for American Journal of Medical Genetics for Pompe disease, supplement, 2012

Invited Editor for Pediatrics for Newborn Screening in Pompe Disease, supplement, 2017

Patents/Inventions:

29 Duke Invention Disclosures

45 Issued Patents (US and foreign)

13 Pending Patent Applications (US and foreign)

Representative Patents

US Patent #10,647,969, "Method of Treating Glycogen Storage Disease," issued 5/12/2020

US Patent #8,809,282, "Methods of Treatment in Diseases Treated with Therapeutic Proteins," issued 8/19/2014

US Patent #8,679,478 "Methods of Lysosomal Storage Disease Therapy," issued 8/19/2014

Professional Awards and Special Recognitions:

I.C.S.E.	Delhi Board	November 1978	Distinction
H.S.C.E.	Maharashtra	March 1981	Distinction
I M.B.B.S.	Bombay	October 1982	Ranked 5th/583 overall at University of Bombay Distinction in Anatomy, I M.B.B.S.
II M.B.B.S.	Bombay	April 1984	Distinction in Microbiology, II M.B.B.S. First in Pathology - Awarded Dr. S.B. Kekre's and Dr. Manek Bilimoria's Prizes in II M.B.B.S. Distinction in Pharmacology, II M.B.B.S.
III M.B.B.S.	Bombay	October 1985	Ranked 3rd/603 overall at University of Bombay
D.C.H.	Bombay	April 1989	Distinction
M.D.	Bombay	March 1990	Ranked first overall at institution (Pediatrics)

- Fellow Travel Award **for Outstanding Research to the Society of Inherited Metabolic Disorders Conference in Perdido Beach, AL**, March 1995.
- Fellow Travel Award from the **Society for the Study of Inborn Errors of Metabolism in Toledo, Spain**, September 1995.
- Special Recognition by University President Nannerl O. Keohane at Annual Meeting of Duke University Board of Trustees, **for original research in Down syndrome**, 1999.
- Special Recognition Honors from Triangle Down Syndrome Network Board of Directors, **for contributions professionally and personally in the lives of individuals with Down syndrome**, 2001.
- Interviewed by Wall Street Journal for work in Down syndrome research, published **in article “New Hope for Treating Down Syndrome”**, April 18, 2005.
- Exceptional Parent Maxwell J. Schleiffer Distinguished Service Award, **for passion, dedication, professionalism and inspiration to people with disabilities, particularly those with Pompe disease**, 2005.
- Interviewed by Wall Street Journal for work in Pompe disease, published **in article “Genzyme Drug for Rare Pompe Disease Approval,”** April 29, 2006.
- Ruth and A. Morris Williams, Jr Faculty Research Prize, **for intellectual vigor, dedication, and scientific ingenuity needed to make a critical impact on the future of medical research**, 2008.
- Recognized in list of North Carolina Best Doctors, 2009, 2011-current.
- National Down Syndrome Congress, Christian Pueschel Memorial Research Award, **for outstanding clinical research that improves lives through greater understanding of Down syndrome**, 2010.
- Anna’s Angels Award, recognition by Anna’s Angels Foundation **for passion and devotion to Down syndrome research**, 2012.
- Association of Glycogen Storage Disease, **Lifetime Membership**, September 2014.
- Dr SS Agarwal Oration Award for **“Novel Therapies for Genetic Disorders”**, given by the Society for Indian Academy of Medical Genetics, during the IAMGCON, 2015.
- **Rare Disease Hero Award in Lysosomal Disease**, given by the Rare Disease Report, October 2016.
- **Sandor Oration Award**, given by the Indian Society of Inborn Errors of Metabolism for work in rare diseases in India, February 2017.
- Recognized as one of the 2021 **Pioneering Women in Science for Duke Health**, February 2021.
- Recipient of the Duke Medical Alumni Association’s **Distinguished Faculty Award**, February 2021.
- Featured in the 9th Annual Women’s Issue of *Durham Magazine* as **Women of Achievement**, May 2021.
- **2021 Emmanuel Shapira Award**, given to a Society for Inherited Metabolic Disorders Member for best paper in the field of biochemical genetics and metabolism published in *Molecular Genetics and Metabolism*, “Investigation of ALPL variant states and clinical outcomes: An analysis of adults and adolescents with hypophosphatasia treated with asfotase alfa”, 2021.
- **2022 Recipient of the North Carolina Award for Science**, State Highest Honor, administrated by the N.C. Department of Natural and Cultural Resources, November 2022.
- Received the 2022 HSNC (Hindu Society of North Carolina) **award for Pioneering research and Treatment for Glycogen Storage Diseases (GSD)**
- Received the **2024 Faculty Mentoring Award** for the Duke University School of Medicine, Department of Pediatrics, June 2024.

Mentoring Activities:

A) FACULTY

NAME	MENTORSHIP ROLE	CURRENT POSITION
Laura Case, PT, DPT, MS, PCS, C/NDT	Involvement and design of PT endpoints for clinical trials of neuromuscular disorders such as Pompe disease, SMA, Duchenne muscular dystrophy	Associate Professor of Orthopedic Surgery Duke Medical Center Pediatrics Physical Therapy Duke Children's Hospital Durham, NC
Jennifer L. Cohen, MD	Gene therapy for Pompe disease IUERT to treat lysosomal disorders	Assistant Professor of Pediatrics, Department of Pediatrics, Division of Medical Genetics, Duke Medical Center, Durham, NC
Mai ElMallah, MD, PhD	Pulmonary aspects of Pompe disease. Role of AAV gene therapy in correcting systemic and neurologic aspects of Pompe disease	Chief, Division of Pulmonary and Sleep Medicine' Department of Pediatrics, Duke University Medical Center, Durham, NC
Areeg El-Gharbawy, MD	Metabolomics – role in GSD I and other liver GSDs	Associate Professor of Pediatrics, Department of Pediatrics, Division of Medical Genetics, Duke University Medical Center, Durham, NC
Harrison Jones, PhD	Development of respiratory muscle strength training (RMST) as an adjunctive therapy for Pompe disease. Speech and articulation challenges in Down syndrome	Associate Professor of Surgery, Department of Surgery, Head and Neck Surgery and Communication Sciences, Duke University Medical Center, Durham, NC
Sujay Kansagra, MD	Clinical research approaches for rare diseases	Associate Professor of Pediatrics Pediatric Neurologist School of Medicine Duke Medical Center Durham, NC
Gwen O'Grady, PhD	Development of an algorithm for systematic evaluation of hearing in Pompe disease	Audiologist Division of Speech Pathology and Audiology Duke Medical Center and Duke Children's Hospital Durham, NC
Grace Prakalapakorn, MD	Ophthalmologic endpoints as a way to measure treatment response in clinical trials for infantile Pompe disease.	Associate Professor of Ophthalmology; Assistant Professor in Pediatrics, Duke Medical Center, Durham, NC

Veronica Gough	Member, Pre-Prelim Committee	2018 – Gersbach Lab	2022
Apoorva Iyengar	Member, Pre-Prelim Committee	2021 – Reddy Lab	2023
Alan Rosales	Member, Pre-Prelim Committee	2021 – Asokan Lab	2023
Tong Chen	Member, Pre-Prelim Committee	2021 – Bissig Lab	2024
Makenzie Beaman	Member, UPGG Thesis Committee	2021 – Crawford Lab	2024

Mentorship Committee for Undergraduate Students

Student	Type	Approximate Start	Approximate End
Emily Duerr	Committee Chair (primary faculty advisor)	2022 – Kishnani Lab	2023

Mentor to High School Students (select list of more than 50 students that I have mentored)

Student	Time Period	Current
Vivek Ramaswamy	2001-2002	Chairman and President, Roivant Science
Shankar Ramaswamy	2005-2006	Co-Founder and Chief Executive Officer, Kriya Therapeutics
Rahul Jawaney	2010-2011	Cardiology Fellowship at Cleveland Clinic
Karishma Desai	2011-2012	Dermatology residency, Leonard M. Miller School of Medicine, University of Miami
Shaylee Boger	Aug. 3-Aug 12, 2017	Sophomore at Trinity College, who was honored with 2017 Sanofi Genzyme Torch award (for contributions to the LSD community)
Rasika Rajagoplan		Senior Manager, People and Culture Business Partner at Curology
Neha Jumani	2022 – Present	

Education / Teaching Activities:

- Resident teaching, medical student and fellows training at Duke University Medical Center.
- Genetic counselor teaching of biochemical genetics at Duke University Medical Center.
- Medical student genetics teaching course at Duke University Medical Center.
- Participation and presentations at Pediatric Grand Rounds.
- Participation and presentations in Pediatric Faculty Research Conferences.
- Participation and presentations in weekly Genetics and Metabolism research and teaching seminars.
- Presentations at Grand Rounds in Outreach centers for Duke University and by invitation to outside institutions.
- Participation and presentations in the Duke Clinical Research Unit Rounds.
- Participation in Liaison Committee on Medical Education (LCME) of Department of Pediatrics, Duke University Medical Center.
- Invited lecturer at Clinical Correlation Molecules, Cells & Tissues Course, “Glycogen Storage Disease”, Duke University Medical Center.

Invited Lectures and Presentations:

1. Pulmonary Hypertension in Glycogen Storage Disease Type I (GSDI). Annual American Glycogen Storage Disease Association, Atlanta, GA, 1995.

2. Down Syndrome – Overview and management, Pediatric Grand Rounds, Rex Hospital, Durham, NC, 1996.
3. Down syndrome – Overview and management, Pediatric Grand Rounds, Rocky Mount, NC, 1997.
4. Nutritional deficiencies in Glycogen Storage Disease Type I (GSDI). Annual American Glycogen Storage Disease Association, Raleigh, NC, 1997.
5. Mutation in canine Glucose-6-Phosphatase Deficiency (glycogen storage disease type Ia
6. , GSD-Ia), American Maltese Association, 1997.
7. Clinical & Molecular Evaluation in Glycogen Storage Disease type III. Association for Glycogen Storage Disease Annual meeting, Davenport, IA, 1998.
8. Overview of Management Issues and Current Trends in Down syndrome. Coastal Down syndrome Quarterly Meeting, Shallotte, SC. March 1998.
9. Cholinergic Therapy and overview of current trends in Down syndrome. Down syndrome Association of Charlotte, NC, October 1998.
10. Cholinergic Therapy and Celiac disease in Down syndrome. Down syndrome Family Alliance of Greenville, SC, November 1998.
11. Overview of Management Issues and Current Trends in Down syndrome. Triangle Down Syndrome Society, Durham, NC, July 1999.
12. Canine model of Glycogen Storage Disease Type Ia. Association for Glycogen Storage Disease Annual meeting, Seattle, WA, September 1999.
13. Down syndrome: Treatment with Donepezil. Pfizer and Eisai Pharmaceuticals, October 1999.
14. Down syndrome: A Health care update Conference at Children’s Hospital of Pittsburgh, Research Panel and speaker for treatment strategies in Down syndrome, November 1999.
15. "Life during CAP" session at the NIH. Invited speaker to serve as a role model to discuss what CAP’s should be trying to accomplish during their tenure to make them remain competitive in academic medicine, Washington, DC, March 2000.
16. Participation in Australian Radio National network presentation regarding Donepezil hydrochloride on four individuals with Down syndrome, March 2000.
17. Participation in the BBC Radio Network presentation regarding Donepezil hydrochloride in the treatment of individuals with Down syndrome, March 2000.
18. Invited speaker at launch meeting for multicenter trial for role of Donepezil in cognition in individuals with Down syndrome, Charleston, SC, December 2000.
19. Invited speaker at 2001 Down Syndrome Family Conference, Columbia, SC, May 2001.
20. Invited speaker at Association for Glycogen Storage Disease, "Recent advances in treatment trials for glycogen storage disease, type III", Tampa, FL, September 2001.
21. NPR Radio presentation on clinical and treatment aspects in Down syndrome, October 2001.
22. Invited panel member of medical experts and speaker at "Fired Up" Down syndrome meeting, "Cholinergic therapy in Down syndrome - updates and advances", Nashville, TN, November 2001.

23. Invited speaker at National Down Syndrome Society (NDSS) meeting, "Cholinergic therapy in Down syndrome - an update", Nashville, TN, July 2002.
24. Invited speaker, It's in Your Genes Program by Haddassah Group, Screening for Jewish Genetic Diseases Charlotte, NC, 2002.
25. Invited speaker to Triangle Down Syndrome Network meeting "Down Syndrome, an update on management and new therapies", Cary, NC, 2003.
26. Invited speaker to II International Conference on Prospects in the treatment of rare diseases, Trieste, 2002.
27. Invited speaker to a teaching course for medical students, Yale "Lysosomal storage diseases, from bench to bedside," Yale, Connecticut, March 2003.
28. Invited Grand Round Speaker, Johns Hopkins "Pompe Disease: An update", Baltimore, MD, September 2003.
29. Invited speaker at Association for Glycogen Storage Disease, "Hepatocellular carcinoma in glycogen storage disease, type I, Portland, OR, September 2003.
30. Invited speaker at International Pompe Association meeting "Enzyme replacement Therapy with recombinant human acid alpha glycosidase (rhGAA) in Infantile Pompe Disease: Duke Experience", Heidelberg, Germany, October 2003.
31. Invited speaker at The Challenge of Lysosomal Storage Disorders: From Clinical Manifestations to Therapy. "Pompe Disease an update of ERT in infantile Pompe disease," Los Angeles, CA, November 2003.
32. Invited speaker at Neurogenetics teaching Seminar Advances in the Diagnosis and Management of Lysosomal Storage Disorders "Pompe disease, an overview and update of ERT," New York University, NY, November 2003.
33. Invited speaker at International Down Syndrome meeting "Therapeutic interventions in Down Syndrome," Barcelona, Spain, March 2004.
34. Invited Grand Round Speaker, LeBonhers Children Hospital "Pompe Disease: The Past, present and Future," Baltimore, MD, April 2004.
35. Invited speaker at The Annual symposium on Lysosomal Storage Disorders, "Pompe Disease, current and future therapeutic options," Madrid, Spain, April 2004.
36. Invited speaker at National Down Syndrome Society (NDSS) meeting "Treatment with cholinesterase inhibitors," Washington, DC, April 2004.
37. Invited speaker at Annual Symposium of WORLD Lysosomal Disease Clinical Research Network "Longitudinal data and follow up of patients with infantile Pompe disease," Minneapolis, Minnesota, May 2004.
38. Invited speaker at Latin American LSD meeting "Pompe Disease, therapeutic options and results of treatment trials," Santiago, Chile, August 2004.
39. Invited speaker at Clinical Advances in Pediatrics meeting "Overview of Glycogen Storage Disease" and

- “Update on Pompe Disease,” Kansas City, Missouri, November 2004.
40. Invited expert speaker at American College of Medical Genetics at Pompe Disease Management Guideline Working Group meeting “Overview of Pompe” and “Surgery and Anesthesiology in Pompe disease,” Miami, FL, October 2004.
 41. Invited speaker at Exceptional Parents on line seminar on “Lysosomal Storage disorders,” January 14, and January 28, 2005.
 42. Invited speaker to the Society of Inherited Metabolic Disorders “Long term issues and complications of Glycogen Storage Disease,” Asilomar, CA.
 43. Invited speaker at 6th Annual Taiwan Human genetics Society meeting “Pompe disease, natural history and change after ERT,” March 2005.
 44. Invited speaker to the American College of Medical Genetics “Glycogen Storage Diseases, long term outcome and complications,” Dallas, TX, March 2005.
 45. Invited expert speaker at ENMC meeting “Clinical spectrum and Natural course of children and adults with GSDII,” “Tetrasaccharides as markers for GSDII,” and “How should muscle strength and function be assessed in infants/children/adults?” Naarden, Netherlands, April 2005.
 46. Invited panel member and speaker at NDSS research conference on “Cognitive research in Down syndrome,” Cincinnati, OH, May 2005.
 47. Invited to co-chair “Annual LSD Registries Meeting,” Phoenix, AZ, May 2005.
 48. Invited Speaker at Annual Symposium of WORLD Lysosomal Disease Clinical Research Network “Update and long term follow up data of patients with infantile Pompe disease,” Phoenix, AZ, May 2005.
 49. Invited expert speaker at MDA meeting on “Challenges in Drug Development for Muscle Disease: A Stakeholders’ Meeting,” Bethesda, MD, August 2005.
 50. Invited speaker at “Pompe Disease Management Forum,” Cambridge, MA, August 2005.
 51. Invited speaker at “1st Disease Severity Index Meeting,” Paris, France, September 2005.
 52. Invited speaker and Chairperson of Association for Glycogen Storage Disease on “GSD’s overview and long-term complications,” Calgary, Alberta, Canada, September 2005.
 53. Invited speaker at “International Conference on Inborn Errors of Metabolism,” New Delhi, India, September 2005.
 54. Invited speaker at International Collaborative Gaucher Group (ICGG) US Regional Coordinators Meeting, Palm Beach, FL, October 2005.
 55. Invited speaker at ASHG Annual Meeting, Salt Lake City, UT, October 2005.
 56. Invited speaker at 10th Annual LSD Latin American Symposium “Evidenced Based Medicine in LSD: From Experimentation to Individualization,” San Jose, Costa Rica, November 2005.
 57. Invited speaker at Issues in Presymptomatic Diagnoses of Lysosomal Storage Diseases on “Clinical Overview and Update of Clinical Trials of Myozyme for Pompe Disease: Role of Inborn Screening,” Bethesda, MD, December 2005.
 58. Invited speaker at the Zavesca[®] Consultant Meeting, San Francisco, CA, December 2005.

59. Invited speaker at FDA meeting, College Park, MD, January 2006.
60. Invited speaker at Grand Rounds Meeting, New York, NY, February 2006.
61. Invited speaker at FDA Expert Panel Meeting for Pompe Disease, Bethesda, MD, February 2006.
62. Invited speaker at Steps Forward in Pompe Disease Symposium and chairperson for “Cardiology & Anesthesiology Perspectives” workshop, Berlin, Germany, April 2006.
63. Invited speaker at Conference of Kennedy Krieger, sponsored by Taishoff Family Foundation. Improving speech, language and cognitive outcomes: novel approaches combining pharmacotherapy and educational intervention in children with DS “Rivastigmine for language and memory enhancement in DS,” Baltimore, MD, April 2006.
64. Invited speaker at Genzyme Pompe Disease Consultant Meeting, Dallas, TX, April 2006.
65. Invited keynote speaker at Dr. M.P. Bhagat oration at GSMC & KEMH “Therapy for Lysosomal Storage disorders – No longer elusive!” Mumbai, India, June 2006.
66. Invited speaker at the Department of Pediatrics, University of Malaya “LSDs: the burden of disease” and “ERT: Medical milestones,” Malaysia, June 2006.
67. Invited speaker at Hospital Kuala Lumpur “Clinical Spectrum of LSDs” and “Role of ERT in treating LSDs,” Malaysia, June 2006.
68. Invited speaker at The Children’s Medical Institute of the National University Hospital “LSDs: the burden of disease” and “ERT: Medical milestones,” Singapore, June 2006.
69. Invited speaker at KK Women’s and Children’s Hospital “Down Syndrome, management issues and trends” and “Updates in LSD’s,” Singapore, June 2006.
70. Invited speaker at Pediatric Grand Rounds at Morgan Stanley Children’s Hospital of New York, Columbia University Medical Center “Cardiac Manifestations of LSDs,” New York, July 2006.
71. Invited speaker at National Down Syndrome Congress “Cholinergic Therapy in Down syndrome: An update of clinical trials at Duke,” Atlanta, GA, July 2006.
72. Invited speaker and chairperson at the International Congress of Inborn Errors of Metabolism, Chiba, Japan, September 2006.
73. Invited speaker to the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting "Pompe Disease: Diagnostic Advances and New Treatment Options." To discuss "Epidemiology and Pathophysiology of Pompe disease," Washington DC, October 2006.
74. Invited keynote speaker at the AMDA/IPA Pompe Disease Conference, San Antonio, TX, November 2006.
75. Invited speaker to the Health Resources and Services Administration (HRSA) Evidence-base Evaluation and Decision Process for the Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children (ACHDGDNC). To discuss “Evaluation of Pompe Disease, for newborn screening,” Washington, DC, October 2006.
76. Invited speaker to the Immune Tolerance Network NSC Meeting – Session on Enzyme Deficiency Disease and Network Steering Committee Meeting. To discuss “Clinical Consequences of Immune

- Responses to Enzyme Replacement Therapy in Pompe's Disease," Washington, DC, November 2006.
77. Invited keynote speaker at the AMDA/IPA Pompe Disease Conference, "Pompe disease, clinical update, long term effects of ERT and prognostic factors," San Antonio, TX, November 2006.
 78. Invited Speaker at Annual Symposium of WORLD Lysosomal Disease Clinical Research Network "Myozyme as a treatment for Pompe disease, updates in research", Orlando, Florida, Dec 2006.
 79. Invited speaker at Pediatric Grand Rounds at New York Presbyterian Hospital-Cornell "LSD's - Cardiac Manifestations as clues in diagnosis and management updates," New York, Jan 2007.
 80. Invited speaker at Idiopathic and Primary cardiomyopathy in children, research, directions and strategies conference "Role of ERT in metabolic cardiomyopathies," Bethesda, MD, Jan 2007.
 81. Invited speaker at Grand Rounds presentation to faculty and graduate students in the Department of Human Genetics at Emory University "Down Syndrome Clinical and research Updates," Atlanta, GA, Feb 2007.
 82. Invited speaker and Chairperson for ACMG "Innovations in the management of Pompe disease," Nashville, TN, March 2007.
 83. Invited speaker to the AAN meeting "First FDA approved treatment for muscle disease," Boston, MA, April 2007.
 84. Invited speaker to the Centers for Disease Control and Prevention (CDC), the Georgia Division of Public Health, and the Georgia Chapter of the March of Dimes for the 5th Annual Birth Defects Monitoring and Prevention "Clinical Trials, Research Updates in Down Syndrome," Atlanta, GA, August 2007.
 85. Invited speaker to the United Pompe Foundation Patient and Family Meeting "Pompe Disease: Diagnostic Advances and New Treatment Options," Los Angeles, CA, August 2007.
 86. Invited speaker to the United Pompe Foundation Patient and Family Meeting "New Advances for Pompe Disease," San Francisco, CA, August 2007.
 87. Invited speaker to the United Pompe Foundation Patient and Family Meeting "New Advances for Pompe Disease," Los Angeles, CA, August 2007.
 88. Chairperson for the Latin American Training Meeting and Symposium, "Early Diagnosis and Treatment," Uruguay, Montevideo, September 2007.
 89. Invited speaker to the Latin American Training Meeting and Symposium, "Monitoring Patient Care in a Multidisciplinary Approach," Uruguay, Montevideo, September 2007.
 90. Invited as Distinguished speaker to the American Society of Human Genetics 57th Annual Meeting "The Bridge between Research and Practice," San Diego, CA, October 2007.
 91. Invited speaker to the American Society of Human Genetics 57th Annual Meeting "Early Intervention for LSDs: What is Appropriate Care and Management of the Pre-Symptomatic Individual?" and "A Collaborative Discussion," San Diego, CA, October 2007.
 92. Invited speaker to the CDC Workshop: Setting a Public Health Research Agenda for Down syndrome, Atlanta, GA, November 2007.
 93. Invited speaker to the MDA Directors Meeting, "Pompe disease a treatable neuromuscular disorder,"

Providence, RI, November 2007.

94. Invited speaker to the American College of Medical Genetics Diagnostic Confirmation of LSD Work Group Meeting, “Variability in clinical presentation of LSDs,” Washington DC, November 2007.
95. Invited speaker and International Board Representative, India Charitable Access Program, Mumbai, India, February 2008.
96. Invited speaker and Chairperson to the “Clinical Experts Forum and Pompe Meeting,” Prague, Czech Republic, February 2008.
97. Invited speaker to the “Diagnostic Guidelines on Acid Maltase Deficiency (Pompe Disease) Development Meeting,” Dallas, TX, February 2008.
98. Invited Highlights Plenary Speaker to the American College of Medical Genetics Annual Clinical Genetics Meeting, “Alglucosidase Alfa: One Small Step for Patients with Pompe, One Giant Leap for Neuromuscular Diseases,” Phoenix, AZ, March 2008.
99. Invited Guest Speaker at All India Institute of Medical Sciences Annual Genetics Meeting, “New advances in diagnosis and management of Lysosomal Storage Disorders,” and “Advances in Down Syndrome,” New Delhi, India, August 2008.
100. Invited Guest Speaker at KEM Hospital Pediatrics Meeting, “Updates in Glycogen Storage Disorders,” Mumbai, India, August 2008.
101. Invited speaker at Association of Glycogen Storage Disease Annual Conference, “The Era of Therapeutics”, Moline, IL, September 2008.
102. Invited speaker at Association of Glycogen Storage Disease UK Pompe Workshop and IPA Meeting, “Management Guidelines for the Pompe Infant,” and “Clinical and Scientific Updates in Pompe disease,” Reading, UK, September 2008.
103. Invited speaker at Association of Glycogen Storage Disease, UK Meeting, “Updates in GSD I and GSD III,” Reading, UK, September 2008.
104. Invited speaker at FDA Panel Meeting, at the closed and open session, “Pompe Disease -Clinical Spectrum, Pathophysiology and Treatment response to Myozyme,” Washington, DC, October 2008.
105. Plenary Speaker at American Society of Human Genetics Meeting, “Pompe Disease, course of the disease and treatment options,” Philadelphia, PA, November 2008.
106. Plenary Speaker at National MDA Clinic Director’s Conference, “Updates in Pompe Disease, from bench to bedside,” Las Vegas, NV, January 2009.
107. Invited speaker at Neurology Grand Rounds at University of Rochester, “Pompe Disease, lessons learned and application to other neuromuscular disorders,” New York, NY, March 2009.
108. Plenary lecture at American College of Medical Genetics Meeting, “Stuffed too Full Lysosomal Storage Disorders and the Heart,” Tampa, FL, March 2009.
109. Invited speaker at Royal Children’s Hospital, “Early diagnosis and efficacy of treatment with Myozyme for Pompe Disease,” Melbourne, Australia, April 2009.
110. Invited speaker at Westmead Metabolic Meeting, “Importance of diagnosis of Glycogen Storage Disease

- and efficacy of treatment of Pompe Disease,” Sydney, Australia, April 2009.
111. Invited speaker at Australian Gaucher Treaters Meeting, “Gaucher Disease – Updates in Management,” Sydney, Australia, April 2009.
 112. Invited speaker at Pompe Treaters Meeting, “Diagnosis of Pompe Disease,” “Enzyme Replacement Therapy with Myozyme,” “Multidisciplinary Disease Management,” “Differential Diagnosis & High-Risk Testing for Pompe Disease,” Sydney, Australia, April 2009.
 113. Invited speaker at Association for Glycogen Storage Disease Meeting, Research Updates in GSD I, II, III, Denver, CO, September 2009.
 114. Invited chair for “Clinical presentation and multidisciplinary management of Pompe Disease at the 3rd European Symposium “Steps Forward in Pompe Disease,” Munich, Germany, November 2009.
 115. Invited speaker for 3rd European Symposium “Steps Forward in Pompe Disease “and “Immunological Aspects of Treatment of Pompe Disease,” Munich, Germany, November 2009.
 116. Invited speaker for University of Pittsburgh Neurology Grand Rounds, “Pompe Disease – A Treatable Neuromuscular Disease, Lessons, Learned and Challenges Ahead,” Pittsburgh, PA, December 2009.
 117. Invited speaker for Lysosomal Disease Network (LDN) Annual WORLD Symposium, “Immunological Aspects of Treatment of Pompe Disease,” Miami, FL, February 2010.
 118. Invited speaker for 13th North American Lysosomal Storage Disease (LSD) Registries Meeting. Panel session: “Increase knowledge, Improving Outcomes: The Evidence for Early Intervention,” Dallas, TX, May 2010.
 119. Invited guest speaker at KEM Hospital “Updates in Pompe disease,” Mumbai, India August 2010.
 120. Invited speaker at ENMC Workshop on Pompe “Long-term Outcome in Infantile Survivors of Pompe Disease,” Naarden, - Netherlands, September 2010.
 121. Invited speaker at AGSD Annual Conference, “Development of guidelines for GSD’s and recent advances in the field,” Orlando, FL, October 2010.
 122. Co-chair and invited speaker at FDA/NIH Rare Disease Investigators Training Course, “Role of Urinary Hex4 as a Biomarker for Pompe Disease,” Rockville, MD, October 2010.
 123. Invited speaker for 4th European Symposium at Steps Forward in Pompe Disease “Updates on Immunological Aspects of Treatment of Pompe Disease,” London, UK, November 2010.
 124. Co-Chaired American College of Medical Genetics “Newborn Screening Translational Research Network Meeting,” Las Vegas, NV, February 2011.
 125. Invited speaker for Lysosomal Disease Network (LDN) 7th Annual WORLD Symposium, “The Pompe Registry: Baseline Data from the First Five Years,” Las Vegas, NV, February 2011.
 126. Invited member for the NICHD Workshop on Cognition, Bethesda, MD, March 2011.
 127. Invited guest speaker for Jaikei University “Immune Modulation in Pompe disease, Issues at Hand,” Tokyo, Japan, June 2011.
 128. Invited speaker for Jaikei University “Pompe Disease – Updates and Emerging Issues,” Tokyo, Japan, June 2011.

129. Invited speaker for Patient Symposium for Pompe Disease, “Lessons Learned from Pompe Disease,” Tokyo, Japan, June 2011.
130. MUSC Grand Rounds, “Clinical and Research Updates on Pompe Disease,” Charleston, SC, July 2011.
131. Invited speaker for 33rd Annual Association for Glycogen Storage Disease “GSD 101;” “Care Guidelines Update (all types);” Breakout Session #1: Research Reviews and Updates Type 0, III, VI, and IX;” Breakout Session #2 Teens/Young Adult GSD,” Indianapolis, IN, September 2011.
132. Invited speaker for Drug Information Association (DIA) 1st Annual Rare Diseases & Orphan Products Summit, Washington, DC, October 2011.
133. Invited guest speaker at the Carolina Institute for Developmental Disabilities Investigator Forum Series 2011-2012, “Clinical Trials to Enhance Cognition in Down Syndrome,” Chapel Hill, NC, December 2011.
134. Invited speaker for Steps Forward in Pompe Disease, “Registry data on current practices of diagnosing LOPD and infantile Pompe disease: Emphasis on the need for early recognition;” “Immunological Challenges in Pompe Disease,” Budapest, Hungary, December 2011.
135. Invited speaker for Indian Association for Study of the Liver (INASL) Mid-Term Single Theme Conference – Metabolic Liver Disease, “Metabolic liver disease – getting the definitions right;” “Glycogen storage disorders and the liver;” “How do I interpret tests for Metabolic liver disease?” Mumbai, India, January 2012.
136. Invited presenter for Lysosomal Disease Network (LDN) 8th Annual World Symposium, “Long Term Outcome and Clinical Experience on Immune Tolerance Induction Therapies in Infantile Pompe Disease” “Characteristics Associated with Delays in Diagnosis of Pompe Disease Among Patients Enrolled in the Pompe Registry,” San Diego, CA, February 2012.
137. Invited speaker for 2012 Annual Clinical Genetics Meeting (ACMG), “Cardinal Signs and Symptoms of Common and Rare Important Inborn Errors of Metabolism,” Charlotte, NC, March 2012.
138. Invited speaker for 2012 Society for Inherited Metabolic Disorders (SIMD), “The use of non-depleting anti-CD4 monoclonal antibody for immune tolerance induction in Pompe disease,” Charlotte, NC, March 2012.
139. Lectures and Case Presentations at Instituto Fernandes Figueira (IFF), Brazil, “Duke University Hospital experience on Pompe disease – Diagnosis, Treatment and Management and Immunomodulation Discussion,” Rio de Janeiro, Brazil, April 2012.
140. Lectures and Case Presentations in Brazil at IGEIM – Genetic and Inborn Errors of Metabolism Institute, “Patient Evaluation: Duke Experience and multidisciplinary discussion,” San Paulo, Brazil, April 2012.
141. Lectures and Case Presentations at AACD Symposium, “Duke University Hospital experience on diagnosis, treatment and overall management of Pompe disease,” Sao Paulo, Brazil, April 2012.
142. Speaker for Challenging the Paradigms: Liver Transplantation for Metabolic Disease at Children’s Hospital of Pittsburgh of UPMC, “Glycogen Storage Disease,” Pittsburgh, PA, May 2012.
143. Expert Speaker for FDA PMC Meeting, “Success with Immune Modulation Protocols in naïve setting

- and in entrenched immune response setting in infantile Pompe disease,” Washington, DC, May 2012.
144. Speaker and Chairperson for the Workshop on Natural History Studies for Rare Diseases: Meeting the Needs of Drug Development and Research at NIH, “The Role of Retrospective Chart Reviews In Natural History Studies: Lessons Learned From Pompe Disease” Bethesda, MD, May 2012.
 145. Invited Presenter for Myozyme™ Launch South Africa, “Clinical Updates in Pompe disease,” Johannesburg, SA, June 2012.
 146. Invited Presenter for Myozyme™ Launch South Africa, “Lysosomal Storage Disease updates and therapies on the horizon,” Durban, SA, June 2012.
 147. Invited Presenter for Myozyme™ Launch South Africa, “A treatable cardiomyopathy: Pompe disease clinical findings and updates,” Cape Town, SA, June 2012.
 148. Invited speaker at Portland Pompe Conference, “Clinical and Research Updated in Pompe Disease,” Portland, OR, July 2012.
 149. Invited speaker for annual Association of Glycogen Storage Disease (AGSD) Annual Conference, “On the Horizon – Type 2 & 3,” Las Vegas, NV, August 2012.
 150. Invited speaker for The 2nd Middle East Lysosomal Storage Disease Meeting, “Updates in Pompe Disease”, Dubai, October 2012.
 151. Speaker at Indian Association of Neurology Annual Conference (IANCON 2012), “Treatable Neuromuscular Disorders in Pompe Disease”, Ahmedabad, INDIA, October 2012.
 152. Invited speaker for DIA/NORD’s US Conference on Rare Diseases & Orphan Products, “Policy and Special Challenges in Rare Diseases: Role of Academic Centers in Orphan Product Development, Washington, DC, October 2012.
 153. Invited Speaker for DIA/NORD’s US Conference on Rare Diseases & Orphan Products, “Research and Regulation: Immune Tolerance”, Washington, DC, October 2012.
 154. Invited Speaker for Genzyme Dinner Symposium at the American Society of Human Genetics (ASHG) Symposium, “Addressing the Needs of Newly-Diagnosed Patients with Lysosomal Storage Diseases: San Francisco, November 2012.
 155. Neuromuscular Grand Rounds Speaker at University Hospitals Case Medical Center, “Pompe disease: A treatable Neuromuscular Disease”, Cleveland, OH, December 2012.
 156. Genetics Grand Rounds Speaker at University Hospitals Case Medical Center, “Clinical Updates in Pompe disease, Cleveland, OH, December 2012.
 157. Co-Chair on Translational Research Session and Invited Presenter at Lysosomal Disease Network WORLD Symposium, “Approach to Management of Cross-Reactive Immunologic Material (CRIM) – Negative Infantile Pompe Patients Treated with ERT: Role of Immune Modulation in Changing the Natural History”, Orlando, FL, February 2013.
 158. Panelist at Medscape Neurology CME Activity, Town Hall Live Symposium, “Advances in Treatment of Lysosomal Diseases in Today’s World: Translating Science in to Practice”, at Lysosomal Disease Network WORLD Symposium, Orlando, FL, February 2013.

159. Invited speaker at Medigencon Program at Azad Medical College, “Therapeutics in LSDs – strides”, New Delhi, INDIA, February 2013.
160. Invited speaker at Medigencon Program at Azad Medical College, “Pompe Disease – unfolded: New Delhi, INDIA, February 2013.
161. Invited speaker and Chair at ACMG Annual Clinical Genetics Meeting, “Hypophosphatasia: Clinical Expression and Differential Diagnosis of Genetic Metabolic Bone Disorder”, Phoenix, AZ, March 2013.
162. Invited speaker at ACMG Annual Clinical Genetics Meeting, “HCA Happenings –Lysosomal Storage Disorders: Beyond the Classic Phenotype”, Phoenix, AZ, March 2013.
163. Invited speaker at 2nd Working Group on Aldurazyme use post-transplant Genzyme Meeting, Amsterdam, Netherlands, May 2013.
164. Invited speaker at Soft Bones, an HPP Patient Group First Educational Patient Meeting, “Hypophosphatasia: Current Knowledge and Clinical Update”, Chicago, IL, June 2013.
165. Invited speaker at UC Irvine Neurology Grand Rounds, “Bench to Bedside Research in Pompe Disease”, Orange, CA, June 2013.
166. Invited speaker at Miller Children’s Hospital UCI/CHOC Pediatrics Residents, “Clinical Update in Liver Glycogen Storage Disease (GSDs)”, Long Beach, CA, June 2013.
167. Invited speaker at Pompe Patient and Family Meeting at UC Irvine & United Pompe Foundation, “Glycogen Storage Diseases – An Overview”, Marian Del Rey, CA, June 2013.
168. Invited speaker for Genzyme Pompe Patient Meeting, “LOPD – “Emerging Issues”, San Jose, CA, June 2013.
169. Invited speaker at Kaiser Santa Clara Facility for Pompe Disease HCP Program, “Pompe disease update to Healthcare Providers at Kaiser”, Santa Clara, CA, July 2013.
170. Invited speaker for Children’s Hospital of Oakland, CHORI Seminar Services – “Pompe Disease”, Oakland, CA, July 2013.
171. Invited speaker for Arkansas Children’s Hospital CHAR Lectureship, “Pompe Disease: a treatable Neuromuscular Disorder, Little Rock, AR, July 2013.
172. Invited speaker for the NYMAC Pompe Disease Newborn Screening Symposium; “Infantile Pompe Disease: Diagnosis & Management, Westchester Medical Center, Tarrytown, NY, November 2013.
173. Invited presenter for Grand Rounds at the 3rd Annual UCLA Intercampus Lysosomal Disease Symposium, “Pompe Disease: Clinical Research and Updates, Los Angeles, CA, December 2013.
174. Invited panelist for the Children’s Liver Foundation and Indian Academy of Pediatrics, “Liver failure in a neonate”, “Hepatomegaly and seizures – what is the link?”; “Recurrent Vomiting”, Splenohepatomegaly – How do we approach?”; Parel, Mumbai, INDIA, December 2013.
175. Invited speaker for IAP, Pune in collaboration with Genzyme India, CME on Lysosomal Storage Disorders, “Diagnosis & Management of Lysosomal Storage Disorders, Pune, INDIA, December 2013.
176. Invited speaker for IAP, Nagpur in collaboration with Genzyme India, CME on Lysosomal Storage Disorders, “Diagnosis & Management of Lysosomal Storage Disorders, Nagpur, INDIA, December

2013.

177. Invited speaker for Genetics Chapter, IAP in collaboration with Genzyme India, CME on Lysosomal Storage Disorders, “Diagnosis & Management of Lysosomal Storage Disorders: Janpath, New Delhi, INDIA, December 2013.
178. Invited speaker for Lysosomal Storage Disease Network World Symposium, “Emerging Natural History of Cross-reactive Immunologic Material (CRIM) Negative Infantile Pompe Disease patients treated with Recombinant Human GAA”, San Diego, CA, February 2014.
179. Invited speaker for India Charitable Access Program (INCAP) at the IMAB Meeting, “Presentation of data on infantile Pompe in India”, Bengaluru, INDIA, February 2014.
180. Invited speaker for India Charitable Access Program (INCAP) at the IMAB Meeting, “Updates in Management of Pompe Disease”, Bengaluru, INDIA, February 2014.
181. Invited speaker for 2nd National Symposium Approach to Rare, Treatable Genetic Diseases for Medigencon 2014, “Pompe disease: Past, present and future”, Bengaluru, INDIA, March 2014.
182. Invited speaker for American College of Medical Genetics (ACMG), “Diagnosis of Inherited Metabolic Bone Disorders; The Critical Role of the Medical Geneticist”, Nashville, TN, March 2014.
183. Invited presenter for Alexion Hypophosphatasia Advisory Board Meeting, “HPP Disease Overview/Advisor Feedback, Denver, CO, May 2014.
184. Invited presenter for Alexion Hypophosphatasia Advisory Board Meeting, “Adult HPP Cases”, Denver, CO, May 2014.
185. Invited speaker for Food and Drug Administration (FDA)-Center for Drug Evaluation and Research (CDER) Workshop on Immune Responses to Enzyme Replacement Therapies: Role of Immune Tolerance Induction, “Immune responses to enzyme replacement therapy (ERT), Silver Spring, MD, June 2014.
186. Invited facilitator and speaker for Newborn Screening Advisory Board Meeting, “Roles, Responsibilities, and Timing for IOPD Patient Follow-up, San Diego, CA, June 2014.
187. Invited presenter for Texas Department of State Health Services Newborn Screening Grand Rounds, “Pompe Disease: Bench to Bedside Journey and Newborn Screening Initiatives, Austin, TX, July 2014.
188. Invited speaker and panelist for Action Plan Workgroup 2 member for Muscular Dystrophy Coordinating Committee Muscular Dystrophies Workshop, “Diagnosis, Screening, and Biomarkers for Muscular Dystrophy”, Bethesda, MD, July 2014.
189. Invited speaker for Department of Pediatrics at Armed Forces Medical College, “Newborn Screening”, Pune India, August 2014.
190. Co-chair of the Newborn Screening Translational Research Network (NBSTRN) LSD Workgroup Meeting, Bethesda, MD, September 2014.
191. Facilitator and Presenter for Alexion Hypophosphatasia Registry Scientific Advisory Board Meeting, “Adult case presentation: how sure are we of nomenclature”, London, UK, September 2014.
192. Chair and Presenter for 7th European Symposium Steps Forward in Pompe Disease, “Improving the

- management of Pompe disease: Immunological factors in Pompe Disease Management: Clinical experience and implications for newborn screening, Turin, Italy, November 2014.
193. Invited speaker for 11th Annual Lysosomal Disease Network World Symposium, “Prophylactic immune modulation in infantile Pompe disease; collective experience treating CRIM-positive and negative patients in the naïve setting”, Orlando, FL, February 2015.
 194. Invited speaker for Medigencon, “Glycogen Storage Diseases – Advances in management and Pompe Disease – Ask the Expert”, New Delhi, India, February 2015.
 195. Invited speaker for IMAB, “Newborn Screening for Pompe Disease”, New Delhi, India, February 2015.
 196. Invited speaker for Brazil Genzyme Pompe Disease National Meeting, “Challenges and controversies in the diagnosis of Pompe Disease – Experience at Duke University, Rio de Janeiro, Brazil, March 2015.
 197. Invited speaker for Brazil Genzyme Pompe Disease National Meeting, “Immunomodulation and multidisciplinary management in Pompe disease – Clinical Experience at Duke University, Rio de Janeiro, Brazil, March 2015.
 198. Invited Presenter at Pompe Round Table, “Infantile Pompe Disease – CRIM and Immune Modulation, the emergent phenotype”, Buenos Aires, Argentina, April 2015
 199. Invited Presenter at Pompe Round Table, “Pompe Disease, What have you learned? New Challenges”, Buenos Aires, Argentina, April 2015
 200. Invited participant in Roundtable Discussion at Japan Pompe Meeting, “Significance of Early Treatment in IOPD and Opportunities for Newborn Screening, Tokyo, Japan, June 2015.
 201. Invited presenter at the Japan Pompe Meeting, “Immunotolerance Induction for ERT in IOPD, Tokyo, Japan, 2015.
 202. Keynote Presenter at the Symposium on ATP1A3 in Disease, “First-hand experience of a clinical trial in a rare disease, Washington, DC, August 2015.
 203. Invited presenter at the Meet-the-Expert Session at SSIEM Symposium, “Improving outcomes in Pediatric – onset Hypophosphatasia, Lyon, France, September 2015.
 204. Invited presenter at the Pompe Newborn Screening Meeting, “National Pompe Newborn Screening Update, New York, NY, October 2015.
 205. Invited speaker for the AMDA/IPA Pompe Patient and Scientific Conference, “ERT: What Have We Learned So Far Roundtable, San Antonio, TX, October 2015.
 206. Invited speaker for IAMGCON 2015 2nd Annual Meeting of Society for Indian Academy of Medical Genetics, Dr S Agarwal Oration “Novel Therapies for Genetic Disorders, Jodhpur India, December 2015.
 207. Invited speaker for IAMGCON 2015 2nd Annual Meeting of Society for Indian Academy of Medical Genetics, Diagnostic Revolutions Session “Pompe Disease – Importance of early diagnosis”, Jodhpur India, December 2015.
 208. Invited presenter at “Stay the Course to Success” – 1st Off Site Meeting for the Liver & Metabolic Therapeutic Area Team at uniQure, Introduction to the top 3 liver disease indications and brief introduction to the tier 2 liver disease indications, Amsterdam, Netherland, January 2016.

209. Invited Presenter at LDN World Symposium, “New perspective for ERT in Pompe disease: extending the action of the enzyme to cytosolic targets, San Diego, CA, March 2016.
210. Invited Presenter at LDN World Symposium, Amicus Satellite Dinner Symposium, “The Many Faces of Lysosomal disease: A Global Perspective”, San Diego, CA, March 2016.
211. Invited speaker at the 98th Annual Meeting of the Endocrine Society (ENDO 2016), “Biochemical and Physical Function Outcomes in Adolescents and Adults with Hypophosphatasia Treated with Asfotase Alfa for up to 4 years: Interim Results from a Phase II Study, Boston, MA, April 2016.
212. Invited speaker at the Society of Inherited Metabolic Disease (SIMD) Annual Meeting, “Ask the Experts Table” – Lysosomal Disorders, Ponte Vedras Beach, FL, April 2016.
213. Invited speaker at the Society of Inherited Metabolic Disease (SIMD) Annual Meeting, “Diet Therapy in GSD”, Ponte Vedras Beach, FL, April 2016.
214. Invited speaker at the NDSC DSMIG USA Meeting, Pharmacological Interventions to Improve Cognition and Adaptive Functioning in Down Syndrome: Strides to Date”, Orlando, FL, July 2016.
215. Invited Speaker by Baebies to present at the FDA Meeting, “Lysosomal storage disorder”, Gaithersburg, MD, August 2016.
216. Invited speaker for the SSIEM Annual Conference, Alexion Satellite Symposium, “Improving functional outcomes in adolescents and adults with hypophosphatasia”, Rome, Italy, September 2016.
217. Invited Presenter at the Association of Glycogen Storage Disease Annual Meeting, “GSD II Newborn screening & GSD III and IV Mouse Model – what we have learned”, Toronto, Ontario, Canada, September 2016.
218. Lead Discussor for 2nd South Asia LSD Symposium, “Symposium 1: LSDs in South Asia. Regional Perspectives, and “Symposium 4: Pompe Disease”, New Delhi, India, September 2016.
219. Chairperson for 2nd South Asia LSD Symposium, “Symposium 4: Pompe Disease”, New Delhi, India, September 2016.
220. Plenary Speaker for 2nd South Asia LSD Symposium – “Present status & new frontiers in Pompe Disease”, New Delhi, India, September 2016.
221. Invited Speaker and leader (introductions, closing remarks and wrap up) for Alexion’s HPP Registry Scientific Advisory Board and Alexion Supporter Hypophosphatasia and Physician Education (SHaPE), “Adults Clinical Data”; “HPP Patients, Case Study Session”; “Case Studies: Asfotase alfa in clinical practice and the patient perspective”; Q & A for The HPP Registry, Prague, Czech Republic, October 2016.
222. Invited Presenter at 8th Steps Forward in Pompe Disease, “Immunomodulation in Infantile Pompe Disease”, Schiphol, Amsterdam, Netherlands, November 2016.
223. Invited lecture at St. Xavier’s College, “Today’s Science is Tomorrow’s Future – bench to bedside experience with rare diseases”, Mumbai, India, February 2017.
224. Invited speaker at ISIEM 2017 (IV National Conference of the India Society of Inborn Errors of Metabolism, “Sandor Oration Award: Bench to bedside experience in developing a treatment for Pompe

- Disease: The Journey Continues”, Chennai, India, February 2017.
225. Invited presenter for the 13th Annual WORLD Symposium, Satellite Symposium, “Newborn Screening for Lysosomal Diseases: Recent Progress and Unanswered Questions”, San Diego, CA, February 2017.
 226. Invited presenter for Satellite Symposium at the Annual ACMG 2017 Meeting, “Pompe Disease: Early Diagnosis and Optimal Management, Phoenix, AZ, March 2017.
 227. Invited Faculty Member for Round Table Workshops at the Gaucher Leadership Academy: Substrate Reduction Therapy Eliglustat Clinical Efficacy, and invited speaker on Eliglustat in Switch Patients – real world experience”, Mainz, Germany, June 2017.
 228. Invited presenter for three sessions at the IGSD 2017 Annual Meeting, “Causes & Development of Myopathy in GSD IIIa”, “Immunomodulatory enzyme replacement therapy using tolerogenic nanoparticles containing rapamycin for Pompe Disease”, Population Newborn Screening for Pompe Disease”, Groningen, The Netherlands, June 2017.
 229. Invited speaker for the Association of Public Health Laboratories (APHL) National Newborn Screening Meeting on New Disorders (Pompe, MPS I, X-ALD), “Clinical Considerations: Pompe Disease: Bethesda, MD, June 2017.
 230. Invited speaker for Shire’s R & D Day Research Series: Shaping What’s Next in LSDs – Hot Topics, “Immune tolerance induction for patients who have developed ADAs to ERT: London, UK, July 2017.
 231. Invited faculty speaker for IANCON 2017 Meeting Symposium XVI: Neurology and Humanities Session talk on “Pompe disease, Chennai INDIA, September 2017
 232. Invited speaker for the 2nd MMM Genetics Meeting – a symposium on “Genetics and Genomics in Cardiovascular Diseases – ‘Cardiac Manifestations in Pompe Disease-Infantile and Late Onset, Chennai INDIA, September 2017.
 233. Invited speaker for the annual AGSD Conference, “GSD VI & IX Diagnosis and Management Guidelines”, Chicago, IL, September 2017.
 234. Invited speaker for the annual ASHG Conference, “Clinical and Translational Insights in Pompe Disease: Disease Pathology, Patient Identification, and Treatment, Orlando, FL, October 2017.
 235. Invited leader and presenter for Alexion’s HPP Registry SAB Meeting, “A Review of the best practices to report CRIM data in relation to the genotype,” Madrid SPAIN, November 2017.
 236. Invited presenter for the 14th Annual WORLD Symposium, Satellite Symposium – Excel Continuing Education Talk, “Overcoming the challenges of Pompe Disease”, San Diego, CA, February 2018.
 237. Invited presenter for the 14th Annual WORLD Symposium, Satellite Symposium, Early Treatment of Lysosomal Disorders: A closer look at Fabry and Pompe disease, “What have we learned about early treatment of Pompe Disease”, San Diego, CA, February 2018.
 238. Invited opening speaker for The Council of Entrepreneurial Development (CED), the North Carolina Biotechnology Center, and North Carolina Biosciences Organization (NCBIO), CED Life Science 2018 Conference, “Innovation Delivers A Better Tomorrow: The Pompe Journey”, Raleigh, NC, February 2018.

239. Chair of CME Accredited Roundtable Discussion for EOCME/Exerpta Medica, “Focus on Lysosomal Diseases: New Frontiers for Accelerating Diagnosis and Optimizing Treatment”, Durham, NC, June 2018.
240. Invited speaker for the HPP Soft Bones Meeting, “Role of Functional Testing in Adults patients with Hypophosphatasia (HPP), Chicago, IL, June 2018.
241. Invited presenter at the 40th Annual Association for Glycogen Storage Disease Conference, “GSD1a Research Updates”, Davenport, IA, September 2018.
242. Invited speaker at the 5th Annual Conference of Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition and the 28th Annual Conference of the Pediatric Gastroenterology Chapter of IAP, “Diet in GI/Liver disease: Culprit? Saviour? Or both?” Mumbai INDIA, October 2018.
243. Panel Participant at the Indian Medical Advisory Board (IMAB), “Review and Status updates of INCAP cases under respective members and centers”, New Delhi INDIA, October 2018.
244. Invited presenter at the Steps Forward in Pompe Disease 2018, “Immune-modulation in infants treated with ERT with alglucosidase alfa: Global experience over a decade of learning”, Copenhagen, Denmark, November 2018.
245. Invited speaker for Pompe Registry North American Board Meeting, “Infantile early treatment – WG analysis: Review of IOPD early treatment analysis”, Toronto, CANADA, November 2018.
246. Invited faculty presenter for the 15th Annual LDN World Symposium Genzyme/Med-IQ Satellite Symposia. “Bridging Gap between Research and Clinical Advances in Gaucher Disease Type 3”, Orlando, FL, February 2019.
247. Invited presenter for the 15th Annual LDN World Symposium Satellite Symposium, “Biomarkers: Ready for Prime Time in the Clinical Management of Lysosomal Disorders?” Orlando, FL, February 2019.
248. Co-Chair for the 15th Annual LDN World Symposium for the Translational Research IB Session, “Implementation and Impact of Newborn Screening, Orlando, FL, February 2019.
249. Invited presenter for the 15th Annual LDN World Symposium Pompe Satellite Symposium, “Hand in Hand --- Patient and Physicians Journey in Pompe Disease”, Orlando, FL, February 2019.
250. Invited speaker for the LuMind and Alzheimer’s Association and the Global Down Syndrome Foundation co-sponsored Alzheimer’s & Down Syndrome Workshop, Session 5: Practical Considerations for Clinical Trials, “Inclusion/Exclusion Criteria Considerations, Bethesda, MD, March 2019.
251. Invited speaker for the LuMind and Alzheimer’s Association and the Global Down Syndrome Foundation co-sponsored Alzheimer’s & Down Syndrome Workshop, Session 5: Practical Considerations for Clinical Trials, “Inclusion/Exclusion Criteria Considerations, Bethesda, MD, March 2019. Presenter for ACMG Annual Clinical Genetics Meeting Platform Presentations – Clinical Genetics and Therapeutics, “Factors Affecting Outcomes in Classic Infantile Pompe Disease Patients Treated with Enzyme Replacement Therapy: Lessons Learned from the Pompe Registry”, Seattle, WA, April 2019.
252. Presenter, Welcome and Introduction, Case Studies Panel for ACMG Annual Clinical Genetics Meeting Satellite Symposia – Improving Care for Patients with Pompe Disease: A Look at Emerging Therapies

and Multidisciplinary Management Strategies, Seattle, WA, April 2019.

253. Presenter for ACMG/SIMD Joint Plenary Session Part 1 – Thinking Metabolic for the Genetics Clinician: You Took the Call from the Department of Health: What Now? “You got the NBS call for presumptive positive Pompe. What Now? Seattle, WA, April 2019.
254. Invited Presenter for 18th Annual Asian Oceanian Myology Center Meeting (AOMC) for Session VIII “Pompe”, Mumbai INDIA, June 2019.
255. Invited Speaker for Gene Connect Masterclass a series of webinars, “Pompe Disease: Recognize Early – Treat Early, Lessons learned from New Born Screening”, Mumbai INDIA, June 2019.
256. Invited Speaker for the 19th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS) Thematic Session, “Immune Barriers to Protein/Gene Replacement Therapies – “Response Antibodies Challenges in Pompe Disease”, Boston, MA, June 2019.
257. Invited presenter at the 5th International Forum of Lysosomal Disorders – Pompe Workshop, “Treatment of Pompe Disease”, Tokyo JAPAN, July 2019.
258. Invited Panelist for Amicus Newborn Screening Summit, “Ethical Considerations for Newborn Screening and “Newborn Screening Initiatives: Going Beyond State NBS, Webex, July 2019.
259. Invited presenter at the 41st Annual Association for Glycogen Storage Disease Conference, “GSD III”, Houston, TX, September 2019
260. Invited presenter at the 2019 AMDA/IPA International Pompe Patient and Scientific Conference, Session: “Natural History of Pompe vs. New History of Treatment in infantile onset Pompe disease”, San Antonio, TX, October 2019
261. Invited Chair at the 2019 AMDA/IPA International Pompe Patient and Scientific Conference, Session: The Basics of Clinical Trials; Member of Expert Roundtable: “20 Years of Treatment and Care of Pompe Patients”; and Session: “Next Generation Therapy: Enzyme Replacement Therapy (ERT) – Update on Valerion’s approach”, San Antonio, TX, October 2019
262. Invited Plenary Speaker at the 5th International GSD Conference (IGSD2019), Plenary Title: “Ketotic Hepatic GSD”, Porto Alegre, Brazil, November 2019
263. Invited Plenary Speaker at the 5th International GSD Conference (IGSD2019), Plenary Title: “Gene Therapy for Pompe disease: What’s new?” Porto Alegre, Brazil, November 2019.
264. Invited Session Speaker at the 5th International GSD Conference (IGSD2019), Session Title: “Immunological and treatment aspects in high sustained rhGAA antibodies in Pompe patients”, Porto Alegre, Brazil, November 2019
265. Invited Session Speaker at the 5th International GSD Conference (IGSD2019), Session Title: “First-in-human study of ATB200/AT2221 in patients with Pompe disease: 24 months functional assessment results from ATB200-02 trial”, Porto Alegre, Brazil, November 2019
266. Invited Speaker, Session Chairperson and Panelists at the Indo-US Symposium on Genetic Neuromuscular Disorders & Sixth Annual National Conference of the Society for Indian Academy of Medical Genetics (SIAMGCON 2019), “Understanding the natural history of muscle involvement in

- Glycogen storage disorders” and “Metabolic manipulation with Pompe disease prototype”; Chairperson for Session – “Emerging therapies for genetic neuromuscular disorders; Panelist on Panel discussion – “Creation of an Indian and Indo-US Consortium on Genetic Neuromuscular Disorder, Hyderabad, India, November 2019
267. Invited speaker at Taipei Veterans Hospital – “Management of pre-symptomatic patients with late onset Pompe Disease”, Taipei Taiwan, January 2020
 268. Invited Speaker at satellite symposium at The LDN World Symposium, “Gaucher disease: Can we build a better roadmap for patient care?”, Orlando, FL, February 2020
 269. Invited Speaker at satellite symposium at the LDN World Symposium, “Respiratory Involvement in Pompe disease”, Orlando, FL, February 2020
 270. Co-Chair of Clinical Trials II Session for the LDN World Symposium, “Clinical Outcomes”, Orlando, FL, February 2020
 271. Invited Speaker at the Virtual ACMG Digital Edition– “Lessons Learned: The Role of NBS for Pompe Disease and Mucopolysaccharidosis Type 1: Early Intervention Influences outcome”, April 2020
 272. Co-Chair for Session “Pediatric/Development Conditions” for the National Institute of Health (NIH) Clinical Trials in Down syndrome for Co-Occurring conditions across the lifespan virtual workshop, May 2020
 273. Invited Speaker for the National Institute of Health (NIH) Clinical Trials in Down syndrome for co-occurring conditions across the lifespan virtual workshop, “Overview of Clinical Trials in the Down syndrome population”, May 2020
 274. Moderator for Panel “Consideration for Participation in Clinical Trials in Pediatric and Adult Populations” for the National Institute of Health (NIH) Clinical Trials in Down syndrome for co-Occurring conditions across the lifespan virtual workshop, May 2020
 275. Invited presenter for Rare Disease Day, JPAC (Japan, Australia, and South Korea) Pompe Virtual Learning Summit, "The Story Behind Development of a Treatment for Pompe Disease and the importance of early diagnosis” May 2020
 276. Invited speaker for the Virtual Conference on Lysosomal Diseases (Med-Lysosomal 2020), Jerusalem, Israel, “Immune modulation for patients receiving therapeutic proteins”, June 2020
 277. Presenter at the Virtual MDA Pompe Disease Patient-Focused Drug Development Meeting, “Scientific Overview of Pompe disease across the disease spectrum”, July 2020
 278. Invited Presenter at the Virtual Online Symposium for International Congress on Neuromuscular Diseases (ICNMD), “Insights into the Phenotypes of Pompe Disease”, September 2020
 279. Association for Glycogen storage disease Virtual Annual Conference, “Updates in Glycogen Storage Disease Type III, September 2020
 280. Invited Lecturer for hypophosphatasia Lecture Series Virtual “Understanding Immunogenicity to therapeutic proteins”, October 2020
 281. Keynote Speaker for the New England Consortium of Metabolic Programs Virtual Annual Meeting,

- “Updates and Insights into Hepatic Glycogen Storage Disorders”, November 2020
282. Invited Speaker for the Virtual AMDA (Acid Maltase Deficiency Association) – “Efficacy of the Vaccines for COVID-19 Vaccines for Pompe Patients”, January 2021
 283. Invited Speaker for North American Rare Disease Registries Virtual Meeting, “Newborn Screening for Pompe Disease in the US: Early Findings from the 2020 Pompe Registry Data Analysis, January 2021
 284. Serve as a Panelist for the Translation Session at the NIMH Virtual Workshop Gene-based Therapeutics for Rare Genetic Neurodevelopmental therapeutics, “What aspects of success stories can be translated to new neurodevelopmental therapeutics?”, January 2021
 285. Invited Speaker at The LDN World Virtual Symposium, Late Breaking Science Session, “Efficacy and safety results of the avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients”, February 2021
 286. Invited Speaker for the Virtual Immunogenicity Advisory Board, “Discussion on immune strategies to be considered in Hypophosphatasia treated with asfotase alfa”, March 2021
 287. Distinguished Speaker Panelist for the WuXi AppTec Rare Disease Webinar, “Closing the Gap in Pompe Disease: Where Are We Heading”, Webinar, April 2021
 288. Speaker for the Indian Society for Inborn Errors of Metabolism (ISIEM) and Indian Academy of Medical Genetics (IAMG) sponsored 4th South Asia LSD Symposium, Pompe Disease Session “Rx outcomes in IOPD with treatment initiation in 1st month of life”, Virtual, April 2021
 289. Presenter at the Lysosomal Disease Network Annual Meeting, Clinical Research Studies Session, “Pompe Disease Study”, Virtual, April 2021
 290. Speaker at the 16th International Congress on Neuromuscular Diseases (ICNMD), “A journey of long-term commitment in the Pompe Community”, Virtual, May 2021
 291. Planning Committee and Speaker for NIH Workshop (NCATS) on Early Diagnostic Strategies to Identify Patients for Gene-Targeted Therapies Meeting, June 2021
 292. Grand Round speaker for the UPMC Children’s Hospital of Pittsburg Pediatric Grand Rounds, “Lessons Learned from Rare Diseases: Bench to Bedside and Back”, June 2021
 293. Invited Speaker at Sanofi Genzyme Pompe Academy 2021 Meeting, “Early Treatment for Pompe Disease: Lessons learned from NBS”, Virtual, June 2021, Argentina
 294. Speaker during the Pompe Session of the APHL (Association of Public Health Laboratories) hosted New Disorders and Short-term Follow-up Virtual National Meeting, “Treatments and Therapies for Newborn Screening Conditions”, August 2021
 295. Invited participant in the FDA CBER 2-day Advisory Committee on Gene Therapy toxicity risks of AAV Therapy, September 2021
 296. Talk for Indian Society of Inherited Errors of Metabolism (ISIEM) and Indian Academy of Medical Genetics (IAMG) South Asia Gaucher Summit Celebrating 30 Years of Gaucher Care, “Journey so far....!!!”, October 2021
 297. Presenter for the Hybrid Patient Forum sponsored by the Australian Pompe Association – Australia and

- New Zealand Pompe Down-Under, “Infantile Pompe Disease and Newborn Screening”, virtual, October 2021
298. Participant in the Virtual FDA-CERSI Workshop: "Prenatal Somatic Cell Gene Therapies -- Charting a Path Forward for Clinical Applications", October 2021
 299. Panelist for NORD Rare Disease Center for Excellence Corporate Council Meeting – Access to Care discussions on “Collaborative Science to Address unmet needs in Rare Diseases and Disease Management Guidelines”, virtual, November 2021
 300. Cedar-Sinai Keynote Talk for the 11th Annual Symposium of Lysosomal Storage Disease, “Updates in Pompe Disease”, virtual, December 2021
 301. Keynote Speaker at Sanofi Genzyme 14th International Lysosomal Disease Web Conference, “Updates in Pompe Disease”, virtual, January 2022
 302. Platform Speaker for 18th Annual WORLD Symposium, Late-Breaking Science Session, “Avalglucosidase alfa improves health-related quality of life (HRQoL) in patients with late-onset Pompe disease (LOPD) vs. alglucosidase alfa: Patient-reported outcome measures (PROMs) from the phase 3 COMET trial, San Diego, CA, February 2022
 303. Participated as a panelist for the Accredited Satellite Symposium, “Improving Diagnosis and Enhancing the Standard of Care for Pompe Disease”, ACMG Annual Clinical Genetics Meeting, Nashville, TN, March 2022
 304. Presented as the 2021 Emmanuel Shapira Award Winner for the SIMD Annual Meeting, “Investigation of ALPL variants states and clinical outcomes: An analysis of adults and adolescents with Hypophosphatasia treated with asfotase alfa”, SIMD Annual Meeting, Orlando, FL, April 2022
 305. Speaker for Satellite Symposium, “Exploring Next Generation ERT for Pompe Disease: Strategies for Individualizing Treatment Decisions”, SIMD Annual Meeting, Orlando, FL, April 2022
 306. Invited Speaker for at the Organization for Rare Disease India (ORD) Pompe Foundation International Pompe Day Virtual Webinar, “Management of Pompe – Yesterday, Today And Tomorrow”, April 2022
 307. Invited speaker at the BIO and NC BIO and in partnership with Rare Disease Innovations Institute, Inc. legislative breakfast educating legislators on Gene & Cell Therapy & Access, “Transforming the clinical outcomes of individuals with Rare diseases: The Gene Therapy Journey, at the Legislative Building, Raleigh, NC, June 2022
 308. Invited didactic speaker for Soft Bones Project ECHO-TeleECHO, “Functional Assessments of Hypophosphatasia in Adults”, virtual seminar, July 2022
 309. Invited Keynote speaker for the annual SERN-SERGG meeting, “New Insights into Hepatic Glycogen Storage Disease”, Asheville, NC, July 2022
 310. Invited session speaker for the annual SERN-SERGG meeting, “Long-term Follow-up of Cipaglucosidase Alfa/Miglustat in Ambulatory Patients with Pompe Disease: An Open-label Phase I/II Study (ATB200-02), Asheville, NC, July 2022
 311. Invited presenter for the Sanofi sponsored Satellite Symposium for the Society for the Study of Inborn

- Errors of Metabolism (SSIEM), “Pompe disease, a new era: the latest avalglucosidase alfa clinical data and early real-world experiences”, Freiburg, Germany, August 2022
312. Invited presenter for NORD Center of Excellence for Rare Disorders at Boston Children’s Hospital sponsored Combined Pediatrics and Metabolism Grand Rounds, “New Insights into hepatic GSDs: clinical implications and a need for definitive therapies, Virtual, September 7, 2022
 313. Virtual Presenter at the National Italian GSD Patient Association GSD/Pompe Conference, “Pompe Disease Overview and Recent Updates”, Bari, Italy, October 2022
 314. Invited Speaker at the Annual APS-Jahrestagung 2022 Hepatic Glycogen Storage Diseases Focuses Meeting, “The different types of gene therapy in hepatic GSDs”, Kassel, Germany, October 2022
 315. Invited Speaker at the 2022 Sanofi Steps Forward in Pompe Disease Meeting, “IOPD Management US Experience – Lessons Learned After 15 Years of Experience”, and “Clinical Trials in Patients with LOPD – New Treatment Options Available: Avalglucosidase Alfa” for Session Titled Pompe Disease: Patient’s Outcome and Management Insights with Enzyme Replacement Therapy (ERT), Berlin, Germany, November 2022
 316. Invited Speaker for a Satellite Symposium at the WORLD Symposium, “Exploring Next-generation Therapies to Mitigate Disease Progression in Pompe Disease, Orlando, FL, February 2023
 317. Presented at the Sanofi Medical Booth at WORLD Symposium, “30-Year Registry”, Orlando, FL, February 2023.
 318. Invited Speaker for Sanofi Satellite Symposium at the WORLD Symposium, “The Next Step Forward: Real World Experience in Patients with Late-Onset Pompe Disease, Orlando, FL, February 2023.
 319. Invited Presenter for the Clinical Application Session at the WORLD Symposium, “Efficacy and safety of avalglucosidase alfa in participants with late-onset Pompe disease after 145 weeks of treatment during the COMET trial, Orlando, FL, February 2023.
 320. Invited Speaker for a Satellite Symposium at the Society of Inherited Metabolic Disease Annual Meeting, “Managing Late-onset Pompe Disease in the Era of Newborn Screening”, Salt Lake City, UT, March 2023.
 321. Invited Speaker for the South Asia LSD Symposium, “Newer Therapies in Pompe disease and other Glycogen Storage Diseases”, Bangalore, India, April 2023.
 322. Invited Speaker for India Charitable Access Program (INCAP) at the Indian Medical Advisory Board (IMAB) Meeting, “Managing Pompe Disease with Nexviazyme (Avalglucosidase alfa-ngpt)”, Bengaluru, India, April 2023.
 323. Invited to do pre-recorded presentation for the Abbott Nutrition Health Institute (ANHI) Metabolic Conference, “Pompe Disease: Clinical Management and Updates”, San Antonio, TX, May 2023
 324. Invited speaker for the Annual Association for Glycogen Storage Disease Conference, “Newborn Screening in Pompe, Orlando, FL, June 2023
 325. Platform Session Speaker for Southeast Regional Genetics Network (SERN)/Southeastern Regional Genetics Group (SERGG), “Long-term Efficacy and Safety of Cipaglucosidase Alfa/Miglustat in

- Ambulatory Patients with Pompe Disease: A Phase III Open-label Extension Study (ATB200-07)", Charleston, SC, July 2023
326. Invited Speaker for the Amicus Consulting Internal Speaking Event, "A Journey through time-lessons learned in development of a therapy for a rare disease", Washington, DC, July 2023
 327. Invited Speaker for the Society for Inherited Metabolic Disorders (SSIEM) Annual Conference for Amicus, "Switching treatment from alglucosidase alfa to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease", Jerusalem, Israel, August 2023
 328. Invited Speaker for the Society for Inherited Metabolic Disorders (SSIEM) Annual Conference, Sanofi Pompe Medical Satellite Symposium, "Efficacy and safety of avalglucosidase alfa in participants with late-onset Pompe disease after 145 weeks' treatment during the COMET Trial", Jerusalem, Israel, August 2023
 329. Invited Speaker for Sanofi sponsored Satellite Symposium for the World Muscle Society Annual Meeting, "Optimizing Care: Real World Experience in Patients with Late-Onset Pompe Disease", Charleston, SC, October 2023
 330. Invited Poster Presenter for the World Muscle Society Annual Meeting, "COMET: Effects of avalglucosidase alfa and treatment switch from alglucosidase alfa on week 145 QMFT individual item responses", Charleston, SC, October 2023
 331. Invited Virtual Presenter for the Australian Pompe Association Meeting, "Newborn screening for late-onset Pompe disease and infant on-set Pompe disease, October 2023
 332. Serve as a panelist at the North America Rare Disease Summit, "Addressing Management of Rare Diseases. Hospital Networks & Reference Centers, New York, NY, November 2023
 333. Served on the special panelist at the Duke Medical Alumni Association All-Alumni Luncheon, host by the Golden Blue Devils, "Panel Discussion: - Team Medicine: From Breakthrough Research to Lifesaving Care", Durham, NC, November 2023
 334. Plenary Session Speaker for The Indian Society of Human Genetics (ISHG) 2024 Conference, "Pompe disease: An exemplar for diagnosis, treatment, and prevention, Satellite, Ahmedabad INDIA, January 2024.
 335. Serve as a speaker for the Indian Medical Advisory Board (IMAB) Meeting, "Pompe disease and it's management", Ahmedabad, Gujarat INDIA, January 2024.
 336. Serve as chair and speaker for a Satellite Symposium at WORLD Symposium, "Optimizing Outcomes in Late-Onset Pompe Disease: Integrating New Therapies, Whole-person Makers of Disease Monitoring, and Shared Decision-making into Practice", San Diego, CA, February 2024.
 337. Served as a speaker at a Satellite Symposium at the WORLD Symposium, "From Bench to Bedside: the Example of Pompe Disease", San Diego, CA, February 2024.
 338. Serve as speaker at a Satellite Symposium at the WORLD Symposium, Gaucher Disease: The Evolving Big Picture (Part II - Gaucher Disease Across the Lifespan, "Implications for Pregnancy, Gaps in

Knowledge, Future Directions”, San Diego, CA, February 2024

339. Speaker at a Satellite Symposium at the WORLD Symposium, “A Focus on Bone Manifestations in Gaucher Disease Type 1 Patients”, San Diego, CA, February 2024.
340. Serve as a speaker at a Satellite Symposium at the American College of Medical Genetics Annual Clinical Genetics Meeting, “A New Treat Approach for Late-Onset Pompe Disease”, Toronto, Canada, March 2024.
341. Speaker at the Newborn Screening virtual Webinar for the Neuromuscular Disease Network for Canada (NMD4C), “A new understanding of Pompe disease in the era of Newborn Screening”, April 2024
342. Speaker/ Chair at the AMDA/IPA International Pompe Patient and Scientific Conference, “Natural History of Pompe vs. New History with ERT”, San Antonio, TX, May 2024.
343. Expert Panelist at the AMDA/IPA International Pompe Patient and Scientific Conference, “Expert Roundtable: 25 Years of Treatment and Care of Pompe Patients”, San Antonio, TX, May 2024.
344. Speaker for Adult Polyglucosan Body Disease (APBD) GSD IV Focus Group Meeting, “Where GSD IV and APBD Align”, Virtual, May 2024
345. Speaker at the AGSD (Association for Glycogen Storage Disease) Annual Conference, “GSD VI and IX Updates and “Pompe Disease Updates, Minneapolis, MN, June 2024

Clinical Activity:

- Director, Metabolic Clinic which serves as a tertiary referral center for inborn errors of metabolism and lab interpretations with clinical correlations. Serves as international center for Glycogen Storage disorders.
- Director, Lysosomal Storage Disease Program, Durham, NC.
- Clinical Medical Genetics staff physician, full hospital privileges, consultant for Inpatient Metabolic and Genetics Services.
- Clinical Research – Principal investigator for several trials (over 100 to date) –investigator initiated, foundation and pharmaceutical supported: Enzyme replacement therapy (ERT) for Pompe disease, small molecule and ERT for Gaucher disease, hypophosphatasia, SMA, gene therapy approaches for Duchenne Muscular dystrophy, Pompe disease, SMA, clinical trials of small molecules for enhancement of cognition in Down syndrome, SMA, natural history studies and registries for Pompe disease, MPSI, MPS IV, Gaucher disease, Glycogen Storage diseases I and III, Down syndrome and hypophosphatasia.

Participation in academic and administrative activities of the University and Medical Center:

- Chief, Division of Medical Genetics, Duke University Medical Center, 2007 – present
- Medical Director, Alice and YT Chen Pediatrics Genetics and Genomics Research Center, 2007 – present
- Committee Member for Chancellor’s Duke Medicine Innovation Council, 2011 – present
- Committee Member for Duke University Medical Alumni Awards, 2009 – present
- Faculty advisor and mentor – Duke undergraduate and 3rd year medical students, 2008 – present
- Mentorship committee for junior faculty members in Pediatrics and Medicine, 2008 – present

- Distinguished Professor Selection Committee, Duke University Medical Center, School of Medicine, 2013 – present
- Focused Group Committee Member on Rare Diseases, Duke University Medical Center, 2013 – present
- Committee Member, Regenerative Medicine, Duke University Medical Center, 2013
- Member of the Human Genetics Genomics Summit– Working Group, 2014
- Member of Duke Translational Research Advisory Committee, Duke University Medical Center, 2014-present
- Duke O’Brien Center for Kidney (DOCK) Research Executive Committee, 2015 – present
- Evaluator for “Pitch Your Innovative Clinical Products and Business Idea for Investment”, Duke Health Innovation Jam, Duke Institute for Health Innovation, September 2015-2020
- Committee member, Internal Advisory Group for Children’s Discovery Institute (CDI), Duke Pediatrics, February 2017- present
- Affiliate Member of the CHDI (Children’s Health and Discovery Institute), March 2018-present
- Committee member, Duke University School of Medicine, Precision Medicine and Genetics/Genomics Work Group, January 2018-present
- Faculty Collaborator for Duke Innovation and Entrepreneurship Initiative, July 2018-present
- Faculty Expert Member for Rare Diseases, Duke School of Medicine Gene Therapy Initiative, October 2019-present
- Participate in Strategic Education Sessions on Research, Translation and Commercialization with the Duke Board of Trustees for Academic year 2019-2020
- Member of the Duke Precision Genomics Collaborators Executive Leadership Committee, January 2020-present
- Member of the Duke Initiative on Research Translation and Commercialization (RTC) Working Group, October 2020-present
- Steering Committee Member for Duke University School of Medicine Marcus Center for Cellular Cures (MC3), July 2022-present
- Member of the Duke Office of Translation & Commercialization (OTC) Oversight Board, May 2023